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EXECUTIVE SUMMARY 
 This report presents the results of a project to develop a family of U.S. Drug 
Consequences Indices (DCIs). The DCIs are a complementary set of indices that measure the 
harmful consequences of illegal drugs in a standardized way. The National DCIs measure trends 
in illicit drug-related consequences for the U.S. as a whole, and the State DCIs measure these 
consequences across both states and years. These various metrics quantify with a single number 
what is otherwise not directly measurable, that is, the diverse and complex construct of drug-
related consequences. Each index was constructed from an array of theoretically-relevant social 
indicators measuring the health, social and economic, and crime and disorder consequences of 
illegal drug use and distribution during the ten-year period 2000 to 2009. Composite drug harm 
indices have been developed in recent years for official use in other countries, but the family of 
DCIs presented in this report are the first indices developed in a U.S. context that summarize 
over a multi-year period the multidimensional phenomenon of drug-related consequences. 
 The value of the DCIs is in their ability to summarize different aspects of drug-related 
harm in a more efficient and parsimonious manner than is possible with a collection of drug-
related indicators taken separately. This is no easy task either conceptually or methodologically, 
but if implemented successfully the DCIs could prove useful to a wide variety of stakeholders in 
the drug policy community. Indeed, the DCIs have several envisioned applications. They can 
help monitor trends in drug-related consequences across states and over time, assist with 
benchmarking and performance assessment, provide data-driven input to policy formulation and 
resource allocation, and enhance the utility of drug data systems for reporting, outcome 
evaluation, and policy analysis. The DCIs can also help fulfill statutory reporting requirements, 
as well as improve the effectiveness of communication with legislators, professionals in drug 
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abuse and law enforcement, the media, and the general public. Future planned updates to the 
DCIs as more recent data become available will enhance their value to these various stakeholder 
groups.  
 The process of constructing the DCIs involved a series of interrelated steps with a view to 
producing a balanced set of policy tools. First, to guide indicator selection, a conceptual 
framework was developed to coherently organize the broad spectrum of drug-related 
consequences. Second, existing drug data systems were inventoried to determine which 
consequences were actually quantifiable. Third, these data sources were assessed according to a 
data quality framework to determine their suitability for contributing specific indicators toward 
construction of the DCIs. Fourth, the chosen data were acquired, and the selected indicators were 
statistically treated (e.g., to deal with missing data) and operationalized. Finally, the indicators 
were normalized, weighted, and aggregated into a composite indicator.  
 The National DCI was constructed for years 2000-2009 from 30 underlying indicators 
measuring a wide array of illicit drug-related consequences. Figure I presents the overall DCI 
results, as well as the scores for the three underlying domains that inform the index. DCI scores 
were set to a benchmark value of 100 for year 2000. Overall, as the graph shows, illicit drug-
related consequences in the U.S. increased rapidly during the first two years of the decade, 
reaching peak levels roughly 30% above baseline during 2002-2004, before returning to near-
benchmark levels in 2008-2009. Consequences measured by the Social and Economic domain, 
which increased more than 55% by 2002, drove the initial increase in the National DCI, whereas 
Health domain consequences registered substantially higher only during the latter part of the 
2000s, increasing 24-26% over baseline by 2006-2009. Conversely, Crime and Disorder 
consequences decreased steadily throughout the decade, reaching a point 27% below the 2000 
 ix 
 
benchmark by 2009 (after a slight one-year uptick). Drug-specific indices were also developed at 
the national level, revealing divergent ten-year trends in drug-related consequences that ranged 
from increasing (heroin) to initially increasing then declining (methamphetamine and cocaine) to 
relatively stable (marijuana).  
  The State DCIs described interstate variations and trends in drug-related consequences 
both overall and for the four major drugs of abuse from 2000-2009. They were constructed from 
a select set of 13-16 underlying drug indicators depending on the specific index. As the interstate 
variations depicted in Figure II demonstrate, illegal drugs and their associated consequences are 
highly regionalized in the U.S. According to the State Heroin Index, the heroin problem is 
primarily concentrated in the New England and mid-Atlantic states, with additional pockets in 
the midwest and west. The State Methamphetamine Index shows that methamphetamine is a 
serious problem in the western half of the United States—especially Hawaii and other West 
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Coast states—but also that states well into the U.S. heartland experience serious consequences 
due to methamphetamine. According to the State Cocaine Index, states along the Gulf and East 
Coasts, and Illinois in the midwest, have the most serious cocaine problems, whereas states 
across a large section of the U.S. extending from the northwest to the upper midwest are 
relatively less affected by the cocaine problem. Finally, results from the State Marijuana Index 
show that marijuana-related consequences are the most geographically dispersed, which is at 
least partly attributable to the drug’s overall higher prevalence.  
 The State DCIs also revealed important state-level trends in drug-related consequences. 
For example, heroin-related consequences steadily increased from 2000-2009, with 45 states 
experiencing an uptick in the Heroin Index. Some of this increase may be attributable to 
prescription opioid abuse, however, as certain indicators informing the Heroin Index 
unavoidably capture consequences from opiates as well as heroin. The trends for 
methamphetamine over the period 2000-2009 confirm the general epidemiology of an eastward 
expansion of the methamphetamine problem from its point of origin in Hawaii and other western 
states into the American heartland from 2000 to 2006 and its subsequent, albeit partial, 
retrenchment as of 2009. Although remaining a significant problem in many places, 34 states 
showed double-digit declining rates in the Methamphetamine Index from 2005-2009. For 
cocaine, some states experienced steady increases and others steady declines through the early 
2000s. However, by 2006, trends in cocaine-related consequences had improved to the point that, 
between 2005 and 2009, 36 states experienced double-digit declining rates in the State Cocaine 
Index. Trends in the State Marijuana Index were split roughly 60/40 between states experiencing 
increases and decreases, respectively, from 2000 to 2009. Lastly, overall drug-related 
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consequences were examined at the state-level, with the north central U.S. ranking consistently 
better than other states with respect to the range and severity of drug-related problems. 
 The family of U.S. DCIs has many potential uses and applications. First, they provide a 
parsimonious yet comprehensive snapshot of trends and variations in drug-related consequences. 
This can be useful for communicating with policymakers, practitioners, and the general public 
about drug policy needs, objectives, and progress. Further, the DCIs can support more 
sophisticated uses such as benchmarking, performance assessment, and related policy analytic 
work. In this role, the DCIs by themselves are not suited to supporting causal claims about policy 
effectiveness, but they can inform assessments of whether trends and interstate variations in 
drug-related problems are in accordance with the intended impact of a particular policy or set of 
policies. Relatedly, the DCIs provide relevant information on state and regional variations in the 
nature and extent of illicit drug problems, which can inform strategic thinking about policy 
objectives, resource allocation, and the prioritization of interventions and initiatives.  
 Another benefit of the DCIs is that they contribute to federal efforts to increase the utility 
of existing drug data systems, especially at the state or local level. For example, missing data in 
drug-related information systems often confounds the ability of interested stakeholders to 
compare states on relevant outcome and performance indicators. In generating estimates of 
missing data within a multiple imputation framework, this project was able to utilize key 
information systems that would not have been possible otherwise. The DCIs employed a 
conceptually coherent approach to guide measurement of drug-related consequences, keying on a 
number of relevant dimensions across health, social and economic, and crime and disorder 
domains. In this respect, the DCIs and their underlying data can facilitate assessments regarding 
which dimensions are a state’s strongest assets, and which are in need of improvement. They can 
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also inform future data collection efforts by identifying current data gaps in the measurement of 
drug-related consequences. 
Despite their potential utility, the DCIs have a number of limitations. First, the indices are 
only as valid and reliable as their underlying indicators. We have attempted to address these 
concerns to the extent possible by employing both a conceptual and a data quality framework for 
selecting relevant social indicators. Some things could not be overcome, however, such as the 
error introduced by imprecise measures of drug type in some data systems or long delays in 
reporting by source agencies and organizations. Also, the issue of weighting is particularly 
sensitive and subjective when constructing composite indicators. There is no clear consensus 
among experts on composite index construction for how to best determine a set of weights for 
combining diverse issues, such as those related to drug consequences. In response to this, we 
have performed a series of robustness analyses that show the DCIs perform well as constructed. 
 There are a number of possible future directions for the research begun here. First, and 
foremost, the DCIs can be updated on a regular basis as new data is released. Indeed, one of the 
primary objectives for this project was to set up an ongoing monitoring system that could track 
trends in drug-related consequences over time. There is also opportunity for constructing similar 
indices involving other substances, such as other illegal drugs, tobacco, alcohol, and prescription 
drugs. It would also be fruitful to construct comparative indices at the substate level (e.g., 
counties, cities, zip codes) in order to provide more localized assessments of drug policy and 
related outcomes. Finally, research on index construction concerning inputs on the policy side 
would be a logical extension to the current work. Some research of this type has already been 
done at the international level in the alcohol field. In summary, the DCIs developed in the 
context of this project sought to measure drug-related consequences in a parsimonious yet 
 xiii 
 
comprehensive manner, with the ultimate objective of providing a useful set of communicative 
and policy analytic tools. 
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I. INTRODUCTION 
When confronted with complex social problems that transect multiple domains and 
interests—such as the health, crime, economic, and quality of life burdens of illegal drug use—
public agencies in the era of government accountability face the difficult task of effectively 
measuring policy and programmatic success. Composite indices (CIs), also known as composite 
indicators, have gained increasing acceptance as practical tools for performance assessment, 
benchmarking, policy analysis, and public communication (Organisation for Economic Co-
operation and Development, 2008; Zhou, Ang, and Zhou, 2010). Formally, a CI is a 
mathematical aggregation of individual social indicators that captures a multidimensional 
concept in a single model-based number per year or region (OECD, 2008). CIs have therefore 
shown promise both for parsimoniously monitoring multifaceted phenomena over time and for 
efficiently comparing complex social problems across jurisdictions, such as countries, states, and 
cities. Their appeal to policymakers, analysts, and the general public has resulted in the 
development of literally hundreds of CIs in a broad array of substantive areas, including business 
and technology, sustainability, quality of life, governance, road safety, violence, and, 
increasingly, drug policy (see e.g., Bandura, 2008; Brand et al., 2007; Brumbaugh-Smith et al., 
2008; Hermans et al., 2009; Ritter, 2009).  
 This report presents the results of a project to develop a family of U.S. Drug 
Consequences Indices (DCIs). The DCIs are a complementary set of indices that measure and 
summarize the harmful consequences of illegal drugs in a standardized way. The National DCIs 
measure trends in illicit drug-related consequences for the U.S. as a whole, and the State DCIs 
measure these consequences across both states and years. Both overall and drug-specific 
outcomes are examined at the national and state levels. These various metrics quantify with a 
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single number what is otherwise not directly measurable, that is, the diverse and complex 
construct of ‘drug-related consequences.’ Each index was constructed from an array of 
theoretically relevant social indicators measuring the health, social and economic, and crime and 
disorder consequences of illegal drug use and distribution during the ten-year period 2000 to 
2009.  
 The value of the DCIs is in their ability to summarize different aspects of drug-related 
harm in a more efficient and parsimonious manner than is possible with a collection of drug-
related indicators taken separately. Indeed, the DCIs have several envisioned applications. They 
can help monitor trends in drug-related consequences across states and over time, assist with 
benchmarking and performance assessment, provide data-driven input to policy formulation and 
resource allocation, and enhance the utility of existing drug data systems for reporting, outcome 
evaluation, and policy analysis. The DCIs can also help fulfill statutory reporting requirements, 
as well as improve the effectiveness of communication with legislators, professionals in drug 
abuse and law enforcement, the media, and the general public. Future planned updates to the 
DCIs as more recent data become available will enhance their utility among these various 
stakeholder groups.  
 Certainly, aggregating various drug indicators poses daunting conceptual and 
methodological challenges that stem mainly from the type and quality of available data and the 
combination of these into a common metric. Given these challenges, a good amount of debate 
surrounds the general utility of CIs and related composite measures both among experts in index 
construction (Saltelli, 2007) and in the specific arena of drug policy (Caulkins, Reuter, and 
Coulson, 2011; Nutt, 2009; Reuter and Trautmann, 2009:47; Ritter, 2007, 2009; Stevens, 2008). 
The DCIs were therefore developed according to a core set of principles: simplicity, soundness, 
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and transparency. Simplicity is driven by the goal that the DCIs be easily understood by a 
nontechnical audience. Simplicity did not prevail over technical soundness, however, as the 
DCIs were developed building on recommendations of the OECD (2008) Handbook on 
Constructing Composite Indicators and the lessons derived from statistical analysis of several 
well-known composite indicators (Saisana, d’Hombres, and Saltelli, 2011; Saisana, Saltelli, and 
Tarantola, 2005), including those in the substance abuse field (e.g., Brand et al., 2007; 
MacDonald et al., 2005; McAuliffe and Dunn, 2004). Finally, transparency has been central to 
the entire exercise, with full documentation of the assumptions and methods behind the DCIs and 
the accompanying distribution of the underlying indicators used in their construction.  
 This report proceeds as follows. First, the procedures used to locate and operationalize 
the indicators employed in the construction of the DCIs are discussed, including development of 
the conceptual framework, data inventorying process, application of the data quality framework, 
and measurement operations. Second, the methods used to statistically treat the data and then 
weight and aggregate the indicators are introduced. Third, the DCI results are presented. The 
report ends with a summary of the results, a discussion of the utility and limitations of the DCIs, 
and a look toward future research directions. A series of appendices to this report provide 
detailed documentation of the measurement operations and statistical methods used in the 
construction of the DCIs.  
 
II. MEASURING DRUG-RELATED CONSEQUENCES 
 In constructing the DCIs, the process of identifying and measuring drug-related 
consequences involved several interrelated steps. First, to guide indicator selection and 
subsequent aggregation, a conceptual framework was developed to coherently organize the broad 
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spectrum of drug-related consequences. Second, moving from the theoretical to the practical, 
existing drug data systems were inventoried to determine which consequences were actually 
measurable. Third, these data sources were assessed according to a data quality framework to 
determine their suitability for contributing specific indicators toward construction of the DCIs. 
Fourth, the chosen data were obtained and selected indicators were operationalized.  
 
A. CONCEPTUAL FRAMEWORK 
 The development of the Drug Consequences Indices (DCIs) was guided by the 
overarching conceptual framework presented in Figure 1. The framework depicts a policy model 
that distinguishes between policy actions and policy outcomes (Dunn, 2008). Policy actions 
represent inputs (e.g., resources allocated) and processes (e.g., implementation), whereas policy 
outcomes reflect outputs (e.g., units of services delivered) and impacts (e.g., behavioral or 
attitudinal change). This distinction has important measurement and analysis implications. 
Broadly, the framework provides a simple logic model for framing how drug policy actions 
influence drug policy outcomes. Importantly, for this work, it also makes explicit what is and is 
not being measured. A common criticism of CIs is that they often inadvisably commingle input 
and output measures (OECD, 2008). The conceptual framework therefore encourages precision 
of measurement by focusing DCI measurement operations squarely on drug policy impacts, 
which are represented in Figure 1 by a taxonomy of drug-related consequences. These 
consequences are divided into three broad domains: Health, Social and Economic, and Crime 
and Disorder. Each of these is further divided into three subdomains that capture specific aspects 
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of the parent domain. Table 1 defines each subdomain and provides specific examples of the 
types of drug-related consequences included in these definitions. 1 
 This taxonomy was developed based on a comprehensive review of the literature, along 
with feedback from subject area experts. The primary objective at this conceptual development 
stage was to achieve theoretical exhaustiveness in order to avoid biasing the taxonomy toward 
more easily quantifiable constructs and, later, to highlight existing data gaps. A preliminary 
taxonomy was created based on previous scholarship that systematized drug-related harms and 
consequences into a coherent classification system. This included work on drug classification 
and risk assessment (e.g., European Monitoring Centre for Drugs and Drug Addiction, 2009; 
Levitt, Nason, and Hallsworth, 2006; Nutt et al., 2007; Nutt, King, and Phillips, 2010; van 
Amsterdam et al., 2004), the economic costs of drug abuse (e.g., Collins and Lapsley, 2008; 
Mark et al., 2001; Miller et al., 2006; Nicosia et al., 2009; Office of National Drug Control 
Policy, 2004), drug policy analysis (e.g., Babor et al., 2010; Longshore et al., 1998; MacCoun 
and Reuter, 2001), and other composite drug indices (e.g., MacDonald et al., 2005; McFadden, 
2006; Slack et al., 2008; United Nations Office on Drugs and Crime, 2005). 
 To further saturate the taxonomy, a broad-based listing of specific drug harms and 
consequences was prepared from searches of major reference databases (e.g., CINAHL Plus, 
Criminal Justice Abstracts, Google Scholar, PsycINFO, PubMed-Medline). The search strategy 
intersected various combinations of drug type terms (e.g., drug, illegal drug, illicit drug, heroin, 
methamphetamine, cocaine, marijuana) and drug consequence terms (e.g., harm, consequence, 
morbidity, mortality, driving, crime, drug-exposed children). The taxonomy evolved as 
additional drug-related consequences were identified and incorporated into the framework. 
                                                 
1 See Appendix A for an expanded outline of the taxonomy and a more detailed listing of representative types of 
drug-related consequences.  
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Feedback on the taxonomy was elicited throughout its development from subject area experts 
both informally and at professional conferences. 2 The taxonomy of drug-related consequences 
presented in Figure 1 is the culmination of this review and feedback process.  
 
                                                 
2 Official presentations were made at the annual meetings of the International Society for the Study of Drug Policy 
(Utrecht, Netherlands, May 2011) and the American Society of Criminology (Washington, DC, November 2011). 
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Table 1. Drug Consequence Subdomains and Definitions 
Health Consequences 
 
Mortality—Drug-induced or drug-related overdose, disease (e.g., HIV, cancer, organ failure), or 
trauma (e.g., accidents, suicide) resulting in death. 
 
Morbidity—Drug-induced or drug-related injury, illness, disease, or disorder (including drug use 
disorders) resulting in physical and/or psychological impairment. 
 
Drug-Exposed Infants—Negative child health outcomes resulting from in utero or postnatal exposure 
(e.g., through breastfeeding) to drugs, including, e.g., obstetrical complications, HIV exposure, 
congenital defects, low birth weight, and developmental delays.  
 
Social and Economic Consequences 
 
Family Disruption and Child Maltreatment—Family or child drug involvement contributing to domestic 
violence, family strain and dissolution (e.g., divorce, separation), child removal (e.g., foster care), loss 
of parental rights, or child abuse (physical, sexual, emotional) and neglect.  
 
Reduced Attainment and Productivity—Drug involvement that leads to poor educational outcomes 
(e.g., low academic performance, drop-outs), reduced economic well-being (e.g., unemployment, 
reduced or diverted income), or lost productivity (e.g., absenteeism, unsafe workplaces).   
 
Stigmatization and Marginalization—Drug use, dependence, or risky drug-taking practices (e.g., 
injection drug use) that promotes negative outcomes, such as loss of relationships, social alienation, 
homelessness, impoverishment, drug-using lifestyles, or a generally poor quality of life.  
 
Crime and Disorder Consequences 
 
Drugged Driving—Driving under the influence of drugs and related consequences, including road or 
transportation accidents, property damage, reduced road safety, and other driving-related risks. 
 
Crime and Nuisance—Drug-related crime (e.g., aggression and violence, stealing to get money for 
drugs, shoot-outs over drug-selling turf, corruption and money laundering) and public nuisance (e.g., 
visible dealing, drug litter, fear of crime, graffiti). 
 
Community and Environmental Harms—Drug use, distribution, or production that leads to place-
based community deterioration (e.g., diminished social cohesion, devalued housing stock) or 
environmental degradation (e.g., dumping of hazardous waste, deforestation, watershed diversion). 
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B. INVENTORY OF DRUG DATA SYSTEMS 
 Measuring drug-related consequences requires data, preferably data from reputable 
sources that have been gathered consistently and reliably over time and across jurisdictions. In 
order to locate relevant data to populate the taxonomy of drug-related consequences with 
measurable indicators, an exhaustive inventory of current drug data systems was undertaken. 
This process included reviewing published data directories (Coffey et al., 2009; Collins and 
Zawitz, 1990; CSR Incorporated, 2008; Ebener, Feldman, and Fitzgerald, 1993; Garnick, 
Hodgkin, and Horgan, 2002; Hirshon et al., 2009; Manski, Pepper, and Petrie, 2001; NIDA, 
2006; ONDCP, 1990; 2003; Rootman and Hughes, 1980), searching data warehouse holdings 
(e.g., Interuniversity Consortium for Political and Social Research), and surveying the current 
data systems of key government statistical agencies and other private entities. As documented in 
Appendix B, this search strategy cataloged more than 120 ongoing or recent drug data systems, 
ranging from core federally-sponsored systems (e.g., ADAM, DAWN, MTF, NSDUH, TEDS) to 
less well-known and underutilized ones.  
 
C. DATA QUALITY FRAMEWORK 
 Much has been written about the limitations of existing drug data systems and the 
challenges of reliably and validly measuring drug-related outcomes (Caulkins, 2000, 2007; 
Manski, Pepper, and Petrie, 2001; Haaga and Reuter, 1991; Ebener et al., 1993). Informed by 
this prior work, the goal here was to assess the identified data systems along six dimensions 
regarding their quality or “fitness for use”: (1) relevance to the overarching conceptual 
framework, (2) accuracy of the data and credibility of the data source, (3) timeliness and 
punctuality in availability, (4) accessibility in terms of restrictions and cost, (5) interpretability in 
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terms of documentation and metadata, and (6) coherence in definition and format across 
jurisdictions and time (OECD, 2008).  
 Relevance was assessed by reviewing codebooks and metadata to determine whether 
each data source contained indicators that met specific criteria for constructing the DCIs. The 
first criterion plainly required that indicators measure a consequence of drug use or drug 
distribution. The second criterion mandated that relevant indicators be collected serially. The 
third criterion concerned the geographic unit of analysis, with measurement targeted at either a 
national or state level of aggregation. The fourth criterion concerned the drug-specificity of the 
indicators, where measurement focused on either generic indicators of illicit drug consequences 
or drug-specific indicators for the four major drugs of abuse (i.e., heroin, methamphetamine, 
cocaine, and marijuana).  
 
Table 2. Matrix of Index Measurement Criteria 
Geographic Unit of 
Analysis 
Drug Specificity 
All Illicit Drugs  
(Generic) 
Major Illicit Drugs  
(Drug-Specific) 
National (1) National DCI (2) Drug-Specific National DCIs 
State (3) Generic State DCI (4) Drug-Specific State DCIs 
 
 
 As shown in Table 2, these latter two dimensions form a 2 x 2 matrix that highlights 
possible ways of formulating an index of drug-related consequences. 3 The project focused initial 
index development efforts on cells (1) and (4). In both cases, the indices were developed from 
the bottom up using specific indicators that met the indicated measurement criteria (see next 
section). To fill the matrix, indices corresponding to cells (2) and (3) were developed through a 
                                                 
3 More complexity could easily be introduced to this rubric by including substate units of analysis (e.g., county, city, 
zip code) or other substances (e.g., alcohol, tobacco, prescription drugs). 
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series of supplemental analyses starting with the completed drug-specific State DCIs (4). 
Although it would have been preferable to build indices representing cells (2) and (3) using a 
similar protocol, time and resource constraints precluded that work for the current report.  
 Our assessment revealed that most drug data systems failed to meet one or more of the 
indicated relevance criteria. Many systems capture only policy inputs, processes, or outputs; that 
is, they do not directly measure drug-related consequences. This was evident in a number of 
treatment-oriented data systems (e.g., NCJTPS, N-SSATS), as well as many BJS data systems 
that collect operational information on law enforcement, courts, and corrections (e.g., LEMAS, 
NJRP, NCRP). Other data systems collect information primarily on pharmaceuticals and 
therefore fall outside of the scope of this inquiry (e.g., AERS, ARCOS, TLCS). With respect to 
serial availability, data coverage was often limited and incomplete. Leaving aside discontinued 
or superseded data systems, there are recent one-time collections that may or may not have 
planned future releases (e.g., National Survey of Meth Markets, National Survey of Workplace 
Health and Safety, NMVCCS, NSYC) as well as serial data collections with long periods of 
intermittency (e.g., NIS, NRS, SIFSCF, SILJ). A span of eight years, for instance, separates the 
two most recent installments of the Survey of Inmates in State and Federal Correctional Facilities 
(i.e., 2012 vs. 2004).  
 Geographically, most data systems are able to produce statistics at either the national or 
state level. However, some longitudinal surveys of individuals (e.g., NLSY97, NLSY79) capture 
person cohort effects more than national trends or state differences, and at least one major data 
system produces only substate estimates (ADAM). Other data systems represent the coterminous 
U.S. (e.g., NPHS, NRS) or collect data on a select subset of states (e.g., HCUP, NCANDS, 
NIBRS, NTSIP, PRAMS). Concerning drug specificity, a number of state-level data systems 
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report only nonspecific drug type information (e.g., AFCARS, CSSS, NCANDS, OTIS, 
PRAMS). Also, because they use the International Classification of Diseases to code drug-
related health outcomes, some data systems (e.g., NVSS, HCUP) are not able to capture specific 
drug types with precision (e.g., opiates vs. heroin, stimulants vs. methamphetamine). In these 
instances, unless a more accurate indicator was available from another source, we opted for 
measurement with imprecision rather than no measurement at all.  
 Data systems that met the initial relevance criteria were then assessed for fitness along 
the remaining five quality dimensions (i.e., accuracy, timeliness, accessibility, interpretability, 
coherence). While no single dimension was wholly determinative of a particular data source’s 
utility or fitness, preferred data systems included those that were (i) maintained by national 
statistical agencies, (ii) released regularly and punctually, (iii) free-of-charge and provided in an 
easily accessible format, (iv) accompanied by detailed documentation including codebooks and 
metadata, and (v) consistently reported across time and units.  
 
D. SELECTED INDICATORS 
 Data judged to be of potential value were obtained for further inspection and assessment. 
Ultimately, a total of 21 different data systems were selected to contribute one or more indicators 
toward construction of the DCIs. Statistical analyses (e.g., PCA) helped in refining some of these 
choices. All chosen indicators have a clear direction with respect to the overall phenomenon, 
with higher indicator values being undesirable. To represent a fair picture of the various aspects 
of the phenomenon being measured, indicators were normalized as appropriate (e.g., by general 
population, specific demographics). As Table 3 shows, 30 indicators were used in the 
construction of the National DCI. The most populated subdomain is ‘morbidity’ with nine 
 13 
indicators, and the least populated is ‘community and environmental harms’ with a single 
indicator. Similarly, Table 4 shows the indicators underlying each of the drug-specific State 
DCIs, which range from 13 indicators for the State Heroin Index to 16 for the State Marijuana 
Index. 4 The State DCIs are thus relatively less populated, as three out of four indices contain no 
indicators for at least one subdomain (only the Methamphetamine Index is fully populated) and 
all indices have 3-5 subdomains that are populated with only a single indicator. Indirect 
measures were therefore used if empirically and conceptually defensible. For example, there is 
reasonable evidence to suggest a link between marijuana potency and psychosis (Di Forti et al., 
2009; Hall and Degenhardt, 2011), so [m3] potency of seized marijuana was used to measure 
‘morbidity’ in the Marijuana Index. In the next section, we address the statistical treatment, 
weighting, and aggregation of these groups of indicators into their composites. 
  
                                                 
4 See Appendix C for detailed indicator definitions, measurement operations, and source information. The data used 
to construct the DCIs are available upon request from the Office of National Drug Control Policy. 
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Table 3. Taxonomy of Drug-Related Consequences—Core National Index  
Domain and Subdomain Indicator (Source) 
He
al
th
 
Mortality [d1] Drug-related deaths per 100,000 (MCD) 
[d2] IDU-related AIDS deaths per 100,000 (HIV Surveillance Reports) 
Morbidity [d3] Drug exposure poison center cases per 100,000 (NPDS) 
[d4] Drug-related emergency department visits per 100,000 (DAWN) 
[d5] Inpatient hospital drug poisoning discharges per 100,000 (HCUP-NIS) 
[d6] Inpatient hospital drug use disorder discharges per 100,000 (HCUP-NIS) 
[d7] Drug treatment admissions per 100,000 (TEDS) 
[d8] Prevalence of drug dependence or abuse among persons aged 12+ (NSDUH) 
[d9] IDU-related AIDS diagnoses per 100,000  (HIV Surveillance Reports) 
[d10] Prevalence of injection drug use among TB patients (OTIS) 
[d11] Prevalence of noninjection drug use among TB patients (OTIS) 
Drug-Exposed Infants [d12] Prevalence of illicit drug use among pregnant women aged 15-44 (NSDUH) 
[d13] Inpatient hospital discharges for drugs affecting baby per 100,000 women 
aged 15-44 (HCUP-NIS) 
[d14] Percentage of women aged 15-44 who were pregnant upon entering drug 
treatment (TEDS) 
So
ci
al
 &
 E
co
no
m
ic
 
Family Disruption & 
Child Maltreatment 
[d15] Percentage of foster care placements precipitated by child drug abuse 
(AFCARS) 
[d16] Percentage of foster care placements precipitated by caretaker drug abuse 
(AFCARS) 
[d17] Children affected by illicit drug labs per 100,000 (NSS) 
Reduced Attainment 
& Productivity 
[d18] Percentage of people who were unemployed upon entering drug treatment 
(TEDS) 
[d19] Drug positivity rate among the U.S. workforce (DTI) 
[d20] Prevalence of past-year illicit drug use among secondary school students 
(MTF) 
[d21] On-campus drug violations per 1,000 enrolled college students (CSSS) 
[d22] Percentage of high school students offered drugs on school grounds (YRBS) 
Stigmatization & 
Marginalization 
[d23] Percentage of people who were homeless upon entering drug treatment 
(TEDS) 
[d24] Lifetime prevalence of drug injection among high school students (YRBS) 
Cr
im
e 
&
 D
iso
rd
er
 
Drugged Driving [d25] Positive drug-tested drivers involved in fatal vehicle accidents per 100,000 
(FARS) 
[d26] Positive drug-tested drivers involved in police-reported crashes per 100,000 
(GES) 
[d27] Prevalence of self-reported drugged driving among persons aged 16+ 
(NSDUH) 
Crime & Nuisance [d28] Drug-related violent victimizations per 100,000 (NCVS) 
[d29] Drug-related murders per 100,000 (UCR) 
Community & 
Environmental 
Harms 
[d30] Illicit drug production incidents per 100,000 (NSS, DCE/SP) 
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Table 4. Taxonomy of Drug-Related Consequences—Core State Indices 
Domain and 
Subdomain 
Indicator (Source) 
Heroin Index Methamphetamine Index Cocaine Index Marijuana Index 
He
al
th
 
Mortality [h1] Heroin/opiate-related 
deaths per 100,000 (MCD) 
[a1] Stimulant-related deaths 
per 100,000 (MCD) 
[c1] Cocaine-related deaths per 
100,000 (MCD) 
-- 
Morbidity [h2] Primary heroin treatment 
admissions per 100,000 
(TEDS) 
[h3] Inpatient hospital 
diagnoses for heroin 
poisoning per 100,000 (HCUP-
SID) 
[h4] Inpatient hospital 
diagnoses for heroin/opiate 
use disorders per 100,000 
(HCUP-SID) 
[a2] Primary amphetamine 
treatment admissions per 
100,000 (TEDS) 
[a3] Inpatient hospital 
diagnoses for stimulant 
poisoning per 100,000 (HCUP-
SID) 
[a4] Inpatient hospital 
diagnoses for stimulant use 
disorders per 100,000 (HCUP-
SID) 
[c2] Primary cocaine treatment 
admissions per 100,000 
(TEDS) 
[c3] Inpatient hospital 
diagnoses for cocaine 
poisoning per 100,000 (HCUP-
SID) 
[c4] Inpatient hospital 
diagnoses for cocaine use 
disorders per 100,000 (HCUP-
SID) 
[m1] Primary marijuana 
treatment admissions per 
100,000 (TEDS) 
[m2] Inpatient hospital 
diagnoses for marijuana use 
disorders per 100,000 (HCUP-
SID) 
[m3] Potency of seized 
marijuana  (PMP) 
Drug-Exposed 
Infants 
[h5] Prevalence (%) of heroin 
abuse and pregnancy among 
females entering drug 
treatment (TEDS) 
[h6] Inpatient hospital 
diagnoses for narcotics 
affecting fetus or newborn 
per 100,000 females aged 15-
44 (HCUP-SID) 
[a5] Prevalence (%) of 
amphetamine abuse during 
pregnancy among females 
entering drug treatment 
(TEDS) 
  
 
[c5] Prevalence (%) of cocaine 
abuse during pregnancy 
among females entering drug 
treatment (TEDS) 
[c6] Inpatient hospital 
diagnoses for cocaine 
affecting fetus or newborn 
per 100,000 females aged 15-
44 (HCUP-SID) 
[m4] Prevalence (%) of 
marijuana abuse during 
pregnancy among females 
entering drug treatment 
(TEDS) 
 
So
ci
al
 &
 E
co
no
m
ic
 
Family 
Disruption & 
Child 
Maltreatment 
-- [a6] Children affected by 
methamphetamine labs per 
100,000 (NSS) 
-- -- 
Reduced 
Attainment & 
Productivity 
[h7] Prevalence (%) of heroin 
abuse and unemployment 
among people entering 
treatment (TEDS) 
[h8] Opiate positivity rate 
among the general U.S. 
workforce (DTI) 
 
[a7] Prevalence (%) of 
amphetamine abuse and 
unemployment among people 
entering treatment (TEDS) 
[a8] Methamphetamine 
positivity rate among the 
general U.S. workforce (DTI) 
 
[c7] Prevalence (%) of cocaine 
abuse and unemployment 
among people entering 
treatment (TEDS) 
[c8] Cocaine positivity rate 
among the general U.S. 
workforce (DTI) 
 
[m5] Prevalence (%) of 
marijuana abuse and 
unemployment among people 
entering treatment (TEDS) 
[m6] Marijuana positivity rate 
among the general U.S. 
workforce (DTI) 
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Domain and 
Subdomain 
Indicator (Source) 
Heroin Index Methamphetamine Index Cocaine Index Marijuana Index 
[h9] Prevalence (%) of lifetime 
heroin use among high school 
students (YRBS) 
[a9] Prevalence (%) of lifetime 
methamphetamine use 
among high school students 
(YRBS) 
[c9] Prevalence (%) of lifetime 
cocaine use among high 
school students (YRBS) 
[c10] Prevalence (%) of past-
year cocaine use among 12-17 
year olds (NSDUH) 
 
[m7] Prevalence (%) of 
marijuana use before age 13 
among high school students 
(YRBS) 
[m8] Prevalence (%) of recent 
marijuana use on school 
property among high school 
students (YRBS) 
[m9] Average annual marijuana 
initiation rate among 12-17 
year olds (NSDUH) 
Stigmatization 
& 
Marginalization 
[h10] Prevalence (%) of heroin 
abuse and homelessness 
among people entering 
treatment (TEDS) 
[a10] Prevalence (%) of 
amphetamine abuse and 
homelessness among people 
entering treatment (TEDS) 
[c11] Prevalence (%) of cocaine 
abuse and homelessness 
among people entering 
treatment (TEDS) 
[m10] Prevalence (%) of 
marijuana abuse and 
homelessness among people 
entering treatment (TEDS) 
Cr
im
e 
&
 D
is
or
de
r 
Drugged Driving [h11] Heroin/opiate positivity 
rate among drivers involved 
in fatal accidents (FARS)  
[a11] Amphetamine positivity 
rate among drivers involved 
in fatal accidents (FARS) 
[c12] Cocaine positivity rate 
among drivers involved in fatal 
accidents (FARS) 
[m11] Marijuana positivity rate 
among drivers involved in fatal 
accidents (FARS) 
Crime & 
Nuisance 
[h12] Percentage of police 
agencies reporting heroin 
contributes most to violent 
crime (NDTS) 
[h13] Percentage of police 
agencies reporting heroin 
contributes most to property 
crime (NDTS) 
[a12] Percentage of police 
agencies reporting 
methamphetamine 
contributes most to violent 
crime (NDTS) 
[a13] Percentage of police 
agencies reporting 
methamphetamine 
contributes most to property 
crime (NDTS) 
[c13] Percentage of police 
agencies reporting cocaine 
contributes most to violent 
crime (NDTS) 
[c14] Percentage of police 
agencies reporting cocaine 
contributes most to property 
crime (NDTS) 
[m12] Percentage of police 
agencies reporting marijuana 
contributes most to violent 
crime (NDTS) 
[m13] Percentage of police 
agencies reporting marijuana 
contributes most to property 
crime (NDTS) 
Community & 
Environmental 
Harms 
-- [a14] Percentage of police 
agencies reporting local 
methamphetamine 
production (NDTS) 
[a15] Methamphetamine 
laboratory seizure incidents 
per 100,000 (NSS) 
-- [m14] Percentage of police 
agencies reporting local 
marijuana production (NDTS) 
[m15] Outdoor marijuana plots 
eradicated per 100,000 
(DCE/SP) 
[m16] Indoor marijuana grows 
seized per 100,000 (DCE/SP) 
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III. METHODOLOGICAL APPROACH 
 Constructing the U.S. Drug Consequences Indices (DCIs) involved a series of 
methodological steps to statistically treat the indicators and then weight and aggregate them into 
composites. Although the National and State DCIs were constructed using a unified approach, 
certain procedures varied given the different purposes and data structures (i.e., time series for the 
National DCI and time-series cross-section for the State DCIs). This section describes the basic 
statistical considerations and methodologies employed; additional details on methodology and 
robustness analyses are presented in Appendix D.  
 
A. STATISTICAL TREATMENT OF INDICATORS  
The National DCI is based on a selected set of 30 indicators covering the ten-year period 
2000-2009. Statistical treatment of these data entailed both imputation and normalization 
procedures. Overall, data were missing for just 23 (7.7%) of the 300 possible observations (30 
indicators × 10 years). Each indicator had a minimum of five years of observed data, with 22 
indicators having complete records. Missing data for the remaining 8 indicators were imputed 
using either linear interpolation [d22, d24] or trend analysis regressing time (i.e., year) on the 
selected indicator [d4, d8, d12, d21, d27, d28]. 5 Second, to render the indicator values 
comparable, we normalized each indicator by a distance-to-reference value, where year 2000 
served as the base year set to a value of 100.  
 Statistical treatment of indicators for the State DCIs involved multiple imputation of 
missing data, transformation to address outliers and assure distributional assumptions, and 
normalization to a common scale. For each state-year matrix of indicators, missing data 
                                                 
5 Note that the imputations performed here deal with unit nonresponse on the time dimension. Missing data methods 
dealing with item nonresponse were dealt with at the indicator level and are discussed along with each indicator’s 
operationalization in Appendix C. 
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characterized 26.0% (1,693 / 6,500) of the Heroin Index, 22.0% (1,652 / 7,500) of the 
Methamphetamine Index, 24.6% (1,719 / 7,000) of the Cocaine Index, and 21.3% (1,702 / 8,000) 
of the Marijuana Index. These missing data were imputed independently for each index using a 
bootstrap time-series cross-sectional expectation-maximization algorithm implemented in the 
software package Amelia II (Honaker and King, 2010; Honaker, King, and Blackwell, 2012; 
King et al., 2001). This approach has comparative advantages over other imputation methods 
(Blankers, Koeter, and Schippers, 2010), and has proven to work efficiently with various datasets 
and with different degrees of missingness. For our purposes, ten complete datasets were imputed 
with observed values remaining the same but missing values “filled in with a distribution of 
imputations that reflect the uncertainty about the missing data” (Honaker, King, and Blackwell, 
2012:3). For each missing data point in the state-year matrices, the average of the ten imputed 
values was taken as the best estimate.  
 Next, data values outside twice the interquartile range were checked for reporting errors. 
Potentially problematic indicators that could bias the overall results, identified as those having a 
skewness greater than |2| and kurtosis greater than 3.5, were treated by Winsorization or 
logarithmic transformation corrected for zero values. To correct for different ranges and 
measurement units, the indicators were normalized by min-max scaling. In all cases the 
minimum value was set at 0, while the maximum value was set at 10% above the reported 
maximum value for all states over the period 2000-2009. This was done to allow updates to the 
indices where future indicator values are greater, without having to recalculate index scores for 
previous years. See Appendix D for additional technical details.  
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B. WEIGHTING AND AGGREGATION 
 For the National and State DCIs, individual indicators within subdomains were weighted 
equally. However, weights across the nine subdomains were not assumed to be equal. The 
decision on a suitable set of weights was guided by the results of an Analytic Hierarchy Process 
(AHP) conducted with 19 experts in the drug policy and addiction fields. AHP is a widely used 
method for multi-criteria decision-making that employs a hierarchical framework to organize and 
improve problem structuring, measurement, and synthesis (Saaty, 2005; Saaty and Vargas, 2001; 
Vaidya and Kumar, 2006). For this project, participants engaged in a sequential pairwise 
comparison of subdomains for each specific drug and all illicit drugs combined, rating which 
subdomain was the more significant contributor to total drug harm, and by how much. 
Assessments were framed with respect to nonmedical substance use within the policy 
environment of the United States from 2000 to the present. Participants expressed preferences on 
a nine-point scale, ranging from ‘1’ (equally important) to ‘9’ (extremely more important). The 
resulting averages of the AHP-derived weights for each drug type are shown in Figure 2. 
Subdomain weights were largest for specific drug types as follows: heroin (mortality, morbidity), 
methamphetamine (drug-exposed infants, family disruption and child maltreatment, community 
and environmental harms), cocaine (crime and nuisance), and marijuana (reduced attainment and 
productivity, stigmatization and marginalization, drugged driving). 
 The final calculation of the core National and State DCI scores followed three sequential 
aggregation steps whereby the weighted geometric mean was taken at each level of the 
framework from its underlying components. Either equal weights or the AHP-derived weights 
were assigned to the indicators, subdomains, and domains. 6 More specifically, scores for each 
subdomain were first calculated as simple geometric means of the normalized indicators. Scores 
                                                 
6 See Appendix D for robustness analyses involving alternative weighting schemes.  
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for the three domains were then calculated as the AHP-weighted geometric means of the three 
subdomains underlying each domain. Finally, the DCI scores represent the AHP-weighted 
geometric mean of the nine subdomains.  
 The use of the geometric mean, as opposed to the classical arithmetic average, is done for 
both conceptual and methodological purposes. Conceptually, perfect substitutability among the 
index components (as is the case with the arithmetic average) is not desirable. Substitutability (or 
compensability) is understood here as the undesirable offsetting of poor performance in some 
indicators with good performance in others. Methodologically, the use of arithmetic average 
would have been problematic because it would imply that the level of priority given to a 
dimension of drug consequences is invariant to the level of attainment. Instead, the geometric 
mean gives more incentives for improvement to low values.  
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IV. RESULTS: NATIONAL AND STATE DCIs 
 Results are presented in two sections. National-level results are presented first, showing 
both overall and drug-specific trends in drug-related consequences. State-level results follow, 
showing both general and drug-specific trends and interstate variations in drug-related 
consequences. 
 
A. NATIONAL RESULTS 
1. National Drug Consequences Index 
 Trends in the overall National Drug Consequences Index (National DCI) and its three 
major domains (Health, Social and Economic, and Crime and Disorder) are shown in Figure 3 
for the years 2000-2009. The National DCI and domain scores are normalized to a year 2000 
benchmark score of 100. Index scores reflect the AHP-derived weights. As the figure shows, 
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Figure 3. Trends in National Drug Consequences Index and Domains, 2000-2009 
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overall illicit drug-related consequences in the U.S. increased rapidly during the first years of the 
decade, reaching peak levels roughly 30% above baseline during 2002-2004, before returning to 
near-benchmark levels in 2008-2009. Consequences measured by the Social and Economic 
domain, which increased more than 55% by 2002, drove the initial increase in the National DCI, 
whereas Health domain consequences registered higher only during the latter part of the 2000s, 
increasing 24-26% over baseline during 2006-2009. Conversely, Crime and Disorder 
consequences decreased steadily throughout the decade, reaching a point 27% below the 2000 
benchmark by 2009 (after a slight one-year uptick).  
 What is driving the domain-level index scores? Figures 4-6 show trends in the scores for 
each of the major domains along with their subdomain components. As shown in Figure 4, the 
increase in Health consequences was driven primarily by an upsurge in overall drug-related 
‘mortality’ and, since 2005,  the increased burden of ‘drug-exposed infants.’ In contrast, drug-
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Figure 4. Trends in Health Domain and Subdomains, 2000-2009 
 23 
related ‘morbidity’—which is measured by an assortment of indicators ranging from poison 
center calls to IDU-related AIDs diagnoses—remained relatively flat throughout the decade.  
 Figure 5 depicts trends in Social and Economic consequences and its subdomains. The 
noted spike in the early part of the decade was driven largely by the increase in drug-related 
consequences stemming from ‘family disruption and child maltreatment’ (as measured by drug-
related foster care placements and children affected by illicit drug labs) and, to a lesser extent, 
‘stigmatization and marginalization.’ In comparison, social and economic consequences in the 
areas of ‘reduced attainment and productivity’ generally remained at or slightly above the 2000 
benchmark throughout the decade.  
 Lastly, Figure 6 shows trends in the Crime and Disorder domain and its subdomains. 
Notably, all areas reveal a sizable downward trend. Most dramatic is the roughly 40% decline 
through 2009 in ‘community and environmental harms,’ as measured by illicit drug production 
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incidents (including both methamphetamine lab and marijuana grow seizures). However, all 
subdomains show a recent one-year uptick in Crime and Disorder consequences.  
 Table 5 reports the actual index scores for the National DCI and its underlying 
components for the years 2000-2009. The last three columns also report statistics reflecting long-
, medium-, and short-term trends. We highlight here both the medium- (2005 to 2009) and short-
term (2008 to 2009) changes across the nine DCI subdomains. ‘Community and environmental 
harms’ remained a key driver of the downward trend in the DCI, registering a 25% decline from 
2005-2009. Other areas contributing to the reduction in drug-related consequences over the 
medium-term were ‘crime and nuisance’ and ‘family disruption and child maltreatment’ 
(showing 21% and 16% declines, respectively). Conversely, drug-related consequences in the 
areas of  ‘drug-exposed infants,’ ‘mortality,’ and ‘reduced attainment and productivity’ worsened 
over the medium-term (increasing 18%, 14%, and 8%, respectively).
Figure 6. Trends in Crime & Disorder Domain and Subdomains, 2000-2009 
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Table 5. National Drug Consequences Index, 2000-2009 
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
Percent 
Change 
2000-
2009 
Percent 
Change 
2005-
2009 
Percent 
Change 
2008-
2009 
National DCI 100.0 112.5 128.8 132.7 130.1 109.6 109.9 105.5 101.4 104.0 4.0% -5.0% 2.6% 
 Health Consequences 100.0 100.1 101.0 106.5 110.5 111.9 124.0 126.5 124.0 123.9 23.9% 10.7% 0.0% 
  Mortality 100.0 101.6 113.6 121.3 125.4 136.1 156.3 158.7 152.7 155.0 55.0% 13.9% 1.5% 
  Morbidity 100.0 101.2 100.6 99.5 102.9 100.1 103.3 101.4 101.5 100.0 0.0% -0.2% -1.5% 
  Drug-Exposed Infants 100.0 96.5 88.0 103.0 107.5 103.9 115.5 123.8 123.9 122.2 22.2% 17.6% -1.4% 
 Social & Economic Consequences 100.0 128.6 155.1 158.0 156.5 120.2 114.6 110.8 108.1 111.6 11.6% -7.1% 3.3% 
  Family Disruption & Child  
  Maltreatment 
100.0 150.1 180.6 181.6 182.4 137.0 126.4 118.1 112.5 115.8 15.8% -15.5% 3.0% 
  Reduced Attainment & Productivity 100.0 101.1 101.7 102.6 101.2 99.2 98.3 98.4 101.3 106.9 6.9% 7.7% 5.5% 
  Stigmatization & Marginalization 100.0 109.0 125.6 139.8 119.7 109.7 113.1 115.0 109.9 110.0 10.0% 0.3% 0.1% 
 Crime & Disorder Consequences 100.0 95.9 96.6 100.9 90.2 91.1 90.0 77.0 68.8 72.9 -27.1% -20.0% 5.9% 
  Drugged Driving 100.0 92.1 88.2 90.3 95.2 94.7 92.6 90.3 87.1 91.9 -8.1% -3.0% 5.5% 
  Crime and Nuisance 100.0 93.2 97.8 102.8 87.2 95.3 101.2 84.6 71.9 74.9 -25.1% -21.4% 4.2% 
  Community & Environmental Harms 100.0 101.5 97.5 101.5 93.2 82.5 67.7 57.5 56.0 61.6 -38.4% -25.3% 10.2% 
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Contrary to long- and medium-terms trends, Crime and Disorder consequences increased most 
sharply over the short-term (reflecting 4% to 10% increases across all three subdomains). 
Alternatively, there were only modest short-term improvements in the subdomains of ‘morbidity’ 
and ‘drug-exposed infants,’ each decreasing about 1-2%.  
 
2. Drug-Specific National Drug Consequences Indices 
 As mentioned above, we derived drug-specific national estimates of trends in drug-
related consequences using the drug-specific State DCIs as a starting point (refer to next section). 
We did this by taking the simple annual average of the fifty state index scores for each drug-
specific State DCI and its three major consequence domains (Health, Social and Economic, and 
Crime and Disorder), and then normalizing these mean scores to a value of 100 for year 2000. 7 
It is important to recognize that the underlying indicators for the drug-specific national estimates 
discussed here differ from those used to generate the overall national index reported above. The 
results are presented in Figures 7-10.  
 As Figure 7 shows, the National Heroin Index increased 39% between 2000 and 2009. 
The primary driver of this increase were consequences in the Health domain, with index scores 
increasing 44% over the decade, followed closely by the 36% increase observed for Social and 
Economic consequences. Crime and Disorder consequences had a more volatile trend, but still 
increased by approximately 30% over the course of the decade. 
 
                                                 
7 We also produced these estimates weighted by the annual state populations, but there were no substantive 
differences between the two approaches. We therefore present the simple unweighted results.  
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 Figure 8 shows the rising and falling trend in methamphetamine-related consequences, 
with mean National Methamphetamine Index scores increasing 37% from 2000 to 2005, 
followed by a decline of about 20% through 2009 (to a normalized mean index score of 110). 
This pattern was driven in different ways by the underlying domains. For example, Social and 
Economic consequences increased by nearly two-thirds between 2000 and 2003, before 
undergoing a steady decline to below baseline levels reached during 2007-2009 (index scores 85-
87). Initial increases in Health consequences were less steep but of longer duration, peaking in 
2005 before declining to levels that remained well above baseline as of 2009 (with an index 
score of 148). By comparison, Crime and Disorder consequences mirrored the overall rising and 
falling trend in the National Methamphetamine Index. 
In Figure 9 we also see fluctuating trends in cocaine-related consequences, with mean 
National Cocaine Index scores initially declining 5% between 2000 and 2002, before increasing 
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16% from 2002 to 2006 and declining again by 19% as of 2009. Notable at the domain level are 
the cross-cutting trends from 2000 to 2006 in Health (33% increase) and Social and Economic 
(11% decrease) consequences. However, since 2006, index scores in both these domains have 
registered declines of 24% and 36%, respectively.  
Lastly, as shown in Figure 10, mean National Marijuana Index scores remained relatively 
flat throughout the decade, reflecting minimal fluctuations in the Social and Economic and 
Crime and Disorder domains. Although less influential because of its relatively lower weighting 
(AHP weight = 0.18), the Health consequences domain registered a sizable 57% increase 
between 2000 and 2009. Refer to Table 6 for detailed index scores corresponding to each drug 
specific National DCI and its domains. 
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Figure 10. Trends in National Marijuana Index and Domains, 2000-2009 
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Table 6. Drug-Specific National Drug Consequences Indices, 2000-2009 
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
Percent 
Change 
2000-
2009 
Percent 
Change 
2005-
2009 
Percent 
Change 
2008-
2009 
National Heroin DCI 100.0 105.7 109.2 108.7 114.2 119.3 120.7 121.8 128.8 138.8 38.7% 16.6% 8.0% 
 Health 100.0 104.2 109.6 114.4 117.0 120.8 126.9 130.4 139.3 143.8 43.9% 19.2% 3.2% 
 Social & Economic 100.0 103.0 104.6 111.4 112.8 114.6 115.1 121.6 123.7 135.6 35.8% 18.5% 9.8% 
 Crime & Disorder 100.0 110.0 112.5 89.9 106.5 119.3 115.6 103.0 113.6 130.2 30.4% 9.3% 14.9% 
National Methamphetamine DCI 100.0 111.6 125.1 132.5 135.5 136.8 130.9 120.1 111.3 109.9 10.0% -19.8% -1.2% 
 Health 100.0 109.8 126.7 144.8 159.7 183.2 162.8 154.5 134.5 148.2 48.3% -19.2% 9.7% 
 Social & Economic 100.0 133.8 161.0 163.2 153.6 127.6 102.6 84.9 87.1 85.2 -14.5% -32.9% -1.9% 
 Crime & Disorder 100.0 107.2 116.2 120.8 124.5 126.6 125.8 119.7 112.9 111.2 11.0% -12.3% -1.6% 
National Cocaine DCI 100.0 99.0 94.7 104.7 103.9 107.1 110.1 107.0 99.6 89.6 -10.6% -16.4% -10.1% 
 Health 100.0 97.8 102.9 111.0 115.0 122.3 132.7 125.9 112.1 100.8 0.9% -17.5% -9.8% 
 Social & Economic 100.0 99.6 88.6 88.0 85.3 88.3 89.2 82.2 68.8 57.1 -42.9% -35.3% -16.9% 
 Crime & Disorder 100.0 99.1 93.3 112.4 110.4 109.9 109.4 111.8 113.0 105.8 6.0% -3.7% -6.4% 
National Marijuana DCI 100.0 102.2 101.9 97.9 98.8 93.4 96.3 98.4 99.8 103.5 3.5% 10.8% 3.8% 
 Health 100.0 104.2 110.5 115.6 119.7 126.2 134.5 147.0 153.2 157.2 57.4% 24.5% 2.6% 
 Social & Economic 100.0 102.1 101.0 99.1 98.6 93.8 95.6 97.1 97.0 99.8 -0.2% 6.4% 2.8% 
 Crime & Disorder 100.0 101.5 101.2 92.9 94.5 86.1 88.3 89.1 92.1 97.2 -3.0% 12.6% 5.4% 
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B. STATE RESULTS 
 In contrast to the National DCIs, the State DCIs allow us to examine interstate variations 
in drug consequences over time. Figure 11 presents the first set of results, showing state 
differences in the four drug-specific State DCIs for a single year, 2009. The four maps clearly 
highlight the regionalized nature of the drug problem in the United States. The State Heroin 
Index, for instance, reveals a heavy concentration of New England and Mid-Atlantic states with a 
relatively serious heroin problem, together with pockets in the midwest and west. Conversely, 
heroin is a relatively minor problem in the central and north central U.S. and in parts of the 
southeast. The State Methamphetamine Index shows that methamphetamine is a serious problem 
in the western half of the United States—especially Hawaii and other West Coast states—but 
also that states well into the U.S. heartland experience serious consequences due to 
methamphetamine. Alternatively, states in the northeast hardly register a blip on the 
Methamphetamine Index.   
 According to the State Cocaine Index, states along the Gulf and East Coasts, and Illinois 
in the midwest, have the most serious cocaine problem, whereas states across a large section of 
the U.S. extending from the northwest to the upper midwest are relatively less affected by the 
cocaine problem. Interestingly, if the cocaine and methamphetamine maps were overlaid, one 
would see that serious stimulant-related consequences affect a wide cross-section of the U.S. 
Finally, the State Marijuana Index shows that states with the most serious marijuana-related 
consequences represent a diverse group scattered across different regions of the U.S. This 
seemingly random pattern is partly attributable to the general pervasiveness of marijuana as an 
illicit drug, which is reflected in the Marijuana Index’s smaller overall range and higher 
minimum bound relative to the other States DCIs.  
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Figure 11. State Drug Consequences Indices, 2009 
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 It is noteworthy that in 2009 no jurisdiction appeared among the top ten most affected 
states for three or more drugs, although eight states fell in this group for two drugs: California 
and Iowa (methamphetamine, marijuana); Illinois and Maryland (heroin, cocaine); Nevada 
(heroin, methamphetamine); New York and Rhode Island (cocaine, marijuana), and Vermont 
(heroin, marijuana). On the other hand, no state appeared among the least affected for all four 
drugs, although two states fell into this least serious category for three out of four drugs: 
Nebraska and Wyoming (heroin, cocaine, marijuana).  
 The following four sections present detailed results on the drug-specific State DCIs. Each 
section contains a uniform set of graphs and tables. First, a set of choropleth maps shows 
interstate variations in the indices over four representative years (2000, 2003, 2006, 2009). To 
accurately show temporal change in the index scores, each year is mapped according to the 
index’s quintile distribution across all ten years of data (2000-2009). The parenthetical numbers 
in each map legend therefore show the number of states that fall within a particular quintile range 
for a given year. Any change in these numbers reflects the movement of states across the 
quintiles as a particular drug problem worsens or improves over time. 
 Second, time-series cross-section graphs present index trends across all 50 states and 10 
years of data. These graphs facilitate comparison of index scores across states with respect to 
both magnitude and trends in the underlying drug problem. A set of accompanying detailed 
tables reports overall index scores by state and year, with states ordered from highest 
(undesirable) to lowest (desirable) according to the index scores for 2009. Additionally, color 
coding highlights the ten states with the least serious drug problem (green) and the ten states with 
the most serious drug problem (red) for a given year. 8  
                                                 
8 Note that in some years eleven states might be highlighted due to ties in the index scores. 
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 A final set of choropleth maps shows interstate variations in the drug-specific State DCIs 
and their corresponding drug consequence domains (Health, Social and Economic, and Crime 
and Disorder). These graphs are helpful for understanding how states compare on key 
underlying features of the larger drug problem. For presentation purposes, states are divided into 
quintiles based on their respective index and domain scores for 2009. In each instance, barring 
any ties in index scores, the ten most impacted states are indicated by the darkest shade of blue 
and the ten least impacted are designated in the lightest shade of blue. 
 
1. State Heroin Consequences Index 
 Figure 12 shows interstate variations in the State Heroin Index over four select years. The 
figure highlights the highly regionalized nature of the heroin problem, with New England and 
mid-Atlantic states figuring most consistently and prominently across all years; however, states 
in the midwest and west also show elevated index scores across different years. Conversely, 
index scores for states in the north central region of the U.S consistently indicate that heroin is a 
relatively minor problem. Importantly, the maps reveal that heroin-related consequences have 
worsened over the decade. Between 2000-2009, the number of states in the most severe range of 
the Heroin Index (scores of 43-69) increased from 8 to 13, whereas those falling in the least 
severe category (scores of 8-16) decreased from 16 to 3. This general pattern of a worsening 
heroin problem is also captured by the state-specific trends in Figure 13. However, some of this 
increase likely reflects rising prescription opioid abuse (see, e.g., Gilson and Kreis, 2009; Shah et 
al., 2008), a phenomenon unavoidably captured by some of the indicators informing the Heroin 
Index. 
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 Table 7 presents a state-by-year look at the Heroin Index. In 2009, the five states with the 
most serious heroin problem were Massachusetts, New Jersey, New Hampshire, Connecticut, 
and Illinois (with index scores ranging from 69 to 55). The first four states, reflecting what might 
be considered the epicenter of the heroin problem in the U.S., were among the most affected in 
every single year between 2000-2009. Conversely, the five states in 2009 with the least serious 
heroin problem included Nebraska, Iowa, North Dakota, Hawaii, and Kansas (with scores 
ranging from 13 to 17). Two of these states (Nebraska, Iowa) were among the least affected 
states in every year between 2000-2009. Confirming the general upward trend in the heroin 
problem noted earlier, 45 states experienced some increase in the Heroin Index between 2000 
and 2009, with eight states more than doubling their scores (Arkansas, Wisconsin, Alaska, 
Montana, Kentucky, West Virginia, Missouri, Oklahoma). Finally, in the context of an overall 
worsening problem, it is all the more noteworthy that Rhode Island (-23%) and Hawaii (-17%) 
registered rather sizable double-digit percent declines in the Heroin Index between 2000-2009. 
 Figure 14 shows interstate variations for 2009 in the Heroin Index and its three domains. 
As the graph reveals, consequences measured at the domain level are variably distributed across 
the states. States with the most serious heroin-related Crime and Disorder consequences, for 
instance, are clustered in the northeast and midwest, whereas serious heroin-related Health and 
Social and Economic consequences also tend to cluster in the southwest (particularly, Arizona, 
Nevada, and Utah). However, only Massachusetts and Illinois appear in the top quintile for all 
three domains. On the other hand, the plains states of Iowa, Kansas, Nebraska, North Dakota, 
and South Dakota, together with Hawaii, were least affected by heroin-related consequences 
across all three domains. 
  
36 
  
Figure 12. Heroin Consequences Index, Interstate Variations, Select Years 
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Figure 13. Heroin Consequences Index, Trends by State, 2000-2009 
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Table 7. State Heroin Consequences Index, 2000-2009 
State 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
% Change 
2000-2009 
% Change 
2005-2009 
Massachusetts 54.1 61.2 62.9 60.1 63.7 63.9 65.9 63.6 65.8 68.8 27.2% 7.7% 
New Jersey 63.9 66.6 68.4 57.9 58.4 59.0 58.2 55.1 56.6 58.2 -8.9% -1.4% 
New Hampshire 43.0 50.5 47.3 48.9 52.5 55.3 53.2 57.2 49.9 55.6 29.3% 0.5% 
Connecticut 48.4 61.9 57.8 50.1 54.7 56.1 57.2 57.4 60.9 55.5 14.7% -1.1% 
Illinois 40.5 38.7 41.4 41.2 40.3 41.0 46.8 44.8 47.5 54.5 34.6% 32.9% 
Pennsylvania 45.2 41.0 44.5 44.9 50.5 48.2 44.7 47.3 51.5 53.3 17.9% 10.6% 
Michigan 34.7 34.5 35.2 35.7 37.0 38.4 42.5 40.2 49.6 52.0 49.9% 35.4% 
Vermont 43.5 55.9 61.1 59.9 53.2 60.3 55.0 46.3 47.0 51.6 18.6% -14.4% 
Maryland 47.2 49.7 49.4 51.8 50.4 48.1 52.3 50.1 46.4 51.3 8.7% 6.7% 
Nevada 30.4 29.0 31.4 33.4 40.5 38.3 38.2 36.5 40.0 50.0 64.5% 30.5% 
West Virginia 22.4 28.7 29.4 29.6 40.1 40.4 48.7 52.6 54.1 48.6 117.0% 20.3% 
Ohio 25.8 31.5 31.9 29.3 31.6 36.4 37.3 37.1 38.9 47.2 82.9% 29.7% 
Rhode Island 58.6 63.8 63.3 55.9 57.9 54.6 52.8 46.1 51.3 45.2 -22.9% -17.2% 
New York 34.4 37.9 36.2 36.9 34.9 37.4 38.9 38.3 39.4 44.3 28.8% 18.4% 
Maine 32.1 42.3 43.4 48.8 47.1 48.1 42.6 39.0 39.4 42.3 31.8% -12.1% 
Utah 25.9 25.3 28.2 31.6 33.5 39.2 38.8 46.6 44.4 42.2 62.9% 7.7% 
Alaska 18.2 12.5 24.0 11.9 13.8 13.5 16.4 14.6 40.7 41.9 130.2% 210.4% 
Delaware 37.9 33.9 36.1 35.0 35.0 41.8 43.9 45.9 41.5 41.2 8.7% -1.4% 
Missouri 18.9 21.0 19.5 19.7 23.6 26.7 27.4 32.1 32.7 40.1 112.2% 50.2% 
Oregon 27.9 26.9 28.5 26.9 28.2 29.6 33.1 35.6 34.2 40.0 43.4% 35.1% 
Kentucky 16.9 19.4 19.6 23.9 24.8 26.6 30.1 33.1 33.6 38.0 124.9% 42.9% 
Arizona 21.0 22.9 22.7 21.5 25.0 28.3 27.5 30.3 28.8 35.5 69.0% 25.4% 
Louisiana 23.6 24.6 29.7 23.2 31.0 28.8 26.0 25.1 29.8 34.8 47.5% 20.8% 
Washington 26.8 25.4 26.6 25.6 31.6 29.0 29.4 28.4 31.9 34.7 29.5% 19.7% 
New Mexico 34.7 29.8 33.1 31.5 28.5 37.7 36.8 33.1 41.9 34.1 -1.7% -9.5% 
Wisconsin 13.6 15.9 16.8 17.8 18.4 23.1 24.3 21.7 31.3 32.9 141.9% 42.4% 
Montana 14.3 15.1 13.9 27.8 30.5 27.0 30.3 30.2 32.2 32.6 128.0% 20.7% 
Virginia 16.8 20.3 20.8 24.5 23.3 21.8 26.7 21.9 29.6 32.5 93.5% 49.1% 
Indiana 22.6 18.2 17.0 15.5 20.2 25.3 24.5 26.5 23.7 32.3 42.9% 27.7% 
California 34.0 31.8 32.7 31.5 29.6 29.5 27.0 28.4 29.6 31.6 -7.1% 7.1% 
Oklahoma 13.3 14.1 13.0 17.3 18.2 17.0 22.2 23.1 20.5 28.2 112.0% 65.9% 
Arkansas 11.0 11.5 14.7 16.0 17.8 17.3 18.4 17.0 23.0 28.0 154.5% 61.8% 
Alabama 17.1 15.2 16.2 16.0 23.6 28.9 14.0 19.4 21.0 25.2 47.4% -12.8% 
South Carolina 16.6 15.5 18.2 16.5 15.2 19.7 17.7 15.7 17.4 24.7 48.8% 25.4% 
North Carolina 13.9 14.1 16.4 18.7 18.9 21.1 21.9 22.3 21.8 24.0 72.7% 13.7% 
Texas 22.6 24.2 23.3 22.0 22.3 21.8 18.0 21.6 21.9 24.0 6.2% 10.1% 
Idaho 15.7 17.2 16.6 13.6 16.1 18.2 19.5 23.2 20.0 23.6 50.3% 29.7% 
Colorado 17.9 17.7 16.7 18.5 18.6 19.0 20.8 21.0 20.9 23.5 31.3% 23.7% 
Florida 20.1 23.0 23.9 26.0 21.0 19.6 20.6 21.4 22.9 23.4 16.4% 19.4% 
Minnesota 14.7 14.4 15.9 15.8 16.8 18.3 18.5 20.3 21.1 23.1 57.1% 26.2% 
Georgia 13.9 16.2 16.3 16.1 15.9 18.5 17.6 18.1 19.1 23.0 65.5% 24.3% 
Wyoming 13.6 11.3 14.5 17.2 14.0 14.8 14.2 20.8 20.5 22.2 63.2% 50.0% 
Tennessee 12.5 15.2 14.8 18.1 19.5 20.2 21.1 22.0 22.9 21.8 74.4% 7.9% 
Mississippi 11.9 12.4 12.1 12.4 16.0 14.7 18.9 16.6 15.9 20.7 73.9% 40.8% 
South Dakota 11.1 10.7 11.3 11.6 12.6 15.4 13.7 18.6 17.1 18.6 67.6% 20.8% 
Kansas 10.3 10.7 11.5 14.4 14.4 14.0 16.1 17.2 16.8 17.0 65.0% 21.4% 
Hawaii 20.3 18.8 18.7 16.3 18.1 19.2 18.9 17.9 16.3 16.8 -17.2% -12.5% 
North Dakota 11.3 17.6 13.0 13.5 12.1 14.8 13.3 14.5 15.9 15.5 37.2% 4.7% 
Iowa 9.4 10.8 9.6 10.0 11.9 10.2 11.6 12.0 13.7 14.3 52.1% 40.2% 
Nebraska 8.6 8.3 9.5 9.9 9.7 10.7 11.2 11.4 14.4 13.0 51.2% 21.5% 
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2. State Methamphetamine Consequences Index 
 Figure 15 shows interstate variations in the Methamphetamine Index. Confirming the 
recent epidemiology of methamphetamine abuse (Maxwell and Rutkowski, 2008), we see the 
eastward expansion of the methamphetamine problem from its point of origin in Hawaii and 
other western states into the American heartland from 2000 to 2006 and its subsequent, albeit 
partial, retrenchment as of 2009. It is also apparent that the methamphetamine problem has been, 
and continues to be, relatively nonexistent in the northeast U.S. The state-specific trends shown 
in Figure 16 confirm this stratification across the states, as well as the dramatic rise and fall of 
the methamphetamine problem in impacted states. 
 Table 8 provides a state-by-year look at the Methamphetamine Index. In 2009, the five 
states with the most serious methamphetamine problem were Hawaii, Oregon, Nevada, 
Oklahoma and Idaho (with index scores ranging from 77 to 59). Four of these states (Hawaii, 
Oregon, Nevada, and Idaho) were among the most affected in every year between 2000-2009. 
Conversely, the six states (two states tied for fifth position) with the least serious 
methamphetamine problem were New Jersey, Maryland, Delaware, Massachusetts, New York 
and Connecticut (with index scores ranging from 5 to 7). All of these states remained among this 
least impacted group throughout the decade. With respect to state trends in methamphetamine-
related consequences, it is most instructive to look at changes since the middle of the decade 
when the methamphetamine epidemic peaked. Notably, 34 states showed double-digit declining 
rates in the Methamphetamine Index between 2005 and 2009. Moreover, the four states (Hawaii, 
Oregon, Nevada, and Idaho) that had been among the worst affected by methamphetamine in 
every year of the 2000s experienced declines of 8-23% from 2005 to 2009. It is also noteworthy 
that eight states—Rhode Island, New York, Vermont, Mississippi, New Jersey, Massachusetts, 
Michigan, and Alabama—experienced double-digit percent increases in methamphetamine-
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related consequences over the latter half of the decade, although most of these states started from 
very low base numbers. 
 Figure 17 reveals key interstate differences in the consequence domains underlying the 
Methamphetamine Index. In particular, whereas Crime and Disorder consequences mirror the 
distribution of the overall index in 2009, the most serious methamphetamine-related Health 
consequences cluster in the western U.S. but Social and Economic consequences figure more 
prominently in a swath of central U.S. states running from Mississippi and Alabama to 
Michigan. Still, only California, Hawaii, and Oklahoma were in the most severe category across 
all domains in 2009. Conversely, New England and mid-Atlantic states were relatively 
unaffected by methamphetamine in all three areas. In fact, six regional states (Connecticut, 
Delaware, Maryland, New Jersey, Pennsylvania, and Vermont) were among the least affected in 
every consequence domain.  
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Figure 15. Methamphetamine Consequences Index, Interstate Variations, Select Years 
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Figure 16. Methamphetamine Consequences Index, Trends by State, 2000-2009 
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Table 8. State Methamphetamine Consequences Index, 2000-2009 
State 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
% Change 
2000-2009 
% Change 
2005-2009 
Hawaii 76.7 76.9 80.5 83.2 80.2 83.3 80.9 70.7 76.9 76.6 0.0% -8.0% 
Oregon 69.1 76.6 77.2 77.1 77.4 78.3 75.9 66.4 70.0 62.8 -9.0% -20.0% 
Nevada 75.3 78.7 74.4 77.0 73.6 79.7 83.2 73.0 71.5 61.7 -18.0% -23.0% 
Oklahoma 59.6 66.4 66.7 71.9 72.7 65.1 64.0 56.0 50.4 60.7 2.0% -7.0% 
Idaho 69.1 69.4 70.5 71.9 73.0 75.8 75.1 74.5 59.8 58.8 -15.0% -22.0% 
California 49.3 54.9 60.3 62.5 62.7 65.3 66.3 64.1 58.5 58.4 18.0% -11.0% 
Nebraska 59.1 60.7 72.0 64.6 69.4 75.0 68.8 59.5 60.5 57.8 -2.0% -23.0% 
Utah 57.7 61.9 62.7 69.6 71.5 73.4 74.8 66.8 59.4 53.0 -8.0% -28.0% 
Iowa 60.1 55.5 59.2 70.3 68.4 63.3 61.7 53.7 49.7 51.8 -14.0% -18.0% 
Kansas 51.7 58.4 62.9 62.3 57.0 57.9 54.9 49.7 45.4 51.6 0.0% -11.0% 
Arkansas 52.2 55.3 63.7 67.9 67.0 62.4 57.9 56.6 51.5 50.2 -4.0% -20.0% 
Washington 63.8 64.5 65.7 59.9 70.1 63.3 61.9 65.3 53.4 50.0 -22.0% -21.0% 
Missouri 36.7 46.1 58.4 59.8 57.5 53.6 47.9 41.6 47.1 47.5 29.0% -11.0% 
North Dakota 56.2 69.7 78.7 75.3 68.9 73.1 66.7 69.2 58.8 46.7 -17.0% -36.0% 
Arizona 38.1 45.9 53.6 72.0 59.4 67.0 60.7 57.1 47.2 46.1 21.0% -31.0% 
Wyoming 52.4 52.2 65.7 72.3 71.8 71.6 61.0 58.9 50.7 45.6 -13.0% -36.0% 
Mississippi 28.7 37.7 44.7 43.5 36.7 36.2 34.9 35.2 36.4 45.3 58.0% 25.0% 
Montana 65.5 68.1 70.2 67.2 67.5 69.9 76.6 64.2 47.9 44.8 -32.0% -36.0% 
Alabama 18.8 32.1 41.8 40.2 42.8 40.6 36.0 37.7 43.9 44.8 138.0% 10.0% 
Colorado 31.2 39.2 46.8 49.1 56.3 51.7 46.9 47.5 44.8 43.6 40.0% -16.0% 
New Mexico 32.9 43.8 45.5 53.3 52.6 49.7 50.4 49.6 45.4 42.6 29.0% -14.0% 
Indiana 21.6 29.0 43.5 48.0 47.7 47.8 46.8 38.2 40.1 42.2 95.0% -12.0% 
Minnesota 31.2 33.2 41.6 52.6 52.9 57.8 58.7 49.6 41.6 41.8 34.0% -28.0% 
Kentucky 28.0 30.1 32.1 37.7 38.8 40.5 35.1 33.1 34.6 41.2 47.0% 2.0% 
South Dakota 31.8 33.4 42.9 57.9 65.5 59.9 65.5 53.9 36.8 36.0 13.0% -40.0% 
Georgia 22.2 28.0 33.9 42.3 43.8 45.7 36.0 33.4 30.8 34.2 54.0% -25.0% 
Tennessee 26.6 38.7 43.5 46.5 47.5 41.1 41.3 34.3 32.6 29.1 9.0% -29.0% 
Texas 25.3 27.9 28.7 30.5 33.5 33.7 35.9 33.4 28.9 28.9 14.0% -14.0% 
Alaska 34.0 32.5 39.7 36.3 35.0 48.0 36.5 32.9 22.7 27.2 -20.0% -43.0% 
Michigan 8.1 12.6 14.9 14.5 16.9 18.4 17.6 13.4 20.0 21.3 163.0% 16.0% 
Louisiana 17.3 16.9 24.9 24.4 24.0 27.0 23.5 30.4 21.8 21.2 23.0% -21.0% 
South Carolina 9.3 12.3 15.4 20.9 25.5 27.7 23.9 17.7 20.1 20.5 120.0% -26.0% 
West Virginia 11.1 16.8 19.4 26.8 36.6 37.8 26.4 22.8 24.3 19.5 76.0% -48.0% 
Florida 9.2 11.5 18.1 16.6 20.1 19.6 17.8 19.4 18.3 19.0 107.0% -3.0% 
Ohio 9.4 9.5 15.1 16.4 19.7 22.6 18.3 17.7 17.5 16.9 80.0% -25.0% 
North Carolina 9.0 12.3 11.4 18.9 23.7 23.6 21.0 18.8 20.6 16.1 79.0% -32.0% 
Illinois 9.6 15.4 23.0 22.4 24.5 23.9 22.1 17.7 14.9 14.1 47.0% -41.0% 
Virginia 9.9 10.0 11.9 13.0 18.4 16.8 15.9 13.3 13.2 13.8 39.0% -18.0% 
New Hampshire 5.3 8.9 10.9 10.1 9.7 12.5 14.4 11.9 11.2 13.3 151.0% 6.0% 
Maine 9.2 9.5 6.5 8.5 10.5 12.4 14.2 10.1 12.2 12.3 34.0% -1.0% 
Wisconsin 9.3 11.8 17.0 15.0 17.8 16.8 14.7 15.1 12.7 12.0 29.0% -29.0% 
Pennsylvania 8.8 9.2 7.8 8.7 10.0 10.8 11.2 10.5 10.5 9.4 7.0% -13.0% 
Rhode Island 6.1 6.5 7.2 5.0 5.5 5.4 6.6 7.5 5.4 7.8 28.0% 44.0% 
Vermont 6.5 5.2 6.7 6.4 8.1 6.1 8.2 8.0 6.2 7.7 18.0% 26.0% 
Connecticut 5.6 6.4 6.3 5.4 6.0 7.0 8.3 6.3 7.4 7.3 30.0% 4.0% 
New York 7.0 6.5 7.3 7.4 7.5 5.7 7.6 6.6 7.0 7.3 4.0% 28.0% 
Massachusetts 4.0 4.3 4.8 5.0 5.6 5.9 5.6 5.7 6.3 6.9 73.0% 17.0% 
Delaware 5.9 5.8 5.8 7.0 7.0 6.7 8.5 7.2 7.5 6.7 14.0% 0.0% 
Maryland 7.9 6.7 6.8 4.3 6.3 6.6 6.6 7.3 6.3 5.6 -29.0% -15.0% 
New Jersey 4.1 6.1 5.3 4.6 4.1 4.3 5.4 5.5 5.5 5.1 24.0% 19.0% 
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3. State Cocaine Consequences Index 
 Figure 18 shows interstate variations in the State Cocaine Index for select years. As with 
heroin and methamphetamine, the maps reveal substantial regional stratification in the cocaine 
problem. Generally speaking, states along the Gulf and East Coasts as well as in the midwest 
(namely, Illinois) consistently experience the most serious cocaine-related consequences, 
whereas Hawaii and states in the north central and northwest regions of the U.S. are consistently 
among the least affected. The maps also show that after an uptick in the number of states moving 
into the most serious range of the Cocaine Index (going from 6 in 2000 to 15 in 2006), only 9 
states remained in this highest category as of 2009. This general downward trend in cocaine-
related consequences, especially since 2006, is reinforced by the state-specific trends shown in 
Figure 19.  
Table 9 presents a state-by-year look at the Cocaine Index. In 2009, the five states with 
the most serious cocaine problem were Maryland, North Carolina, Delaware, South Carolina, 
and Florida (with index scores ranging from 61 to 55). Four states (Maryland, Delaware, Florida, 
and Louisiana) were among the most serious in every year between 2000 and 2009. The five 
least impacted states in 2009 were Oregon, Nebraska, Hawaii, Montana, and South Dakota 9 
(with index scores ranging from 11 to 13). All of these states remained among the least impacted 
group of states throughout the decade. Trends show that the majority of states over both the long- 
and medium-terms experienced substantial downturns in the Cocaine Index. For example, 36 
states experienced double-digit percent declines in the Cocaine Index between 2005 and 2009. 
Only four states (North Dakota, Iowa, Alabama, and Idaho) experienced double-digit percent 
increases from 2005 to 2009, although all these states except for Alabama had a relatively minor 
cocaine problem to begin with.  
                                                 
9 Although Wyoming (13.2) was virtually tied with South Dakota (13.1) for fifth position. 
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 Figure 20 shows interstate variations in the underlying components of the Cocaine Index 
for 2009. With the exception of Alaska, the most serious cocaine-related Health and Crime and 
Disorder consequences occur in states within the eastern half of the United States. In contrast, 
several states outside this region—namely, California, New Mexico, and Texas—experienced 
relatively severe Social and Economic consequences from cocaine. However, just two eastern 
states (Florida and North Carolina) fell within the most serious category for all three cocaine 
consequence domains. Generally speaking, the states that are least impacted by cocaine problems 
are in the north central and northwest United States, although just three states (Montana, 
Nebraska, Oregon) were in the lowest quintile across all consequence areas.  
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Figure 18. Cocaine Consequences Index, Interstate Variations, Select Years 
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Table 9. State Cocaine Consequences Index, 2000-2009 
State 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
% Change 
2000-2009 
% Change 
2005-2009 
Maryland 47.2 53.3 60.3 57.8 60.4 70.0 65.3 63.8 60.6 60.5 28.2% -13.6% 
North Carolina 51.6 46.6 44.2 61.9 67.9 66.5 72.1 66.9 63.2 58.7 13.8% -11.7% 
Delaware 51.6 55.4 60.5 54.5 55.2 55.6 58.9 60.9 72.2 58.0 12.4% 4.3% 
South Carolina 44.4 46.6 48.2 58.9 63.8 64.3 65.2 68.2 63.0 57.6 29.7% -10.4% 
Florida 55.6 48.4 52.4 62.5 59.6 66.3 64.7 62.5 56.9 54.6 -1.8% -17.6% 
Louisiana 60.7 57.9 53.5 64.8 61.8 58.3 61.7 58.0 51.1 52.1 -14.2% -10.6% 
New York 42.8 43.1 48.8 51.0 53.3 56.9 62.1 60.4 53.5 50.2 17.3% -11.8% 
Illinois 51.5 54.5 50.4 49.2 49.0 50.4 54.4 54.5 51.0 50.0 -2.9% -0.8% 
Rhode Island 48.2 42.3 43.1 47.5 44.0 64.7 57.7 47.8 49.8 49.4 2.5% -23.6% 
Alabama 47.3 48.2 39.2 48.8 45.2 41.4 44.0 46.1 48.1 48.1 1.7% 16.2% 
Mississippi 44.6 48.0 38.0 52.1 46.1 46.2 49.7 50.5 47.1 47.1 5.6% 1.9% 
Georgia 45.3 47.5 45.2 49.7 45.2 51.1 46.1 47.1 45.9 41.9 -7.5% -18.0% 
Virginia 43.9 42.7 41.4 53.4 57.7 49.8 48.1 51.6 44.4 40.3 -8.2% -19.1% 
Tennessee 41.6 41.9 41.6 44.7 45.5 50.1 54.1 50.1 42.9 40.0 -3.8% -20.2% 
Michigan 42.9 44.1 41.4 48.3 50.2 48.4 50.6 46.9 43.3 38.4 -10.5% -20.7% 
Connecticut 44.8 45.0 50.3 44.6 42.3 45.5 50.1 44.5 39.3 36.8 -17.9% -19.1% 
Texas 49.5 48.4 43.1 50.2 47.5 45.8 42.1 42.8 38.7 36.3 -26.7% -20.7% 
Ohio 41.6 47.0 45.3 46.4 49.2 46.6 50.4 45.1 42.0 35.1 -15.6% -24.7% 
Massachusetts 36.5 37.7 32.4 38.6 37.6 43.5 47.1 44.8 39.4 34.0 -6.8% -21.8% 
Pennsylvania 39.1 41.5 41.7 40.3 41.5 42.2 45.1 39.9 37.2 32.5 -16.9% -23.0% 
Wisconsin 33.7 33.9 36.8 41.4 39.9 42.7 45.7 42.1 35.1 31.5 -6.5% -26.2% 
New Mexico 46.0 43.6 47.1 46.3 40.5 41.9 40.5 38.4 38.2 30.3 -34.1% -27.7% 
Arkansas 24.2 31.8 26.0 31.0 29.5 32.9 34.6 32.8 32.9 29.7 22.7% -9.7% 
Kentucky 33.0 31.2 32.5 44.6 40.9 47.9 49.7 45.3 36.6 29.0 -12.1% -39.5% 
West Virginia 29.7 33.2 30.5 40.2 39.9 38.5 46.3 38.1 35.0 27.6 -7.1% -28.3% 
New Hampshire 26.7 27.1 24.4 32.0 31.3 31.0 36.8 33.2 30.9 26.9 0.7% -13.2% 
Alaska 31.1 33.4 29.8 24.8 27.3 24.7 21.8 19.5 30.3 26.5 -14.8% 7.3% 
Missouri 34.8 31.9 33.4 39.0 39.1 38.4 40.0 35.7 32.3 26.2 -24.7% -31.8% 
New Jersey 38.1 34.2 33.2 37.4 36.2 39.8 37.2 33.8 29.5 26.2 -31.2% -34.2% 
Indiana 32.7 30.0 30.0 28.6 30.9 29.6 29.6 31.3 29.1 25.9 -20.8% -12.5% 
Kansas 34.9 31.2 30.5 34.1 33.3 33.0 34.7 34.1 28.4 23.3 -33.2% -29.4% 
Vermont 25.7 20.9 21.2 24.8 30.1 32.0 31.7 35.3 32.6 23.1 -10.1% -27.8% 
Colorado 31.3 32.5 28.5 32.0 31.7 33.8 33.5 31.6 26.7 23.1 -26.2% -31.7% 
Maine 21.7 22.4 16.1 21.9 26.1 25.6 27.0 29.7 27.3 22.8 5.1% -10.9% 
Minnesota 25.0 24.8 21.0 25.9 22.8 22.7 22.5 24.0 25.3 21.7 -13.2% -4.4% 
Iowa 23.4 20.6 18.3 17.2 15.9 17.8 20.4 24.0 20.8 21.7 -7.3% 21.9% 
Arizona 41.1 37.2 32.7 32.8 32.1 32.1 31.4 29.0 24.5 21.0 -48.9% -34.6% 
California 28.3 26.4 25.4 26.1 24.7 24.5 23.5 23.3 22.6 20.0 -29.3% -18.4% 
Nevada 46.2 39.0 35.1 36.5 34.8 32.0 30.6 27.3 24.7 19.9 -56.9% -37.8% 
Oklahoma 28.0 26.4 24.3 26.5 28.8 28.8 28.1 26.8 24.9 19.5 -30.4% -32.3% 
Utah 23.5 19.1 17.2 19.7 20.0 21.6 23.7 24.0 20.4 18.6 -20.9% -13.9% 
Washington 25.9 22.3 20.3 22.3 21.4 23.1 25.5 22.9 20.3 17.7 -31.7% -23.4% 
North Dakota 14.8 17.2 13.3 13.8 13.1 13.2 13.4 14.5 14.6 17.0 14.9% 28.8% 
Idaho 16.3 16.6 13.7 12.0 12.7 12.7 12.8 15.9 15.0 14.7 -9.8% 15.7% 
Wyoming 12.6 14.4 13.5 13.6 13.5 13.1 15.1 17.4 14.5 13.2 4.8% 0.8% 
South Dakota 15.8 15.4 13.5 14.6 14.7 13.3 12.3 15.2 19.1 13.1 -17.1% -1.5% 
Montana 15.6 16.5 15.0 15.2 14.1 16.1 16.1 17.4 14.2 13.0 -16.7% -19.3% 
Hawaii 14.4 15.9 14.5 15.7 14.4 12.4 15.1 19.0 14.0 12.7 -11.8% 2.4% 
Nebraska 17.3 15.6 16.5 15.0 13.7 13.0 13.4 14.8 13.3 12.5 -27.7% -3.8% 
Oregon 20.0 20.3 15.7 14.7 14.3 14.3 15.4 15.1 13.4 11.1 -44.5% -22.4% 
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4. State Marijuana Consequences Index 
 Figure 21 shows interstate variations in the State Marijuana Index. This series of maps 
reveals that marijuana-related consequences are more geographically dispersed than for other 
drugs. Thus, unlike the other drugs, the maps resemble a checkerboard pattern with 
comparatively less regionalization and consistency across years. Figure 22 confirms this 
assessment in revealing that trends in marijuana-related problems are volatile and varied across 
the states.  
 The relative inconsistency of the Marijuana Index across states and years is reinforced by 
the pattern in Table 10. In 2009, Iowa, New York, Vermont, Kentucky and Missouri were the 
five states with the highest Marijuana Index scores (ranging from 58 to 52). Supporting the 
notion that marijuana problems are not as concentrated within a particular state or region of the 
country as with the other drugs, none of these states appeared among the most serious in all ten 
years of the decade. The six states with a least serious marijuana problem in 2009 were 
Nebraska, Utah, Mississippi, New Jersey, Wyoming, and Virginia 10 (with index scores ranging 
from 25 to 33). Only Nebraska fell within this least seriously affected group in all ten years. 
Regarding long-term trends, 20 states registered double-digit percent increases in the Marijuana 
Index between 2000 and 2009, whereas 13 experienced double-digit declines.  
 Lastly, as shown in Figure 23, interstate variations in the Marijuana Index and its 
domains are also variably distributed with little evidence of regionalization in marijuana-related 
problems. No states consistently fell within the most serious category, and just three states 
(Nebraska, Mississippi, Utah) were in the bottom quintile for all three domains. These results are 
more reflective of the general state-level variability in the Marijuana Index, with seven states 
(Alabama, Alaska, Maryland, New Mexico, South Carolina, South Dakota, and Wisconsin) 
                                                 
10 Virginia and Wyoming (32.9) tied for the fifth position on the Marijuana Index.  
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appearing among the most impacted in one domain but among the least impacted in another. For 
example, Alaska fell in the bottom (least serious) tier for Health consequences, a middle tier for 
Social and Economic consequences, and the top (most serious) tier for Crime and Disorder 
consequences.  
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Figure 21. Marijuana Consequences Index, Interstate Variations, Select Years 
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Figure 22. Marijuana Consequences Index, Trends by State, 2000-2009 
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Figure 22. Marijuana Consequences Index, Trends by State, 2000-2009
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Table 10. State Marijuana Consequences Index, 2000-2009 
State 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
% Change 
2000-2009 
% Change  
2005-2009 
Iowa 30.2 33.9 34.4 30.5 34.7 33.8 58.0 58.5 55.5 57.7 91.1% 70.7% 
New York 39.4 45.0 45.8 43.5 48.7 47.4 47.8 47.3 50.8 57.0 44.7% 20.3% 
Vermont 46.9 56.8 51.0 58.1 54.0 52.0 61.6 61.9 57.7 54.7 16.6% 5.2% 
Kentucky 44.1 46.5 45.9 48.2 47.1 43.7 39.7 44.0 46.8 53.4 21.1% 22.2% 
Missouri 38.3 42.4 44.1 42.3 43.7 45.1 46.5 41.3 47.6 52.1 36.0% 15.5% 
Montana 43.7 45.8 43.8 49.1 50.7 46.1 43.4 50.3 48.2 51.9 18.8% 12.6% 
California 39.3 39.6 38.9 39.1 39.9 41.3 42.3 43.8 46.0 49.8 26.7% 20.6% 
Rhode Island 43.3 55.9 45.5 42.9 43.3 40.0 44.3 40.6 40.9 48.8 12.7% 22.0% 
Indiana 46.7 45.8 45.4 47.7 45.4 42.9 43.4 40.6 44.3 48.5 3.9% 13.1% 
Washington 44.3 45.3 48.4 47.3 49.8 46.0 45.0 47.4 47.9 48.4 9.3% 5.2% 
Minnesota 38.8 40.2 38.0 37.8 38.1 35.7 35.4 40.0 43.6 45.8 18.0% 28.3% 
Hawaii 39.4 45.2 47.9 48.9 45.5 41.1 47.6 47.9 47.1 44.7 13.5% 8.8% 
Michigan 41.4 39.2 43.7 46.8 43.7 42.3 43.8 41.8 41.9 44.4 7.2% 5.0% 
Illinois 49.1 44.1 43.7 40.2 40.5 41.0 38.9 42.6 42.5 44.4 -9.6% 8.3% 
New Mexico 51.1 49.4 41.9 42.2 40.5 40.4 38.0 42.5 41.0 44.3 -13.3% 9.7% 
North Dakota 32.9 30.5 34.6 35.8 35.2 32.9 32.2 46.7 43.9 44.2 34.3% 34.3% 
Maine 44.2 53.0 46.1 40.3 37.6 42.2 41.9 45.2 41.8 44.2 0.0% 4.7% 
Idaho 48.3 50.8 50.5 44.6 58.7 39.2 38.1 40.1 43.5 44.1 -8.7% 12.5% 
New Hampshire 52.2 50.4 52.4 43.1 40.3 37.2 43.0 39.0 49.1 43.9 -15.9% 18.0% 
Oregon 40.3 45.5 45.1 43.3 45.4 39.7 38.4 42.1 39.6 43.7 8.4% 10.1% 
Ohio 44.6 43.7 42.0 40.5 42.4 39.5 39.7 40.5 43.0 43.2 -3.1% 9.4% 
Kansas 46.8 40.5 42.8 41.7 40.7 38.1 36.8 37.9 37.3 42.8 -8.5% 12.3% 
Alaska 46.1 46.5 56.5 43.2 52.9 47.8 41.2 41.8 45.3 42.3 -8.2% -11.5% 
Arizona 36.1 35.5 35.3 30.7 37.8 39.1 35.5 36.9 40.0 41.3 14.4% 5.6% 
Alabama 37.7 43.5 48.4 48.6 50.4 45.8 54.6 48.4 45.2 41.2 9.3% -10.0% 
Nevada 57.7 64.0 58.0 59.4 58.3 56.8 55.2 40.4 40.3 41.2 -28.6% -27.5% 
Maryland 31.5 33.7 33.2 28.9 29.2 31.5 44.9 42.0 42.8 39.1 24.1% 24.1% 
Louisiana 36.0 35.2 34.0 33.9 35.8 32.2 33.5 38.3 34.5 39.1 8.6% 21.4% 
Florida 33.7 34.8 38.0 37.8 34.7 32.1 34.2 34.9 38.2 38.1 13.1% 18.7% 
Arkansas 31.1 31.8 31.9 30.7 33.0 33.8 36.4 37.3 34.6 38.0 22.2% 12.4% 
Wisconsin 40.6 40.6 45.7 42.5 41.2 36.6 37.3 38.3 34.3 37.9 -6.7% 3.6% 
South Carolina 30.4 28.7 31.2 31.0 36.0 29.8 34.0 33.9 35.7 37.2 22.4% 24.8% 
Connecticut 31.7 34.0 37.8 31.9 31.9 33.7 29.2 33.1 31.5 37.2 17.4% 10.4% 
Georgia 35.6 35.2 38.4 34.3 34.0 33.9 32.3 30.2 35.6 36.7 3.1% 8.3% 
South Dakota 29.5 35.1 34.1 33.6 27.5 28.6 26.7 29.8 36.5 36.5 23.7% 27.6% 
Pennsylvania 36.1 33.0 40.8 35.2 35.6 34.7 36.3 36.1 33.8 35.8 -0.8% 3.2% 
West Virginia 40.1 43.6 34.3 33.3 33.7 30.9 32.1 37.3 37.7 35.8 -10.7% 15.9% 
Oklahoma 38.9 38.2 39.3 41.7 38.4 37.8 36.4 33.6 31.9 35.3 -9.3% -6.6% 
Tennessee 46.6 46.2 32.3 37.1 36.2 33.3 37.9 37.4 32.7 35.3 -24.2% 6.0% 
North Carolina 38.6 35.9 36.5 30.9 28.8 27.1 25.9 29.5 34.4 34.8 -9.8% 28.4% 
Delaware 35.9 32.2 35.6 36.9 34.2 33.7 32.9 30.5 29.6 34.6 -3.6% 2.7% 
Massachusetts 37.5 36.9 32.8 28.6 30.6 30.9 31.5 33.0 35.2 33.9 -9.6% 9.7% 
Colorado 42.6 45.3 37.9 37.3 35.7 32.3 32.6 31.9 33.9 33.8 -20.7% 4.6% 
Texas 39.7 39.8 37.0 32.6 31.7 27.8 28.1 27.7 30.8 33.5 -15.6% 20.5% 
Virginia 29.7 30.1 36.2 29.8 28.8 28.3 30.7 31.8 31.0 32.9 10.8% 16.3% 
Wyoming 32.1 32.2 35.2 35.3 34.5 35.3 29.9 33.9 38.1 32.9 2.5% -6.8% 
New Jersey 29.3 35.1 36.7 29.1 30.3 27.7 28.8 30.1 31.4 32.7 11.6% 18.1% 
Mississippi 33.5 30.7 28.3 27.5 24.9 23.7 25.0 28.6 27.8 27.5 -17.9% 16.0% 
Utah 46.9 29.6 32.1 34.2 32.2 28.8 32.0 32.1 26.8 26.6 -43.3% -7.6% 
Nebraska 28.1 25.6 28.2 28.2 30.8 27.7 24.1 26.9 26.3 24.9 -11.4% -10.1% 
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Figure 23. Marijuana Consequences Index and Domains, Interstate Variations, 2009
Figure 23. Marijuana Consequences Index, Interstate Variations, 2009 
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5. Generic State Drug Consequences Index  
 To provide a more general assessment of drug problems at the state level, we calculated 
the mean annual state rank of index scores across the four drug-specific State DCIs and the three 
domains. In particular, we first determined the annual state rankings for the 50 states for each 
drug-specific index and corresponding domains. We then obtained the drug-specific mean ranks 
by state for all years combined (2000-2009). Lastly, we took the average of the mean annual 
ranks across the four drugs. The results, where higher ranks are undesirable, are presented 
graphically in Figure 24. Table 11 also reports the specific mean rank scores, with color coded 
cells indicating the bottom (red) and top (green) ten ranked states. Overall, nine states had a 
mean annual index rank above 30, which was generally consistent with the state appearing 
among the ten most affected jurisdictions in at least two domains. Only Illinois was ranked in the 
most serious quintile in all three domains. Conversely, six states had a mean annual rank below 
20, which generally corresponded to a state being among the least affected jurisdictions in at 
least two domains. Three states—Nebraska, South Dakota, and Wyoming—were ranked among 
the least affected in all three categories. Notably, several states—New Hampshire, Arizona, 
Tennessee, and Wisconsin—ranked among the top ten in one domain but the bottom ten in 
another. Regionally, the north central U.S. was least likely to experience severe effects from 
multiple illegal drugs, and this finding remained consistent across consequence domains.  
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Table 11. Mean Annual Ranks Across State DCIs and Domains, 2000-2009 Combined 
State State DCIs Health Social & Economic Crime & Disorder 
Nevada 37.63 38.16 44.03 23.98 
Illinois 34.19 34.73 35.30 31.41 
New Mexico 33.33 35.23 38.80 21.18 
New York 31.80 36.59 26.25 30.76 
Rhode Island 31.76 32.40 29.09 30.96 
Michigan 31.53 28.49 34.19 31.56 
Washington 31.10 35.15 28.03 31.06 
Missouri 30.41 35.58 34.35 28.23 
Kentucky 30.38 26.98 38.28 27.40 
Oregon 29.65 33.43 26.95 28.53 
Ohio 29.60 26.43 26.66 33.79 
Alabama 29.60 20.55 32.40 26.18 
Vermont 29.38 24.88 24.61 30.75 
California 29.20 27.03 38.53 24.45 
Maryland 28.68 37.09 20.39 26.03 
Montana 28.30 24.86 30.99 23.18 
New Hampshire 28.26 17.83 26.65 31.19 
Louisiana 28.04 25.45 32.03 27.61 
Hawaii 27.21 24.76 25.76 26.74 
Indiana 26.88 20.84 30.30 30.75 
Arizona 26.35 31.31 33.11 20.46 
Delaware 25.96 33.69 20.59 26.26 
Idaho 25.80 25.69 24.98 22.45 
Florida 25.65 30.03 23.86 26.05 
West Virginia 25.61 20.04 28.30 29.79 
Pennsylvania 25.58 18.80 24.76 29.18 
Connecticut 25.30 25.85 24.78 26.10 
Tennessee 25.29 21.23 32.61 20.95 
Utah 25.09 30.43 28.85 19.85 
Maine 24.84 18.74 20.09 28.88 
Alaska 24.41 19.59 13.70 30.39 
Oklahoma 23.38 30.60 25.99 20.34 
Massachusetts 23.29 25.26 22.26 26.34 
Kansas 23.26 25.98 30.33 21.15 
Texas 23.08 24.69 24.40 25.39 
Georgia 22.99 21.66 25.65 23.60 
North Carolina 22.64 21.33 25.64 18.65 
Wisconsin 22.29 14.95 15.05 30.74 
South Carolina 22.24 23.81 17.21 25.74 
Colorado 22.03 30.91 20.40 22.83 
Arkansas 21.04 17.00 27.60 22.15 
Minnesota 20.86 26.18 19.90 23.39 
New Jersey 20.74 20.01 18.76 25.61 
Virginia 20.38 22.63 15.59 23.79 
Iowa 19.73 22.46 18.64 23.23 
Mississippi 19.01 15.13 13.59 25.43 
North Dakota 18.76 20.56 16.24 17.53 
Wyoming 16.93 19.95 18.56 16.46 
South Dakota 13.01 19.41 7.56 20.00 
Nebraska 12.60 10.70 12.45 16.60 
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V. SUMMARY AND DISCUSSION 
 The family of U.S. Drug Consequences Indices (DCIs) offers a parsimonious means to 
measure drug-related consequences over time and across states. The National DCI was 
constructed from 30 indicators measuring the health, social and economic, and crime and 
disorder consequences of illegal drugs. The findings revealed that drug-related consequences, as 
measured by the index, increased from 2000 through the middle part of the decade, reaching 
peak levels in 2002-2004, before returning to benchmark levels by 2008. Various underlying 
factors, often moving in opposite directions, drove these trends. Social and Economic 
consequences, for instance, increased dramatically through the early 2000s before declining to 
near-benchmark levels by decade’s end. Health consequences, on the other hand, rose steadily 
from 2002 to 2006 before leveling off about 25% above baseline. Conversely, Crime and 
Disorder consequences decreased steadily throughout the decade, reaching a point 27% below 
the benchmark year as of 2009. 
 A series of drug-specific National DCIs was also constructed using the State DCIs as a 
starting point. These results showed the divergent national trends in drug-related consequences 
by drug type. According to the National Heroin Index, for instance, heroin consequences 
increased steadily over the decade, reaching 39% above baseline by 2009. In contrast, both 
methamphetamine and cocaine consequences increased through the middle part of the decade 
before declining back toward baseline levels. In particular, the National Methamphetamine Index 
increased 37% through 2005, declining to a point that remained 10% above baseline by 2009. 
The National Cocaine Index, in contrast, began to increase later and less sharply, peaking at 10% 
above baseline in 2006, before returning to a point 10% below baseline in 2009. Finally, the 
National Marijuana Index showed an overall flat trend across the decade.  
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 The drug-specific State DCIs, which were based on 13 to 16 indicators each, showed 
interstate variations and trends in drug-related consequences for the four major drugs of abuse 
from 2000-2009. One of the main conclusions to be drawn from this series of analyses is that 
illegal drugs and their associated consequences are highly regionalized in the U.S. According to 
the State Heroin Index, the most severe heroin problems are largely concentrated in the 
northeast, with additional pockets in the midwest and west. The State Methamphetamine Index 
showed that methamphetamine is a primary problem for the western United States, especially 
Hawaii and other Pacific states, but it also revealed that states well into the U.S. heartland suffer 
serious consequences from methamphetamine. The State Cocaine Index revealed that states 
along the Gulf and East Coasts, and Illinois in the midwest, experience the greatest cocaine-
related consequences. Finally, results from the State Marijuana Index showed that marijuana-
related consequences tend to be the most geographically dispersed.  
 The State DCIs also uncovered common trends across many states. For example, 45 
states experienced an increase in the State Heroin Index between 2000 and 2009. The trends in 
the State Methamphetamine Index showed that methamphetamine consequences increased 
substantially in the western half of the U.S. through mid-decade before declining toward baseline 
levels in 2009. Indeed, 34 states showed double-digit declining rates in the index between 2005 
and 2009. For cocaine, some states experienced steady increases and others steady declines 
through the early part of the decade. However, by 2006, trends in cocaine-related consequences 
had improved to the point that, between 2005 and 2009, 36 states experienced double-digit 
percent declines in the State Cocaine Index. Conversely, marijuana-related consequences were 
highly variable across states and years. Indeed, between 2000-2009, there was roughly a 60/40 
split, respectively, in the number of states registering increases versus declines in the State 
Marijuana Index. Lastly, overall drug-related consequences were examined at the state-level 
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using the mean annual state rank across the four drug-specific State DCIs. These results showed 
some stratification across the states, with north central U.S. ranking consistently better than other 
states with respect to the range and severity of drug-related problems. 
 The family of U.S. DCIs have many potential uses and applications. First, they provide a 
parsimonious yet comprehensive snapshot of trends and variations in drug-related consequences. 
From an administrative perspective, this can be useful for communicating with policymakers, 
practitioners, and the general public about drug policy needs, objectives, and progress. Further, 
the DCIs can support more sophisticated uses such as benchmarking, performance assessment, 
and related policy analytic work. In this role, the DCIs by themselves are not suited to supporting 
causal claims about policy effectiveness, but they can inform assessments of whether trends and 
interstate variations in drug-related problems are in accordance with the intended impact of a 
particular policy or set of policies. Relatedly, the DCIs provide relevant information on state and 
regional variations in the nature and extent of illicit drug problems, which can inform strategic 
thinking about policy objectives, resource allocation, and the prioritization of interventions and 
initiatives.  
 Another benefit of the DCIs is that they contribute to federal efforts to increase the utility 
of existing drug data systems, especially at the state or local level. For example, missing data in 
drug-related information systems often confounds the ability of interested stakeholders to 
compare states on outcome and performance indicators. By generating defensible estimates of 
missing data within a multiple imputation framework, this project was able to utilize key 
information systems that would not have been feasible otherwise. The DCIs employed a 
conceptually coherent approach to guide measurement of drug-related consequences, keying on a 
number of relevant dimensions across health, social and economic, and crime and disorder 
domains. In this respect, the DCIs and their underlying data can facilitate assessments regarding 
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which dimensions are a state’s strongest assets, and which are in need of improvement. They can 
also inform future data collection efforts by identifying current data gaps in the measurement of 
drug-related consequences. For example, this research showed that there are few drug-specific, 
state-level indicators of drug consequences in the area of ‘family disruption and child 
maltreatment.’ Future data collection efforts might therefore focus on the development of 
indicators at this level of measurement, possibly in connection with existing data systems such as 
NCANDS and PRAMS. 
 Despite the utility of the DCIs, they have a number of limitations. First, the indices can 
only be as valid and reliable as their underlying indicators. We have attempted to address these 
concerns to the extent possible by employing both a conceptual and a data quality framework for 
obtaining relevant and quality indicators. Some things could not be overcome, however, like the 
error introduced by imprecise measures of drug type in some data systems or delays in reporting. 
Also, the issue of weighting is particularly sensitive and subjective when constructing composite 
indicators. There is no clear consensus among experts on composite index construction as to how 
to best determine a set of weights for combining diverse issues, such as those related to drug 
consequences. We assigned unequal weights based on expert opinion at the level of the 
subdomain and domain in order to create the DCIs. These weights represent one approach. As 
explained in the technical appendices, we have attempted to address some of these concerns by 
conducting various robustness analyses of these assumptions. The results of these analyses lend 
confidence to the weights ultimately used for the final analyses.  
 In focusing on select illegal drugs, the DCIs also do not address other substances, such as 
tobacco, alcohol, or prescription drugs. This is an important delimitation. Whereas certain states 
may experience relatively less serious consequences for the illegal drugs examined in this report, 
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they may suffer from relatively more serious alcohol-related problems or confront emerging drug 
threats that are not captured by the DCIs (McAuliffe et al., 2003).  
 There are a number of possible future directions for the research begun here. First, and 
foremost, the DCIs can be updated on a regular basis as new data is released. Indeed, one of the 
primary objectives for this project was to set up an ongoing monitoring system that could track 
trends in drug-related consequences over time. There is also opportunity for constructing similar 
indices involving other substances, including other illegal drugs, tobacco, alcohol, and 
prescription drugs. It would also be fruitful to construct comparative indices at the substate level 
(e.g., counties, cities, zip codes) in order to provide more localized assessments of drug policy 
and related outcomes. Finally, research on index construction concerning inputs on the policy 
side would be a logical extension to the current work. Some research of this type has already 
been undertaken at the international level in the alcohol field (Brand et al., 2007; Paschall, 
Grube, and Kypri, 2009), whereby an index was developed to measure the strength of national 
alcohol control policies in order to assess how these policies related to key outcomes such as 
heavy drinking and youth initiation. In summary, the DCIs developed out of this project sought 
to measure drug-related consequences in a parsimonious yet comprehensive manner, with the 
ultimate objective of providing a useful set of communicative and policy analytic tools. 
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APPENDIX A: TAXONOMY OF DRUG-RELATED CONSEQUENCES 
 
 This appendix provides a detailed outline of the taxonomy of drug-related consequences 
developed for this project. The taxonomy is meant to be conceptually complete, but does not 
purport to be exhaustive of all possible drug-related consequences.  
 
Table A-1. Detailed Taxonomy of Drug-Related Consequences 
I. Health Consequences 
A. Mortality 
1. Overdose 
2. Drug-Related Disease 
a) HIV/AIDS 
b) Cancer 
c) Organ Failure 
3. Drug-Related Trauma 
a) Accidents 
b) Suicide 
B. Morbidity 
1. Drug-Related Injury 
a) Poisoning/Nonfatal Overdose 
b) Accidents 
c) Intentional Self-Harm/Attempted Suicide 
2. Drug-Related Physical Illness and Disease 
a) Organ Damage 
b) Poor Oral Health 
c) Infectious Disease 
(1) HIV 
(2) Tuberculosis 
(3) Hepatitis 
(4) Syphilis 
d) Other Physical Illness and Disease 
(1) Soft Tissue Infection 
3. Drug-Related Mental and Psychological Impairment 
a) Personality/Anxiety/Mood Disorders 
b) Psychosis and Dementia 
c) Other Mental Dysfunction 
4. Drug Use Disorders 
a) Abuse 
b) Dependence 
C. Drug-Exposed Infants 
1. Miscarriage and Obstetrical Complications 
2. Birth Defects  
3. Infant Health 
a) Low Birth Weight 
b) HIV Exposure 
c) Neonatal Abstinence Syndrome 
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d) Sudden Infant Death Syndrome 
4. Developmental Delays and Cognitive Deficits 
II. Social and Economic Consequences 
A. Family Disruption and Child Maltreatment 
1. Family Dysfunction 
a) Domestic Violence 
b) Divorce/Separation 
c) Child Removal from Home  
(1) Child Welfare Services 
(2) Foster Care 
(3) Loss of Parental Rights 
d) Strained Parent-Child Relations 
2. Child Abuse and Neglect  
a) Drug-Exposed Children 
(1) Accidental Ingestion 
(2) Passive Exposure 
b) Neglect 
(1) Failure to Provide Basic Needs 
(2) Failure to Supervise 
c) Physical Abuse 
d) Sexual Abuse 
e) Emotional Abuse 
B. Reduced Attainment and Productivity 
1. Poor Educational Outcomes 
a) Low Academic Performance 
b) Disrupted Learning Environments 
c) School Drop-Outs 
2. Reduced Economic Well-Being 
a) Lower Wages and Lifetime Earnings 
b) Diverted Income 
c) Unemployment 
3. Lost Productivity 
a) Workforce Reduction 
b) Sickness and Absenteeism 
c) Unsafe and Risky Workplace Environments 
C. Stigmatization and Marginalization 
1. Drug-Using Lifestyles 
a) IV Drug Use  
2. Loss of Relationships 
a) Rejection by Friends and Family 
3. Social Alienation 
a) Shame and Discrimination 
b) Reduced Access to Healthcare, Prenatal Care, and Treatment 
c) Blocked Avenues for Material Success 
4. Homelessness 
5. Impoverishment 
III. Crime and Disorder Consequences 
A. Drugged Driving 
1. Accidents 
2. Property Damage 
3. Reduced Road Safety 
B. Crime and Nuisance 
1. Drug-Related Crime 
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a) Psychopharmacological Crime 
(1) Aggression and Violence 
(2) Sexual Assault 
b) Economic-Compulsive Crime 
(1) Theft for Money to Buy Drugs 
(2) Trading Sex for Drugs 
c) Systemic Crime 
(1) Territorial Disputes 
(2) Gun Violence 
d) Money Laundering and Corruption 
2. Public Nuisance 
a) Drug Market Visibility 
(1) Open Air Dealing 
(2) Annexation of Public Space/Lands 
b) Fear of Crime 
(1) Verbal Accosting 
(2) Aggressive Panhandling 
c) Graffiti 
d) Drug Litter 
(1) Used Needles 
(2) Vials 
C. Community and Environmental Harms 
1. Community Deterioration 
a) Diminished Social Cohesion and Collective Efficacy 
b) Blight and Decay 
c) Devalued Housing Stock 
(1) House Fires and Explosions from Illicit Manufacturing 
(2) Mold and Chemical Residue from Grow Operations 
(3) Reduced Insurability 
2. Environmental Degradation 
a) Dumping of Hazardous Byproducts 
b) Trashing and Deforestation of Public Lands  
c) Watershed Diversion 
d) Contamination of Public Water Systems 
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APPENDIX B: INVENTORY OF DRUG DATA SYSTEMS 
 
 The following table alphabetically lists more than 120 ongoing or recent drug data systems, with information on geographic 
coverage, years of availability, and whether drug-specific data are collected. In general, data sources that are outdated, superseded, or 
one-time collections are not included here, although data systems that share a common purpose and lineage are listed together. 
Geographic coverage indicates whether the data are aggregated at the national, state, and/or local (e.g., county, metropolitan area, zip 
code) levels. Note that geographic indications are not confirmation of representativeness or completeness of coverage at a particular 
level of analysis. Years of availability indicates the time period for which data are available, or known to have been collected if not yet 
released. A plus (+) sign indicates that the data collection is ongoing or has planned future installments. Drug type information 
indicates whether or not drug-specific data are reported. Finally, an asterisk indicates that the data system was used to develop one or 
more of the DCIs. 
 
Table B-1. Inventory of Drug Data Systems 
Data System Sponsor Description Geographic 
Coverage 
Years of 
Availability 
Drug Type 
Information 
Adoption and Foster Care Analysis 
and Reporting System*  
ACF 
NDACAN 
Collects data from state agencies on adoptive 
and foster care children, including caretaker or 
child drug abuse as reasons for removal. 
National, State 1995-2010+ 
(fiscal years) 
No 
Adverse Events Reporting System FDA Collects surveillance reports of adverse drug 
events, including death, disability, and 
hospitalization. 
National 1969-2011+ Yes (pharma-
ceuticals) 
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Data System Sponsor Description Geographic 
Coverage 
Years of 
Availability 
Drug Type 
Information 
Alcohol and Drug Services Study  /  
Services Research Outcome Study  / 
Drug Services Research Survey  
SAMHSA Collects data on substance abuse treatment 
facilities and clients, including client drug use, 
treatment history, and length of stay. 
National 1996-1999 
1995-1996 
1990 
Yes 
Annual Parole Survey /  
Uniform Parole Reports 
BJS Collects data from local parole agencies on 
flows and counts of those under supervision, 
including the number of drug offenders. 
National, State 1980-2010+ 
1975-1979 
No 
Annual Probation Survey / 
National Probation Reports 
BJS Collects data from local probation agencies on 
flows and counts of those under supervision, 
including the number of drug offenders. 
National, State 1980-2010+ 
1977-1979 
No 
Annual Survey of Jails / Annual 
Survey of Jails in Indian Country / 
Census of Jail Facilities / Census of 
Jail Inmates 
BJS Family of data systems that collect 
administrative data from local jails, including 
information on alcohol/drug abuse 
programming.  
National, State 
(census only) 
1970-2010+ 
(select years) 
No 
Arrestee Drug Abuse Monitoring 
Program II / 
Arrestee Drug Abuse Monitoring 
Program /  
Drug Use Forecasting Program 
ONDCP 
 
NIJ 
 
NIJ 
Collects data on recent arrestees, including drug 
use (urinalysis, self-report) and drug market 
characteristics.  
Local 2007-2010+ 
 
1998-2003 
 
1987-1997 
Yes 
Automation of Reports and 
Consolidated Orders System 
DEA Monitors the flow of controlled substances from 
manufacture through commercial distribution to 
final point of sale or retail dispensation. 
National, 
State, Local 
1970s-2011+ Yes (select 
controlled 
substances) 
Behavior Risk Factor Surveillance 
System 
CDC Survey of general population that collects data 
on health conditions and risk behaviors, 
including measures of drug abuse counseling 
and childhood exposure to drug use (select 
years). 
National, State 1984-2010+ No 
Buprenorphine Physician and 
Treatment Program Locator / 
Opioid Treatment Program Directory 
CSAT 
SAMHSA 
Inventory of physicians/programs authorized to 
treat opioid addiction with pharmacotherapies. 
National, 
State, Local 
List updated 
regularly 
Opioids, 
Buprenorphine 
Campus Safety and Security 
Statistics* 
OPE Collects campus crime statistics from 
postsecondary institutions, including data on the 
number of campus drug violations and arrests. 
National, State  2001-2010+ No 
Cannabis Potency Monitoring 
Project* 
NIDA Collects and analyzes data from seized 
marijuana samples, including information on 
marijuana type (e.g., sinsemilla, hash), form 
(e.g., kilobricks, buds), and potency. 
National, 
State, Local 
1967-2011+ Marijuana 
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Data System Sponsor Description Geographic 
Coverage 
Years of 
Availability 
Drug Type 
Information 
Census of Fatal Occupation Injuries BLS Compiles information on all U.S work-related 
fatal injuries, including evidence from 
toxicology reports. 
National, 
State, Local 
1992-2010+ Yes 
(toxicology 
reports, U.S.-
level only) 
Census of Juveniles in Residential 
Placement / 
Children in Custody Census 
OJJDP Collects information on youth residing in 
detention, correctional, and other shelter 
facilities, including the number housed for drug 
law violations. 
National, State 1997-2010+ 
(select years) 
1971-1996 
(select years) 
No 
Census of Law Enforcement Aviation 
Units 
BJS Provides operational details of law enforcement 
agencies that fly aircraft, including participation 
in drug location/interdiction operations. 
National  2007+ No 
Census of Publicly Funded Forensic 
Crime Laboratories 
BJS Collects data on staff and operations of forensic 
labs, including controlled substances and 
toxicological analyses. 
National 2005+ No 
Census of State and Federal Adult 
Correctional Facilities 
BJS Provides information on the types of inmates 
housed, facility, staff, and programs, including 
alcohol/drug abuse programs. 
National, State 1974-2005+ 
(select years) 
No 
Census of State and Local Law 
Enforcement Agencies 
BJS Provides data on state and local law enforcement 
agency personnel and functions, including task 
force participation in drug trafficking 
enforcement.  
National, 
State, Local 
1992-2008+ 
(every 4 years) 
No 
Census of State Court Organization BJS Provides detailed information on the structure 
and framework of state courts, including the 
number of state drug courts. 
National, State 1980-2004+ 
(select years) 
No 
Community Epidemiology Work 
Group 
NIDA Collects, triangulates, and reports local drug-
related data from multiple sources. 
Local 1976-2011+ Yes 
Core Alcohol and Drug Use Survey Core 
Institute 
Collects data on college student drinking, drug 
use, and risky behaviors. 
National 1989-2009+ Yes 
Domestic Cannabis Eradication and 
Suppression Program* 
DEA Collects data on marijuana eradication 
operations, including number of plants seized, 
plots eradicated, and weapons seized 
National, State 1979-2010+ Marijuana 
Drug Abuse Treatment Outcome 
Study / 
Treatment Outcome Prospective 
Study / 
Drug Abuse Reporting Program 
NIDA Series of national evaluations that collect 
treatment process and outcome data, including 
information on client attributes and program 
services. 
Local 1991-1993 
 
1979-1981 
 
1969-1973 
Yes 
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Data System Sponsor Description Geographic 
Coverage 
Years of 
Availability 
Drug Type 
Information 
Drug Abuse Warning Network* 
  
SAMHSA Monitors drug-related hospital emergency 
department visits and drug-related deaths 
investigated by medical examiners and coroners. 
National, 
Local 
1973-2010+ Yes 
Ecstasy Data Testing Project Dancesafe 
Erowid 
MAPS 
Collects ecstasy pill testing results from a 
variety of organizations. 
National, 
State, Local 
1996-2012+ MDMA 
Fatality Analysis Reporting System* NHTSA Collects data on fatal vehicle crashes, including 
police reported drug involvement and 
toxicological results. 
National, State 1975-2010+ Yes 
(toxicology 
reports) 
Federal Justice Statistics Program BJS Collects data on federal arrests, prosecutions, 
convictions, and sentences by offense type. 
National, State 1979-2009+ Yes (offense 
codes) 
Firearms Trace Data ATF Collects data on federal firearm traces, including 
drug-related firearm traces.  
National, State 2006-2010+ No 
General Estimates System* NHTSA Compiles data from national sample of fatal and 
nonfatal vehicle crashes, including information 
on drug-related vehicle crash accidents. 
National  1988-2010+ No 
Health Behavior in School-Aged 
Children 
NICHD International survey of youth that collects data 
on health behavior and risks, including drug use. 
National  1983-2010+ 
(select years, 
U.S. since 
1997) 
Yes (limited) 
Healthcare Cost and Utilization 
Project: 
Nationwide Inpatient Sample* / 
State Inpatient Databases* / 
Nationwide Emergency Department 
Sample / 
State Emergency Department 
Databases 
AHRQ Family of databases that collect data on hospital 
admissions, including admissions for drug-
related health consequences.  
 
National 
State 
National 
 
State 
 
1988-2009+ 
1990-2010+ 
2006-2009+ 
 
1999-2010+ 
Yes (ICD-9-
CM codes) 
Heroin Signature Program /  
Domestic Monitor Program 
DEA Collects data on heroin seizures and undercover 
buys, including the geographic source, price, 
and purity.  
Local 1977-2011+ 
1979-2011+ 
Heroin 
HIV Surveillance Reports* CDC Collects data from state health authorities on 
HIV/AIDS outcomes, including IDU-related 
AIDS diagnoses and deaths.  
National, 
State, Local 
1983-2009+ No 
Inventory of Substance Abuse 
Treatment Services / 
National Master Facility Inventory 
SAMHSA Provides comprehensive inventory of all U.S. 
substance abuse treatment facilities. 
National, 
State, Local 
Updated 
regularly 
No 
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Data System Sponsor Description Geographic 
Coverage 
Years of 
Availability 
Drug Type 
Information 
Juvenile Court Statistics OJJDP Collects data on cases handled by juvenile 
courts, including drug law violations. 
National 1985-2008+ No 
Law Enforcement and Investigations 
Management Attainment Reporting 
System 
Forest 
Service 
Internal reporting system for crimes committed 
on Forest Service lands, including marijuana 
cultivation and methamphetamine lab 
operations. 
National, GIS 
coordinates 
2000s-2011+ Marijuana, 
meth-
amphetamine 
Law Enforcement Management and 
Administrative Statistics 
BJS Collects data on law enforcement agency 
staffing, functions, and services, including 
employee drug testing, drug enforcement 
activities, and drug education units.  
National, 
State, Local 
1987-2007+ 
(select years) 
No 
Law Enforcement Survey for Line 
Officers 
Forest 
Service 
Collected information on services, operations, 
and perceptions of Forest Service officers, 
including trends in marijuana cultivation and 
methamphetamine lab activity in national 
forests. 
National 2006 Marijuana, 
meth-
amphetamine 
Monitoring of Federal Criminal 
Sentences 
USSC Collects data on federal criminal sentences, 
including drug offense incident characteristics. 
National, State 1987-2010+ Yes 
Monitoring the Future* NIDA Collects data from students and young adults on 
drug use, risks, and attitudes. 
National 1975-2011+ Yes 
Narcotics-Related Financial Crimes 
Program 
IRS Collects data on investigations, prosecutions, 
and sentences involving drug-related financial 
crimes. 
National 1995-2010+ No 
National Ambulatory Medical Care 
Survey 
NCHS Collects data from office-based physicians 
providing direct patient care, including treatment 
for drug-related health consequences. 
National 1973-1981, 
1985, 1989-
2009+ 
Yes (ICD-9-
CM codes) 
National Child Abuse and Neglect 
Data System 
ACF 
NDACAN 
Collects data from participating states on 
children coming into contact with state child 
protective services or individual reporters, 
including contact due to  caretaker or child drug 
abuse.  
State 2000-2010+ No 
National College Health Assessment ACHA Collects data from college students on health-
related behaviors, including drug use. 
National 
 
2000-2011+ Yes 
National Corrections Reporting 
Program 
BJS Collects administrative data on prison 
admissions and releases and parole entries and 
discharges in participating jurisdictions, 
including offense type information. 
State 1983-2009+ Yes (offense 
codes) 
National Crime Victimization Survey* BJS Collects household-based data on criminal 
victimization, including drug-related incidents. 
National 1973-2009+ No 
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Data System Sponsor Description Geographic 
Coverage 
Years of 
Availability 
Drug Type 
Information 
National Crime Victimization Survey: 
School Crime Supplement 
BJS Collects data on student experiences with crime, 
including the availability of drugs in school.  
National  1989, 1995, 
1999-2009+ 
(odd years) 
Yes 
National Criminal Justice Treatment 
Practices Survey 
NIDA Collected data from public safety agencies, 
treatment and corrections administrators and line 
staff on substance abuse treatment practices for 
offenders.  
National 2002/08 No 
National Drug Threat Survey* NDIC Collects data from local law enforcement 
agencies on drug availability, drug threats, gang 
involvement in drug distribution, and illicit 
manufacturing and production in community. 
National, State 2003-2011 Yes 
National Epidemiologic Survey on 
Alcohol and Related Conditions 
NIAAA Collects general population data on alcohol use 
disorders and associated disabilities, including 
information on drug use and dependence. 
National 2001/02, 
2004/05 
Yes 
National Forensic Laboratory 
Information System  
DEA Collects data from forensic labs on the analysis 
of drugs seized by law enforcement agencies.  
National, 
State, Local 
1997-2011+ Yes 
National Health and Nutrition Exam 
Survey III 
NCHS Collects national data on the health status of 
individuals, including information on drug use, 
age of onset, frequency of use, and IV drug use. 
National, State 1999-2010+ Yes 
National Hospital Care Survey / 
National Hospital Ambulatory 
Medical Care Survey / 
National Hospital Discharge Survey 
NCHS Collects data on health care delivery in hospital-
based settings and freestanding ambulatory 
surgery centers, including information drug-
related health consequences. Combines the two 
surveys from earlier years. 
National 2011+ 
1992-2010 
 
1965-2010 
Yes (ICD-9-
CM codes) 
National Incident-Based Reporting 
System 
FBI Collects data from participating jurisdictions on 
crimes known to police, including drug crime 
characteristics. 
State, Local 1991-2009+ Yes 
National Incidence Study of Child 
Abuse and Neglect 
ACF Collects data from community professionals on 
incidents of child maltreatment, including 
caretaker/child drug use and drug-affected 
newborns. 
National 1979/80, 
1986/87, 1993, 
2005/6 
No 
National Judicial Reporting Program BJS Collects felony sentencing data from national 
sample of state courts, including information on 
conviction offense and the type and length of 
sentence. 
National  1986-2006+ 
(biennially) 
Yes (limited) 
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Data System Sponsor Description Geographic 
Coverage 
Years of 
Availability 
Drug Type 
Information 
National Longitudinal Survey of 
Youth 1997 /  
National Longitudinal Survey of 
Youth 1979 / 
NLSY79 Children and Young Adult 
Surveys 
BLS Collect data on labor market activities and other 
significant life events from panel of respondents, 
including information on drug use, age of onset, 
use at work/school, use during pregnancy, and 
drug selling involvement. 
National, 
State, Local 
(with geocode 
supplement) 
1997-2008+ 
 
1979-2008+ 
 
1988-2006+ 
Yes (limited 
for NLSY97) 
National Motor Vehicle Crash 
Causation Survey 
NHTSA Collects data on events and factors leading up to 
vehicle crashes, including measures on police 
reported drug involvement, recent medication 
use, and drugs taken. 
National  2005/07+ Yes 
National Poison Data System* / 
Toxic Exposure Surveillance System 
AAPCC Data system contains information and human 
poison exposure case phone calls into all U.S. 
poison centers. Data also contain fatality 
abstracts from human exposure events.  
National, 
State, Local 
1983-2010+ 
 
Yes 
National Pregnancy and Health 
Survey 
NIDA Collected national data on nature and extent of 
substance abuse among pregnant women in 
U.S., including self-report and urinalysis of drug 
use. 
Coterminous 
U.S. 
1992 Yes 
National Roadside Survey  NHSTA Collects data from drivers on alcohol- and drug-
involved driving, including self-reports of the 
type and recency of drug use and drug testing 
results (2007 survey). 
Coterminous 
U.S. 
1973, 1986, 
1996, 2007 
Yes 
National Seizure System* / 
Federal-Wide Drug Seizure System / 
Clandestine Laboratory Seizure 
System 
DEA 
EPIC 
Compiles data from various law enforcement 
agencies on drug seizures, trafficking routes, and 
children affected by labs. 
National, State 1970s-2011+ Yes 
National Survey of American 
Attitudes on Substance Abuse  
CASA Collects data from teenagers and parents on the 
use, availability, and risks of drugs. 
National 1995-2011+ Yes (limited) 
National Survey of Homeless 
Assistance Providers and Clients 
HUD Collected data from homeless clients and service 
providers, including information on drug use, 
onset, addiction severity, consequences, and 
treatment history. 
National 1996 Yes 
National Survey of Meth Markets NIDA Collected data from law enforcement agencies 
on the characteristics of the methamphetamine 
market, including public health and safety risks.  
National 2008 Meth-
amphetamine 
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Data System Sponsor Description Geographic 
Coverage 
Years of 
Availability 
Drug Type 
Information 
National Survey of Parents and Youth NIDA Collected data from national sample of youth (9-
18) and their parents concerning youth drug use, 
perceptions of use, availability, parent-child 
communication, antidrug media awareness, and 
drug prevention activities. 
National 1998-2004 Yes (limited) 
National Survey of Substance Abuse 
Treatment Services / 
Uniform Facility Data Set / 
National Drug and Alcoholism 
Treatment Unit Survey / 
National Alcoholism and Drug Abuse 
Program Inventory / 
National Drug and Alcoholism 
Treatment Utilization Survey /  
National Drug Abuse Treatment 
Utilization Survey 
SAMHSA  
NIAAA 
Census of substance abuse treatment facilities, 
providing data on location, organization, 
structure, services, and utilization, including 
measures on the type of pharmacotherapy and 
detox services provided. 
National, State 2000-2010+ 
 
1995-1998 
1987-1993 
(excl. ’88) 
1984 
 
1979-1982 
(excl. ’81) 
1976-1978 
 
Yes (for detox 
and pharmaco-
therapies) 
National Survey of Workplace Health 
and Safety 
NIAAA Collected data from nation sample of employed 
individuals (18-65), including information on 
workplace substance use norms and employee 
substance use. 
Coterminous 
U.S. 
2002/03 Yes  
 
National Survey of Youth in Custody BJS Collected data from youth in juvenile facilities 
as part of the BJS National Prison Rape 
Statistics Program. About 10% of the sample 
received an alternative survey on substance use 
and treatment.  
National 2008/09+ Yes 
National Survey on Drug Use and 
Health* (formerly National Household 
Survey on Drug Abuse) 
SAMHSA Collects data from U.S. population 12 and older 
on drug use, onset, consequences, and treatment.  
National, State 
(since 1999) 
1971-2010+ 
(select years, 
annual since 
1990) 
Yes 
National Toxic Substance Incidents 
Program / 
Hazardous Substances Emergency 
Events Surveillance 
ATSDR Collects data on spills and leaks of toxic 
substances from participating states, including 
information on incidents related to illicit drug 
production. 
National 
(under 
development), 
State 
2010+ 
 
1990-2009 
Meth-
amphetamine 
National Vital Statistics System—
Mortality Data* 
NCHS Compiles data from death certificates filed by 
the states with the National Vital Statistics 
System, including information on drug-related 
causes of death. 
National, State 1968-2008+ Yes (ICD-10 
codes for 1999 
and later) 
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Data System Sponsor Description Geographic 
Coverage 
Years of 
Availability 
Drug Type 
Information 
National Youth Survey Family Study / 
National Youth Survey 
HHS 
NIJ 
Collects information from sample of youth on 
life events, including information on drug use 
and consequences. 
National 2000-2006 
1976-1993  
Yes 
Online Tuberculosis Information 
System* 
CDC Collects information on TB cases reported to 
CDC from state and local health departments, 
including information on drug use (injection and 
noninjection).  
National, State 1987-2009+ No 
Partnership Attitude Tracking Study PDFA Collects information from students (grades 7-12) 
and parents on drug use and associated risks and 
attitudes, parent-child communication, antidrug 
media awareness, and drug prevention activities. 
National 1993-2010+ Yes 
Pregnancy Risk Assessment 
Monitoring System 
CDC Collects data from women in participating states 
who recently gave birth, including information 
on stressors (someone close has a drinking/drug 
problem) and healthcare provider interventions 
(discussing drug use fetal health).  
State 1988-2009+ No 
Pride Surveys ISA Collects data from students (grades 4-12), 
parents, and teachers on drug use, onset, risks, 
perceptions, availability, and prevention 
messages. 
National, 
State, Local 
1982-2010+ Yes 
Quest Diagnostics Drug Testing 
Index* 
Quest 
Diagnostics 
Collects and reports  data on positivity rates 
from workplace drug testing. 
National, 
State, Local 
1988-2011+ Yes 
School Survey on Crime and Safety OSDFS Collects crime and safety data from public 
elementary and secondary schools, including 
information in the use of drug-sniffing dogs, 
student drug testing, drug-free school initiatives, 
drug education, and drug-related incidents and 
disciplinary actions. 
National 2000, 2004-
2010+ (even 
years) 
No 
State Court Processing Statistics / 
National Pretrial Reporting Program 
BJS Collects data from sample of state court felony 
cases, including information on pretrial drug 
monitoring, drug court participation,  and 
offense type. 
National 1996-2006+ 
1988-1994 
No 
 
Survey of Adults on Probation BJS Collected data from probationers, including 
information on drug use, treatment history, 
supervision conditions (drug testing, drug 
treatment), current offense, and criminal history. 
National 1995 Yes 
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Data System Sponsor Description Geographic 
Coverage 
Years of 
Availability 
Drug Type 
Information 
Survey of Inmates in Federal and 
State Correctional Facilities 
BJS Collets data from state and federal (since 1991) 
inmates, including information on drug use, 
treatment history, drug offense incident 
characteristics, and criminal history. 
National 1974, 1979, 
1986, 1991, 
1997, 2004+ 
Yes 
Survey of Inmates in Local Jails BJS Collects data from jail inmates, including 
information on drug use, treatment history, 
current offense, and criminal history. 
National 1978, 1983, 
1989, 1996, 
2002+ 
Yes 
System to Retrieve Information from 
Drug Evidence 
DEA Compiles administrative and investigative data 
on drug purchases and seizures made by federal, 
state, and local agencies, including information 
on drug price, purity, and quantity. 
National, 
State, Local 
1971-2011+ Yes 
Theft or Loss of Controlled 
Substances 
DEA Collects data from surveillance program of  
incident characteristics and drug information 
following the theft or loss of controlled 
substances. 
National, 
State, Local 
1970s-2011+ Yes 
(prescription 
drugs) 
Treatment Episodes Data Set* /  
Client-Oriented Data Acquisition 
Process 
SAMHSA Collects data on substance abuse treatment 
admissions and client characteristics from 
publically funded treatment programs. 
National, State 1992-2011+ 
1973-1981 
Yes 
Uniform Crime Reports  FBI Compiles data from local law enforcement 
agencies on the volume and rate of criminal 
offenses, including information on the type of 
drug involved in arrest. 
National, 
State, Local 
1960-2011+ Yes (limited) 
Uniform Crime Reports—
Supplementary Homicide Report* 
FBI Collects data from local law enforcement 
agencies on homicide cases, including whether 
the homicide was drug-related. 
National, State 1980-2011+ No 
Worldwide Survey of Substance 
Abuse and Health Behaviors Among 
Military Personnel 
DOD Collects data from  military personnel on 
substance use and health, including information 
on the nature, extent, and consequences of drug 
use and abuse.  
 
National 1980, 1982, 
1988, 1992, 
1995, 1998, 
2002, 2005, 
2008+ 
Yes 
Youth Risk Behavior Survey* CDC Collects data from students on health-risk 
behaviors, including information on drug use 
and offerings of drugs on school property. 
National, 
State, Local 
1991-2011+ 
(odd years) 
Yes 
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APPENDIX C: INDICATOR DEFINITIONS, SOURCES, AND 
MEASUREMENT 
 
  This appendix defines and operationalizes the indicators used in the National and 
State DCIs, and provides source information. Unless otherwise indicated, rates are events per 
100,000 people in the general population. 11 Where applicable, missing data methods used to 
address item nonresponse are discussed. Indicator missingness for entire states and/or years is 
also noted, although missing data methods used to address this type of unit nonresponse are 
discussed in Appendix D of this report.  
 
NATIONAL DRUG CONSEQUENCES INDEX 
 The 30 indicators used to construct the National Index are described below; they are 
numbered [d1] to [d30] for easy reference.  
 
[d1] Drug-related deaths per 100,000 
Definition: Measures the number of U.S. resident deaths in which drug poisoning or a 
drug-related mental or behavioral disorder was listed as a contributing cause of death.  
Source: Multiple Cause of Death data for 1999-2009, CDC WONDER Online Database, 
National Center for Health Statistics, Centers for Disease Control and Prevention.  
Notes: Drug-related deaths include any mention of the following International 
Classification of Diseases, Version 10 (ICD-10) diagnostic codes: F11.0-F11.9 (Mental and 
behavioral disorders due to use of opioids), F12.0-F12.9 (Mental and behavioral disorders due to 
                                                 
11 Population data are drawn from U.S. Census Bureau, Population Division (September 2011), Intercensal 
Estimates of Resident Population by Five-Year Age Groups, Sex, Race and Hispanic Origin for States and the 
United States: April 1, 2000 to July 1, 2010 (ST-EST00INT-ALLDATA). 
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use of cannabinoids), F13.0-F13.9 (Mental and behavioral disorders due to use of sedatives or 
hypnotics), F14.0-F14.9 (Mental and behavioral disorders due to use of cocaine), F15.0-F15.9 
(Mental and behavioral disorders due to use of other stimulants), F16.0-F16.9 (Mental and 
behavioral disorders due to use of hallucinogens), F18.0-F18.9 (Mental and behavioral disorders 
due to use of volatile solvents), F19.0-F19.9 (Mental and behavioral disorders due to multiple 
drug use and use of other psychoactive substances), R78.1 (Finding of opiate drug in blood), 
R78.2 (Finding of cocaine in blood), R78.3 (Finding of hallucinogen in blood), R78.4 (Finding 
of other drugs of addictive potential in blood), T40.0 (Opium poisoning), T40.1 (Heroin 
poisoning), T40.2 (Other opioids poisoning), T40.3 (Methadone poisoning), T40.4 (Other 
synthetic narcotics poisoning), T40.5 (Cocaine poisoning), T40.6 (Other and unspecified 
narcotics poisoning), T40.7 (Cannabis poisoning), T40.8 (Lysergide [LSD] poisoning), T40.9 
(Other and unspecified psychodysleptics [hallucinogens] poisoning), T42.3 (Barbiturates 
poisoning), T42.4 (Benzodiazepines poisoning), and T43.6 (Psychostimulants with abuse 
potential poisoning).  
 
 [d2] IDU-related AIDS deaths per 100,000 
Definition: Measures the estimated number of all-cause deaths of persons with AIDS in 
which injection drug use was a risk factor for HIV transmission.  
Source: HIV Surveillance Reports, 2004-2010 (Annual), Division of HIV/AIDS 
Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers 
for Disease Control and Prevention.  
Notes: Because data for previous years is updated with each newly released report, the 
most current estimates were extracted from the following reports and tables: Vol. 16 (2005) 
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Table 7 for 2000; Vol. 17 (2007 Revised) Table 7 for 2001, Vol. 18 (2008) Table 7 for 2002; 
Vol. 19 (2009) Table 8 for 2003-2004; Vol. 20 (2010) Table 12a for 2005; Vol. 21 (2011) Table 
12a for 2006. Vol. 22 (2012) Table 12a for 2007-2009. CDC’s estimates statistically adjust for 
missing risk-factor information and jurisdiction reporting delays. 
  
[d3] Drug exposure poison center cases per 100,000 
Definition: Measures the number of human exposure cases called into poison control 
centers involving ‘stimulant and street drugs.’  
Source: 2000-2009 Annual Report of the American Association of Poison Control 
Centers’ National Poison Data System (NPDS), Table 22B, (Annual), American Association of 
Poison Control Centers.  
Notes: ‘Stimulant and street drugs’ is an AAPCC general reporting category that includes 
marijuana, cocaine, heroin, methamphetamine, GHB, MDMA, LSD, mescaline/peyote, PCP, and 
other illicit drugs. NPDS was formerly called the Toxic Exposure Surveillance System (TESS).  
 
[d4] Drug-related emergency department visits per 100,000 
Definition: Measures the number of hospital emergency department visits involving any 
mention of illicit drugs.  
Source: Drug Abuse Warning Network, 2009: Selected Tables of National Estimates of 
Drug-Related Emergency Department Visits. (2010). Rockville, MD: Center for Behavioral 
Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.  
Notes: Data coverage includes only years 2004-2009, as prior years are not directly 
comparable due to DAWN’s 2003 redesign. 
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[d5] Inpatient hospital drug poisoning discharges per 100,000 
Definition: Measures the number of inpatient hospital discharges with a principal 
diagnosis of drug poisoning.  
Source: HCUPnet, Healthcare Cost and Utilization Project, Nationwide Inpatient Sample, 
Agency for Healthcare Research and Quality.  
Notes: Definition includes the following International Classification of Diseases, Version 
9, Clinical Modification (ICD-9-CM) diagnostic codes: 965.00-965.09 (Poisoning by opiates and 
related narcotics), 967.0-967.9 (Poisoning by sedatives and hypnotics), 968.0-968.9 (Poisoning 
by other central nervous system depressants and anesthetics), 969.0-969.9 (Poisoning by 
psychotropic agents), 970.0-970.9 (Poisoning by central nervous system stimulants), E850 
(Accidental poisoning by analgesics, antipyretics, and antirheumatics), E851 (Accidental 
poisoning by barbiturates), E852 (Accidental poisoning by other sedatives and hypnotics), E853 
(Accidental poisoning by tranquilizers), E854 (Accidental poisoning by other psychotropic 
agents), and E855 (Accidental poisoning by other drugs acting on central and autonomic nervous 
system). 12   
 
[d6] Inpatient hospital drug use disorder discharges per 100,000 
Definition: Measures the number of inpatient hospital discharges with a principal drug-
related psychosis, dependence, or abuse diagnosis.  
 Source: HCUPnet, Healthcare Cost and Utilization Project, Nationwide Inpatient Sample, 
Agency for Healthcare Research and Quality. 
                                                 
12 For indicators [d5] and [d6], data were obtained from http://hcupnet.ahrq.gov/ using the following operational 
sequence: National Statistics on All Stays  Researcher, medical professional  Trends  Specific diagnoses by 
ICD-9-CM  Principal diagnosis  [Enter codes]  All codes combined  Next.  
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Notes: Definition includes the following International Classification of Diseases, Version 
9, Clinical Modification (ICD-9-CM) diagnostic codes: 292.0-292.9 (Drug-induced mental 
disorders), 304.0 (Opioid type dependence), 304.1 (Sedative, hypnotic or anxiolytic 
dependence), 304.2 (Cocaine dependence), 304.3 (Cannabis dependence), 304.4 (Amphetamine 
and other psychostimulant dependence), 304.5 (Hallucinogen dependence), 304.6 (Other 
specified drug dependence), 304.7 (Combinations of opioid type drug with any other), 304.8 
(Combinations of drug dependence excluding opioid type drug), 304.9 (Unspecified drug 
dependence), 305.2 (Cannabis abuse), 305.3 (Hallucinogen abuse), 305.4 (Sedative, hypnotic or 
anxiolytic abuse), 305.5 (Opioid abuse), 305.6 (Cocaine abuse), 305.70 (Amphetamine or related 
acting sympathomimetic abuse), 305.8 (Antidepressant type abuse), 305.9 (Other, mixed, or 
unspecified drug abuse).  
 
[d7] Drug treatment admissions per 100,000 
Definition: Measures the number of admissions to publicly funded treatment programs 
for a primary illicit drug use disorder.  
Source: Treatment Episode Data Set (TEDS), 1999-2009: National Admissions to 
Substance Abuse Treatment Services, Table 1.2. (2011). DASIS Series: S-56, HHS Publication 
No. (SMA) 11-4646, Rockville, MD: Substance Abuse and Mental Health Services 
Administration. 
 
[d8] Prevalence (%) of drug dependence or abuse among persons aged 12+ 
Definition: Measures the percentage of individuals aged 12 and older who met DSM-IV 
criteria for past-year illicit drug dependence or abuse.  
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Source: Results from the 2010 National Survey on Drug Use and Health: Detailed 
Tables, Table 7.40B. (2011). Rockville, MD: Center for Behavioral Health Statistics and Quality, 
Substance Abuse and Mental Health Services Administration.  
Notes: Data coverage includes 2002-2009, as methodological changes in the NSDUH 
design affect comparability with earlier years. 
 
[d9] IDU-related AIDS diagnoses per 100,000 
Definition: Measures the estimated number of annual AIDS diagnoses in which injection 
drug use was a risk factor for HIV transmission. 
Source: HIV Surveillance Reports, 2004-2010 (Annual), Division of HIV/AIDS 
Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers 
for Disease Control and Prevention.  
Notes: Because data for previous years is updated with each release, the most current 
estimates were extracted from the annual reports and tables as follows: Vol. 16 (2005) Table 3 
for 2000; Vol. 17 (2007 Revised) Table 3 for 2001, Vol. 18 (2008) Table 3 for 2002; Vol. 19 
(2009) Table 4 for 2003-2004; Vol. 20 (2010) Table 2a for 2005; Vol. 21 (2011) Table 2a for 
2006; Vol. 22 (2012) Table 2a for 2007-2009.  
 
[d10] Prevalence (%) of injection drug use among TB patients 
Definition: Measures the percentage of verified tuberculosis (TB) patients aged 15 and 
older who reported illegal injection drug use within 12 months of their diagnosis.  
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Source: Online Tuberculosis Information System, National Tuberculosis Surveillance 
System, United States, 1993-2009. (April 2011). CDC WONDER Online Database, Centers for 
Disease Control and Prevention. 
Notes: Prevalence calculations were based on valid (i.e., nonmissing) data.  
 
[d11] Prevalence (%) of noninjection drug use among TB patients 
Definition: Measures the percentage of verified tuberculosis (TB) patients aged 15 and 
older who reported illegal noninjection drug use within 12 months of their diagnosis.  
Source: Online Tuberculosis Information System, National Tuberculosis Surveillance 
System, United States, 1993-2009. (April 2011). CDC WONDER Online Database, Centers for 
Disease Control and Prevention. 
Notes: Prevalence calculations were based on valid (i.e., nonmissing) data.  
 
[d12] Prevalence (%) of illicit drug use among pregnant women aged 15-44 
Definition: Measures the percentage of pregnant women aged 15-44 who reported past-
month illicit drug use.  
Source: Results from the 2002-2009 National Survey on Drug Use and Health: Summary 
of National Findings. (Annual 2003-2010). Rockville, MD: Center for Behavioral Health 
Statistics and Quality, Substance Abuse and Mental Health Services Administration.  
Notes: Data coverage includes 2002-2009, as methodological changes in the NSDUH 
design affect comparability with earlier years.  
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[d13] Inpatient hospital discharges for drugs affecting baby per 100,000 women aged 15-44 
Definition: Measures the number of inpatient hospital discharges among women aged 15-
44 with a principal diagnosis of drug-related harm to a fetus or newborn.  
Source: HCUPnet, Healthcare Cost and Utilization Project, Nationwide Inpatient Sample, 
Agency for Healthcare Research and Quality. 
Notes: Definition includes the following International Classification of Diseases, Version 
9, Clinical Modification (ICD-9-CM) diagnostic codes: 648.3 (Drug dependence complicating 
pregnancy), 655.5 (Suspected damage to fetus from drugs), 760.72 (Narcotic affecting fetus or 
newborn via placenta or breast milk), 760.73 (Hallucinogen affecting fetus or newborn via 
placenta or breast milk), 760.75 (Cocaine affecting fetus or newborn via placenta or breast milk), 
779.5 (Drug withdrawal syndrome in newborn).   
 
[d14] Percentage of women aged 15-44 who were pregnant upon entering drug treatment 
Definition: Measures the percentage of women aged 15-44 who were pregnant upon 
admission to publicly funded treatment for a primary illicit drug use disorder.  
Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
Notes: Calculations are based on pregnancy data that was overall 90-96% complete for 
females in reporting states during 2000-2009.  
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[d15] Percentage of foster care placements precipitated by child drug abuse 
Definition: Measures the percentage of children in foster care in which child drug abuse 
(including addiction at birth) was reported as a contributing factor for the child’s out-of-home 
placement.  
Source: Adoption and Foster Care Analysis and Reporting System, Foster Care Files, 
2000-2009 [computer files]. Children’s Bureau, Administration on Children, Youth and 
Families. Ithaca, NY: National Data Archive on Child Abuse and Neglect [distributor]. 13  
Notes: The datasets are reported by federal fiscal year ending September 30th. Estimates 
are based on states with at least 75% reporting on this item, which excluded the following state-
years from the calculations: Alaska (2000-2004), Maryland (2007), New York (2000-2009). 
 
[d16] Percentage of foster care placements precipitated by caretaker drug abuse 
 Definition: Measures the percentage of children in foster care in which caretaker drug 
abuse was reported as a contributing factor for the child’s out-of-home placement.  
 Source: Adoption and Foster Care Analysis and Reporting System, Foster Care Files, 
2000-2009 [computer files]. Children’s Bureau, Administration on Children, Youth and 
Families. Ithaca, NY: National Data Archive on Child Abuse and Neglect [distributor].  
 Notes: The datasets are reported by federal fiscal year ending September 30th. Estimates 
are based on states with at least 75% reporting on this item, which excluded the following state-
years from the calculations: Alaska (2000-2004), Maryland (2007), New York (2000-2009). 
                                                 
13 AFCARS data used to create indicators [d15] and [d16] used in this report were made available by the National 
Data Archive on Child Abuse and Neglect, Cornell University, Ithaca, NY; and have been used by permission. Data 
from the 2000-2009 AFCARS Foster Care data sets (Nos. 97, 101, 105, 118, 124, 131, 137, 143, 149, and 153) were 
originally collected by the Children's Bureau, U.S> Department of Health and Human Services. Neither the collector 
of the original data, the funder, the Archive, Cornell University, or its agents or employees bear any responsibility 
for the analyses or interpretations presented here. 
 88 
 [d17] Children affected by illicit drug labs per 100,000 
 Definition: Measures the number of children affected, injured, or killed by a clandestine 
drug laboratory.  
Source: Unpublished data extract provided by the Office of National Drug Control Policy 
from the National Seizure System, El Paso Intelligence Center, Drug Enforcement 
Administration.  
 
[d18] Percentage of people who were unemployed upon entering drug treatment 
Definition: Measures the percentage of people who were unemployed upon admission to 
publicly funded treatment for a primary illicit drug use disorder.  
Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
Notes: Estimates are based on employment data that was overall 95-99% complete across 
all reporting states during 2000-2009. 
 
[d19] Drug positivity rate among the U.S. workforce 
Definition: Measures the proportion of positive drug test results relative to all drug tests 
performed among the combined U.S. workforce, which includes the general workforce and 
federally mandated, safety-sensitive workers. 
Source: Quest Diagnostics Drug Testing Index, Table 1. (September 2, 2011). Online: 
http://www.questdiagnostics.com/dms/Documents/DTI-Reports/2011-09-02_DTI.pdf.  
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[d20] Prevalence (%) of past-year illicit drug use among secondary school students 
Definition: Measures the annual prevalence of illicit drug use among students in grades 8, 
10, and 12 combined.  
Source: Johnston, L. D., O’Malley, P. M., Bachman, J. G., and Schulenberg, J. E. (2011). 
Monitoring the Future National Survey Results on Drug Use, 1975–2010: Volume I, Secondary 
School Students, Table F-2. Ann Arbor: Institute for Social Research, The University of 
Michigan. 
 
[d21] On-campus drug violations per 1,000 enrolled college students 
Definition: Measures the combined number of arrests and disciplinary infractions for 
drug-related violations committed on school property or in areas under school jurisdiction.  
Source: Campus Safety and Security Statistics, Data Analysis Cutting Tool, Office of 
Postsecondary Education. Online: http://ope.ed.gov/security/.  
Notes: Campus Safety and Security Statistics (CSSS) began collecting crime data in 
2001. Denominator data on fall enrollment at degree-granting institutions was obtained from the 
Integrated Postsecondary Education Data System (IPEDS), National Center for Education 
Statistics, U.S. Department of Education.  
 
[d22] Percentage of high school students offered drugs on school grounds 
Definition: Measures the percentage of high school students who reported being offered, 
sold, or given an illegal drug by someone on school property within the past year.  
Source: 2001-2009 High School Youth Risk Behavior Survey Data, Centers for Disease 
Control and Prevention. Online: http://apps.nccd.cdc.gov/youthonline.  
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Notes: Data are collected biennially in odd numbered years. 
 
[d23] Percentage of people who were homeless upon entering drug treatment 
Definition: Measures the percentage of people who were homeless upon admission to 
publicly funded treatment for a primary illicit drug use disorder.  
Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
Notes: Estimates are based on living arrangement data that was 68-95% complete across 
all reporting states during 2000-2009. 
 
[d24] Lifetime prevalence of drug injection among high school students 
Definition: Measures the percentage of high school students who reported ever using a 
needle to inject an illegal drug into their bodies.  
Source: 1991-2009 High School Youth Risk Behavior Survey Data, Centers for Disease 
Control and Prevention. Online: http://apps.nccd.cdc.gov/youthonline.  
Notes: Data are collected biennially in odd numbered years. 
 
[d25] Positive drug-tested drivers involved in fatal vehicle accidents per 100,000 
Definition: Measures the estimated number of drivers involved in fatal vehicle crashes 
who tested positive for illicit drugs (i.e., cannabinoids, heroin/opiates, cocaine, or amphetamines) 
or for whom there was police-reported drug involvement.  
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Source: 2000-2009 Analytic Files, Fatality Analysis Reporting System, National Center 
for Statistics and Analysis, National Highway Traffic Safety Administration.  
Notes: Because of high rates of missing data on drug-related variables, multiple 
imputation was used to estimate missing driver-level crash data. The imputation model used is 
analogous to NHTSA’s multiple imputation procedures for alcohol-related variables (Heitjan and 
Little, 1991; Rubin, Schafer, and Subramanian, 1998; Subramanian, 2002). First, the FARS 
accident, vehicle, and person level datafiles were merged; the merged file was then restricted to 
drivers to make a driver-level dataset (FARS also collects person-level information on 
passengers and pedestrians). Key variables were operationalized in the merged dataset, 14 and 
multiple imputation was then performed using Stata 11 to create ten imputed datasets. 15 Finally, 
the number of drugged drivers involved in fatal vehicle accidents—defined as drivers who tested 
positive for cannabinoids, heroin/opiates, cocaine, or amphetamines, or for whom there was 
police-reported drug involvement—was estimated from the ten imputed datasets using Rubin’s 
rules for combining estimates (Royston, Carlin, and White, 2009).  
 
                                                 
14 Variables included age, gender, restraint use (yes, no), driver fatality (yes, no), valid license (yes, no), nighttime 
(yes, no), weekend (yes, no), setting (rural, urban), roadway (on, off), prior moving violations (none, one, multiple), 
vehicle role (non-collision, struck, striking), vehicle class (passenger car, light truck/van, motorcycle, other), 
cannabis positive (yes, no), heroin/opiate positive (yes, no), cocaine positive (yes, no), amphetamine positive (yes, 
no), police-reported drug involvement (yes, no), police-reported alcohol involvement (yes, no), alcohol BAC, 
NHTSA region, and mandatory testing state  (yes, no). The latter variable was constructed based on states that 
“permit the forced taking of a specimen for a chemical test over the objection of a driver” (Walsh, 2009:5).  
 
The FARS drug codes used to construct the drug testing variables were as follows: marijuana (600/695), 
heroin/opiates (101/104 106/110 115 117/123 126 127 129/135 137/141 143 145 146 148/150 153 154 156 158 
160/162 168/171 174/178 180/186 190 195 196 199/202 204/207 210 213 215/217 220 221 223 225 230 231 
236/238), cocaine (402 407 410 430), and amphetamines (401 417).  
 
15 The Stata imputation command was as follows: mi ice aged male restrnt fatal lstat tod weekend 
area roadway o.nviol m.vehrole m.class marpos herpos cocpos mthpos druginv alcinv 
alcbac i.region forcspec, add(10) seed(2011) match(aged alcbac) cycles(10). 
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[d26] Positive drug-tested drivers involved in police-reported crashes per 100,000 
Definition: Measures the number of drivers with police-reported drug involvement who 
were involved in a vehicle accident resulting in fatality, injury, or property damage.  
Source: 2000-2009 Analytic Files, General Estimates System, National Center for 
Statistics and Analysis, National Highway Traffic Safety Administration.  
Notes: GES collects accident data from a nationally representative sample of police-
reported motor vehicle crashes resulting in fatality, injury, or property damage. Because of high 
rates of missing data on drug-related variables, multiple imputation was used to estimate missing 
driver-level crash data. A similar multiple imputation procedure that used for FARS was also 
employed for GES 16 (see [d25]). However, there were some key differences. First, since GES is 
based on a probability sample, the sampling design was accounted for in the imputation and 
estimation procedure. Second, policy variables were not included because there are no state 
identifiers in the GES. Third, drug testing results were not used since GES only began collecting 
this information in 2009. 
 
[d27] Prevalence of self-reported drugged driving among persons aged 16+ 
Definition: Measures the percentage of individuals aged 16 and older who reported 
driving under the influence of illicit drugs in the past year.  
                                                 
16 The GES imputation model included variables for age, gender, restraint use (yes, no), serious driver injury (yes, 
no), valid license (yes, no), nighttime (yes, no), weekend (yes, no), roadway (on, off), vehicle role (non-collision, 
struck, striking), speed factor (yes, no), hazardous road conditions (yes, no), vehicle class (passenger car, light 
truck/van, motorcycle, other), police-reported drug involvement (yes, no), police-reported alcohol involvement (yes, 
no), and Census region. The Stata imputation command was mi ice aged male restrnt incap tod 
weekend roadway m.vehrole speeder hazard m.class druginv alcinv i.region [pw=weight], 
add(5) seed(2011) match(aged) cycles(10). 
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Source: NSDUH special tables as published in National Drug Control Strategy: Data 
Supplement 2011, Table 52. (2011). Washington, DC: Executive Office of the President. Based 
on special tabulation of National Survey on Drug Use and Health data.  
Notes: Data coverage includes 2002-2009, as methodological changes in the NSDUH 
design affect comparability with earlier years.  
 
[d28] Drug-related violent victimizations per 100,000 
Definition: Measures the number of successful and attempted violent victimizations 
involving rape, robbery, or assault in which the victim perceived the offender to be under the 
influence of drugs.  
Source: Criminal Victimization in the United States, 2000-2008 Statistical Tables, Tables 
26 and 32. (Annual 2002-2010). Washington, DC: Bureau of Justice Statistics, Office of Justice 
Programs.  
Notes: The number of drug-related victimizations was estimated by multiplying the 
number of crimes of violence (from Table 28) with the percentage of violent crimes in which the 
victim perceived the offender to be under the influence of drugs (whether alone or in 
combination with alcohol) (from Table 32). Year 2006 estimates are not used due to concerns 
over comparability with other years (see Rand, 2008), and year 2009 estimates were not 
available at the time of publication. 
 
[d29] Drug-related murders per 100,000 
Definition: Measures the number of murders in which either drug distribution or drug 
intoxication was a contributing factor in the homicide.  
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Source: Crime in the United States, 2004-2009. (Annual 2005-2010). Washington, DC: 
Federal Bureau of Investigation.  
Notes: The number of drug-related murders is derived from CUIS expanded homicide 
tables indicating whether investigators determined that drug distribution (i.e., ‘narcotic drug 
laws’) or drug intoxication (i.e., ‘brawl due to influence of narcotics.’) was a primary 
contributing factor in the murder. 
 
[d30] Illicit drug production incidents per 100,000 
Definition: Measures the total number of methamphetamine labs and marijuana grow 
operations seized by law enforcement.  
Sources: National Drug Control Strategy: Data Supplement 2011, Table 88. (2011). 
Washington, DC: Executive Office of the President. Based on data extract from the National 
Seizure System, El Paso Intelligence Center, Drug Enforcement Administration; Sourcebook of 
Criminal Justice Statistics [Online], Table 4.39 for year 2000, Table 4.38 for years 2001-2009, 
Bureau of Justice Statistics, based on data collected from the Domestic Cannabis 
Eradication/Suppression Program, Drug Enforcement Administration.  
Notes: Illicit drug production incidents include (i) methamphetamine laboratory, 
chemical/glassware/equipment, and dumpsite seizures and (ii) eradicated outdoor marijuana plots 
and seizures of indoor marijuana grows. In 2007, the DEA began including outdoor marijuana 
seizures made on public lands, which may affect comparability with earlier years. 
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STATE DRUG CONSEQUENCES INDICES 
Heroin Index 
[h1] Heroin/opiate-related deaths per 100,000 
Definition: Measures the number of U.S. resident deaths in which heroin/opiate 
poisoning or a heroin/opiate-related mental or behavioral disorder was listed as a contributing 
cause of death.  
Source: Multiple Cause of Death data for 1999-2009, CDC WONDER Online Database, 
National Center for Health Statistics, Centers for Disease Control and Prevention.  
Notes: Heroin/opiate-related deaths include any mention of the following International 
Classification of Diseases, Version 10 (ICD-10) diagnostic codes: F11.0-F11.9 (Mental and 
behavioral disorders due to use of opioids), R78.1 (Finding of opiate drug in blood), T40.0 
(Opium poisoning), T40.1 (Heroin poisoning), T40.2 (Other opioids poisoning), T40.3 
(Methadone poisoning), T40.4 (Other synthetic narcotics poisoning), and T40.6 (Other and 
unspecified narcotics poisoning). Note that as of May 23, 2011, subnational data representing 0-9 
deaths are suppressed in CDC WONDER; state-year data points in that range that we used in 
developing the indices were retrieved prior to that date. 
 
[h2] Primary heroin treatment admissions per 100,000 
 Definition: Measures the number of admissions to publicly funded substance abuse 
treatment programs for a primary heroin use disorder.  
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
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Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: For each reporting state in a given year, the counts for cases with unreported 
primary substance of abuse were proportionately reallocated according to the distribution of 
cases with validly reported data on substance type (including alcohol and other drugs). 17  
 
[h3] Inpatient hospital diagnoses for heroin poisoning per 100,000 
 Definition: Measures the number of all-listed inpatient hospital diagnoses for heroin 
poisoning.  
 Source: HCUPnet, Healthcare Cost and Utilization Project, State Inpatient Databases, 
Agency for Healthcare Research and Quality. 
 Notes: Definition includes the following International Classification of Diseases, Version 
9, Clinical Modification (ICD-9-CM) diagnostic codes: 965.01 (Poisoning by heroin) and E850.0 
(Accidental poisoning by heroin). 18  
 
[h4] Inpatient hospital diagnoses for heroin/opiate use disorders per 100,000 
 Definition: Measures the number of all-listed inpatient hospital diagnoses for heroin 
abuse or dependence.  
                                                 
17 This assumes that the primary substance of abuse for missing and nonmissing cases are similar. Multiple 
imputation was initially explored to handle this pattern of item nonresponse; however, with nearly 2 million cases 
annually, TEDS datafiles were simply too large to support this type of estimation procedure. 
18 For indicators [h3], [h4], [h6], [a3], [a4], [c3], [c4], [c6], and [m2], data were obtained from 
http://hcupnet.ahrq.gov/ using the following operational sequence: State Statistics on All Stays  Researcher, 
medical professional  Trends  [Select state]  Specific diagnoses by ICD-9-CM  All-listed Diagnoses  
[Enter codes]  All codes combined  Next. As of 2009, 44 states participated in SID; however, only 35 states 
made their data freely available through HCUPnet (up from 15 in 2000). HCUPNet data were suppressed for 
confidentiality when state-year values were based on 10 or fewer discharges or fewer than 2 hospitals. 
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 Source: HCUPnet, Healthcare Cost and Utilization Project, State Inpatient Databases, 
Agency for Healthcare Research and Quality. 
 Notes: Definition includes the following International Classification of Diseases, Version 
9, Clinical Modification (ICD-9-CM) diagnostic codes: 304.00-304.03 (Opioid type 
dependence), 304.70-304.73 (Combinations of opioid type drug with any other), and 305.50-
305.53 (Opioid abuse).  
 
[h5] Prevalence (%) of heroin abuse and pregnancy among females entering treatment 
 Definition: Measures the percentage of women who were both primary heroin abusers 
and pregnant upon admission to publicly funded substance abuse treatment programs. 
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: Data were excluded for state-years in which there was more than 20% missing 
data on either primary substance of abuse or pregnancy status.  
 
[h6] Inpatient hospital diagnoses for narcotic affecting fetus or newborn per 100,000 females 
aged 15-44 
 Definition: Measures the number of all-listed inpatient hospital diagnoses among women 
aged 15-44 for narcotics affecting a fetus or newborn.  
 Source: HCUPnet, Healthcare Cost and Utilization Project, State Inpatient Databases, 
Agency for Healthcare Research and Quality. 
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 Notes: Definition includes the following International Classification of Diseases, Version 
9, Clinical Modification (ICD-9-CM) diagnostic codes: 760.72 (Narcotics affecting fetus or 
newborn via placenta or breast milk).  
 
[h7] Prevalence (%) of heroin abuse and unemployment among people entering treatment 
 Definition: Measures the percentage of people admitted to publicly funded substance 
abuse treatment programs who were both primary heroin abusers and unemployed.  
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: Data were excluded for state-years in which there was more than 20% missing 
data on either primary substance of abuse or employment status.  
 
[h8] Opiate positivity rate among the general U.S. workforce 
 Definition: Measures the proportion of positive opiate test results relative to all such tests 
performed among the combined U.S. workforce, which includes the general workforce and 
federally mandated, safety-sensitive workers. 
 Source: Unpublished data extract provided by the Office of National Drug Control Policy 
from the Quest Diagnostics Drug Testing Index. 
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[h9] Prevalence (%) of lifetime heroin use among high school students 
 Definition: Measures the percentage of high school students who reported ever using 
heroin one or more times in their life.  
 Source: 2001-2009 High School Youth Risk Behavior Survey Data, Centers for Disease 
Control and Prevention. Online: http://apps.nccd.cdc.gov/youthonline. Unweighted estimated for 
certain states in 2001 and 2003 were obtained from the Morbidity and Mortality Weekly Report 
(June 28, 2002, Vol. 51, No. SS-4; May 21, 2004, Vol. 53, No. SS-2).  
Notes: Data are collected biennially in odd numbered years. State participation increased 
from 37 (22 weighted) in 2001 to 47 (42 weighted) in 2009. Weighted results mean that the 
overall response rate was at least 60%. 
 
[h10] Prevalence (%) of heroin abuse and homelessness among people entering treatment 
 Definition: Measures the percentage of people admitted to publicly funded substance 
abuse treatment programs who were both primary heroin abusers and homeless.  
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: Data were excluded for state-years in which there was more than 20% missing 
data on either primary substance of abuse or living arrangements.  
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[h11] Heroin/opiate positivity rate among drivers involved in fatal accidents 
Definition: Measures the estimated number of drivers involved in fatal vehicle crashes 
who tested positive for heroin/opiates.  
Source: 2000-2009 Analytic Files, Fatality Analysis Reporting System, National Center 
for Statistics and Analysis, National Highway Traffic Safety Administration.  
Notes: Because of high rates of missing data on drug-related variables, multiple 
imputation was used to estimate missing driver-level crash data. See [d25] for further details.  
 
[h12] Percentage of police agencies reporting heroin contributes most to violent crime 
 Definition: Measures the percentage of police agencies in a state reporting that heroin is 
the drug that most contributes to violent crime in the area.  
 Source: Unpublished data tables from the National Drug Threat Survey (2003-2009) 
provided by the National Drug Intelligence Center. 
 Notes: Surveys administered prior to 2003 were not representative at the state level. 
 
[h13] Percentage of police agencies reporting heroin contributes most to property crime 
 Definition: Measures the percentage of police agencies in a state reporting that heroin is 
the drug that most contributes to property crime in the area.  
 Source: Unpublished data tables from the National Drug Threat Survey (2003-2009) 
provided by the National Drug Intelligence Center. 
 Notes: Surveys administered prior to 2003 were not representative at the state level. 
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Methamphetamine Index 
[a1] Stimulant-related deaths per 100,000 
Definition: Measures the number of U.S. resident deaths in which stimulant poisoning or 
a stimulant-related mental or behavioral disorder was listed as a contributing cause of death.  
Source: Multiple Cause of Death data for 1999-2009, CDC WONDER Online Database, 
National Center for Health Statistics, Centers for Disease Control and Prevention.  
 Notes: Stimulant-related deaths include any mention of the following International 
Classification of Diseases, Version 10 (ICD-10) diagnostic codes: F15.0-F15.9 (Mental and 
behavioral disorders due to use of other stimulants) and T43.6 (Psychostimulants with abuse 
potential poisoning). Note that as of May 23, 2011, subnational data representing 0-9 deaths are 
suppressed in CDC WONDER; state-year data points in that range that we used in developing 
the indices were retrieved prior to that date. 
 
[a2] Primary amphetamine treatment admissions per 100,000 
 Definition: Measures the number of admissions to publicly funded substance abuse 
treatment programs for a primary amphetamine use disorder.  
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: For each reporting state in a given year, the counts for cases with unreported 
primary substance of abuse were proportionately reallocated according to the distribution of 
cases with validly reported data on substance type (including alcohol and other drugs).  
 102 
 
[a3] Inpatient hospital diagnoses for stimulant poisoning per 100,000 
 Definition: Measures the number of all-listed inpatient hospital diagnoses for stimulant 
poisoning.  
 Source: HCUPnet, Healthcare Cost and Utilization Project, State Inpatient Databases, 
Agency for Healthcare Research and Quality. 
 Notes: Definition includes the following International Classification of Diseases, Version 
9, Clinical Modification (ICD-9-CM) diagnostic codes: 969.7 (Poisoning by psychostimulants) 19 
and E854.2 (Accidental poisoning by psychostimulants).  
 
[a4] Inpatient hospital diagnoses for stimulant use disorders per 100,000 
 Definition: Measures the number of inpatient hospital all-listed diagnoses for stimulant 
abuse or dependence.  
 Source: HCUPnet, Healthcare Cost and Utilization Project, State Inpatient Databases, 
Agency for Healthcare Research and Quality. 
 Notes: Definition includes the following International Classification of Diseases, Version 
9, Clinical Modification (ICD-9-CM) diagnostic codes: 304.40-304.43 (Amphetamine and other 
psychostimulant dependence), and 305.70-305.73 (Amphetamine or related acting 
sympathomimetic abuse).  
 
[a5] Prevalence (%) of amphetamine abuse and pregnancy among females entering treatment 
                                                 
19 Beginning in 2009, the ICD-9-CM coding for 969.7 changed to include subcodes 969.70-969.79 for specific drugs 
(e.g., caffeine, amphetamine, methylphenidate). All possible codes were used for 2009 as the use of the new 
subcodes was not fully implemented.  
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 Definition: Measures the percentage of women who were both primary amphetamine 
abusers and pregnant upon admission to publicly funded substance abuse treatment programs. 
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: Data were excluded for state-years in which there was more than 20% missing 
data on either primary substance of abuse or pregnancy status.  
 
[a6] Children affected by methamphetamine labs per 100,000 
 Definition: Measures the number of children affected, injured, or killed by a clandestine 
methamphetamine laboratory.  
 Source: Unpublished data extract provided by the Office of National Drug Control Policy 
from the National Seizure System, El Paso Intelligence Center, Drug Enforcement 
Administration.  
 Notes: The data extract covers all drug labs types (e.g., LSD), the vast majority of which 
are for illicit methamphetamine production.  
 
[a7] Prevalence (%) of amphetamine abuse and unemployment among people entering treatment 
 Definition: Measures the percentage of people admitted to publicly funded substance 
abuse treatment programs who were both primary amphetamine abusers and unemployed.  
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
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Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: Data were excluded for state-years in which there was more than 20% missing 
data on either primary substance of abuse or employment status.  
 
[a8] Methamphetamine positivity rate among the general U.S. workforce 
 Definition: Measures the proportion of positive methamphetamine test results relative to 
all such tests performed among the combined U.S. workforce, which includes the general 
workforce and federally mandated, safety-sensitive workers. 
 Source: Unpublished data extract provided by the Office of National Drug Control Policy 
from the Quest Diagnostics Drug Testing Index. 
 Notes: Data coverage begins in 2002 because generic tests for amphetamine were 
performed in previous years.  
 
[a9] Prevalence (%) of lifetime methamphetamine use among high school students 
 Definition: Measures the percentage of high school students who reported ever using 
methamphetamine one or more times in their life.  
 Source: 2001-2009 High School Youth Risk Behavior Survey Data, Centers for Disease 
Control and Prevention. Online: http://apps.nccd.cdc.gov/youthonline. Unweighted estimated for 
certain states in 2001 and 2003 were obtained from the Morbidity and Mortality Weekly Report 
(June 28, 2002, Vol. 51, No. SS-4; May 21, 2004, Vol. 53, No. SS-2).  
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Notes: Data are collected biennially in odd numbered years. State participation increased 
from 37 (22 weighted) in 2001 to 47 (42 weighted) in 2009. Weighted results mean that the 
overall response rate was at least 60%. 
 
[a10] Prevalence (%) of amphetamine abuse and homelessness among people entering treatment 
 Definition: Measures the percentage of people admitted to publicly funded substance 
abuse treatment programs who were both primary amphetamine abusers and homeless.  
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: Data were excluded for state-years in which there was more than 20% missing 
data on either primary substance of abuse or living arrangements.  
 
[a11] Amphetamine positivity rate among drivers involved in fatal accidents 
Definition: Measures the estimated number of drivers involved in fatal vehicle crashes 
who tested positive for amphetamines.  
Source: 2000-2009 Analytic Files, Fatality Analysis Reporting System, National Center 
for Statistics and Analysis, National Highway Traffic Safety Administration.  
Notes: Because of high rates of missing data on drug-related variables, multiple 
imputation was used to estimate missing driver-level crash data. See [d25] for further details.   
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[a12] Percentage of police agencies reporting methamphetamine contributes most to violent 
crime 
 Definition: Measures the percentage of police agencies in a state reporting that 
methamphetamine is the drug that most contributes to violent crime in the area.  
 Source: Unpublished data tables from the National Drug Threat Survey (2003-2009) 
provided by the National Drug Intelligence Center. 
 Notes: Surveys administered prior to 2003 were not representative at the state level. 
 
[a13] Percentage of police agencies reporting methamphetamine contributes most to property 
crime 
 Definition: Measures the percentage of police agencies in a state reporting that 
methamphetamine is the drug that most contributes to property crime in the area.  
 Source: Unpublished data tables from the National Drug Threat Survey (2003-2009) 
provided by the National Drug Intelligence Center. 
 Notes: Surveys administered prior to 2003 were not representative at the state level. 
 
[a14] Percentage of police agencies reporting local methamphetamine production 
 Definition: Measures the percentage of police agencies in a state reporting any level of 
illicit methamphetamine production in the area.  
 Source: Unpublished data tables from the National Drug Threat Survey (2003-2009) 
provided by the National Drug Intelligence Center. 
 Notes: Surveys administered prior to 2003 were not representative at the state level. 
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[a15] Methamphetamine laboratory seizure incidents per 100,000 
 Definition: Measures the total number of methamphetamine laboratory seizure incidents, 
including operational labs, dumpsites, and chemicals and equipment.  
 Source: Unpublished data extract provided by the Office of National Drug Control Policy 
from the Quest Diagnostics Drug Testing Index. 
 
Cocaine Index 
[c1] Cocaine-related deaths per 100,000 
Definition: Measures the number of U.S. resident deaths in which cocaine poisoning or a 
cocaine-related mental or behavioral disorder was listed as a contributing cause of death.  
Source: Multiple Cause of Death data for 1999-2009, CDC WONDER Online Database, 
National Center for Health Statistics, Centers for Disease Control and Prevention.  
Notes: Cocaine-related deaths include any mention of the following International 
Classification of Diseases, Version 10 (ICD-10) diagnostic codes: F14.0-F14.9 (Mental and 
behavioral disorders due to use of cocaine), R78.2 (Finding of cocaine in blood), and T40.5 
(Cocaine poisoning). Note that as of May 23, 2011, subnational data representing 0-9 deaths are 
suppressed in CDC WONDER; state-year data points in that range that we used in developing 
the indices were retrieved prior to that date. 
 
[c2] Primary cocaine treatment admissions per 100,000 
 Definition: Measures the number of admissions to publicly funded treatment programs 
for a primary cocaine use disorder.  
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 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: For each reporting state in a given year, the counts for cases with unreported 
primary substance of abuse were proportionately reallocated according to the distribution of 
cases with validly reported data on substance type (including alcohol and other drugs). 
 
[c3] Inpatient hospital diagnoses for cocaine poisoning per 100,000 
 Definition: Measures the number of all-listed inpatient hospital diagnoses for cocaine 
poisoning.  
 Source: HCUPnet, Healthcare Cost and Utilization Project, State Inpatient Databases, 
Agency for Healthcare Research and Quality. 
 Notes: Definition includes the following International Classification of Diseases, Version 
9, Clinical Modification (ICD-9-CM) diagnostic codes: 968.5 (Poisoning by surface and 
infiltration anesthetics), 970.8 (Poisoning by other specified central nervous system stimulants) 20 
and E854.3 (Accidental poisoning by central nervous system stimulants).  
 
[c4] Inpatient hospital diagnoses for cocaine use disorders per 100,000 
 Definition: Measures the number of all-listed inpatient hospital diagnoses for cocaine 
abuse or dependence.  
 Source: HCUPnet, Healthcare Cost and Utilization Project, State Inpatient Databases, 
Agency for Healthcare Research and Quality. 
                                                 
20 Beginning in 2010, code 970.8 was broken into subcodes allowing specific reporting for cocaine. 
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 Notes: Definition includes the following International Classification of Diseases, Version 
9, Clinical Modification (ICD-9-CM) diagnostic codes: 304.20-304.23 (Cocaine dependence), 
and 305.60-305.63 (Cocaine abuse).  
 
[c5] Prevalence (%) of cocaine abuse and pregnancy among females entering drug treatment 
 Definition: Measures the percentage of women who were both primary cocaine abusers 
and pregnant upon admission to publicly funded treatment programs. 
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: Data were excluded for state-years in which there was more than 20% missing 
data on either primary substance of abuse or pregnancy status.  
 
[c6] Inpatient hospital diagnoses for cocaine affecting fetus or newborn per 100,000 females 
aged 15-44 
 Definition: Measures the number of all-listed inpatient hospital diagnoses among women 
aged 15-44 for cocaine affecting a fetus or newborn.  
 Source: HCUPnet, Healthcare Cost and Utilization Project, State Inpatient Databases, 
Agency for Healthcare Research and Quality. 
 Notes: Definition includes the following International Classification of Diseases, Version 
9, Clinical Modification (ICD-9-CM) diagnostic codes: 760.75 (Cocaine affecting fetus or 
newborn via placenta or breast milk).  
 110 
 
[c7] Prevalence (%) of cocaine abuse and unemployment among people entering treatment 
 Definition: Measures the percentage of people admitted to publicly funded substance 
abuse treatment programs who were both primary cocaine abusers and unemployed.  
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: Data were excluded for state-years in which there was more than 20% missing 
data on either primary substance of abuse or employment status.  
 
[c8] Cocaine positivity rate among the general U.S. workforce 
 Definition: Measures the proportion of positive cocaine test results relative to all such 
tests performed among the combined U.S. workforce, which includes the general workforce and 
federally mandated, safety-sensitive workers. 
 Source: Unpublished data extract provided by the Office of National Drug Control Policy 
from the Quest Diagnostics Drug Testing Index. 
 
[c9] Prevalence (%) of lifetime cocaine use among high school students 
 Definition: Measures the percentage of high school students who reported ever using 
cocaine one or more times in their life.  
 Source: 2001-2009 High School Youth Risk Behavior Survey Data, Centers for Disease 
Control and Prevention. Online: http://apps.nccd.cdc.gov/youthonline. Unweighted estimated for 
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certain states in 2001 and 2003 were obtained from the Morbidity and Mortality Weekly Report 
(June 28, 2002, Vol. 51, No. SS-4; May 21, 2004, Vol. 53, No. SS-2).  
Notes: Data are collected biennially in odd numbered years. State participation increased 
from 37 (22 weighted) in 2001 to 47 (42 weighted) in 2009. Weighted results mean that the 
overall response rate was at least 60%. 
 
[c10] Prevalence (%) of past-year cocaine use among 12-17 year olds 
 Definition: Measures the percentage of 12-17 year olds in the household population who 
reported using cocaine within the past 12 months.  
 Source: State Estimates of Substance Use and Mental Disorders from the 2002-2009 
National Survey on Drug Use and Health (Annual 2004-2011). Rockville, MD: Center for 
Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services 
Administration. 
 Notes: Data coverage includes 2002-2009, as methodological changes in the NSDUH 
design affect comparability with earlier years. Except for 2002, the estimates for a given year 
represent the combined estimates for the indicated and prior year.  
 
[c11] Prevalence (%) of cocaine abuse and homelessness among people entering treatment 
 Definition: Measures the percentage of people admitted to publicly funded substance 
abuse treatment programs who were both primary cociane abusers and homeless.  
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
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Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: Data were excluded for state-years in which there was more than 20% missing 
data on either primary substance of abuse or living arrangements.  
 
[c12] Cocaine positivity rate among drivers involved in fatal accidents 
Definition: Measures the estimated number of drivers involved in fatal vehicle crashes 
who tested positive for cocaine.  
Source: 2000-2009 Analytic Files, Fatality Analysis Reporting System, National Center 
for Statistics and Analysis, National Highway Traffic Safety Administration.  
Notes: Because of high rates of missing data on drug-related variables, multiple 
imputation was used to estimate missing driver-level crash data. See [d25] for further details.  
 
[c13] Percentage of police agencies reporting cocaine contributes most to violent crime 
 Definition: Measures the percentage of police agencies in a state reporting that cocaine is 
the drug that most contributes to violent crime in the area.  
 Source: Unpublished data tables from the National Drug Threat Survey (2003-2009) 
provided by the National Drug Intelligence Center. 
 Notes: Surveys administered prior to 2003 were not representative at the state level. 
 
[c14] Percentage of police agencies reporting cocaine contributes most to property crime 
 Definition: Measures the percentage of police agencies in a state reporting that cocaine is 
the drug that most contributes to property crime in the area.  
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 Source: Unpublished data tables from the National Drug Threat Survey (2003-2009) 
provided by the National Drug Intelligence Center. 
 Notes: Surveys administered prior to 2003 were not representative at the state level. 
 
Marijuana Index 
[m1] Primary marijuana treatment admissions per 100,000 
 Definition: Measures the number of admissions to publicly funded treatment programs 
for a primary marijuana use disorder.  
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: For each reporting state in a given year, the counts for cases with unreported 
primary substance of abuse were proportionately reallocated according to the distribution of 
cases with validly reported data on substance type (including alcohol and other drugs). 
 
[m2] Inpatient hospital diagnoses for marijuana use disorders per 100,000 
 Definition: Measures the number of all-listed inpatient hospital diagnoses for marijuana 
abuse or dependence.  
 Source: HCUPnet, Healthcare Cost and Utilization Project, State Inpatient Databases, 
Agency for Healthcare Research and Quality. 
 114 
 Notes: Definition includes the following International Classification of Diseases, Version 
9, Clinical Modification (ICD-9-CM) diagnostic codes: 304.30-304.33 (Cannabis dependence), 
and 305.20-305.23 (Cannabis abuse).  
[m3] Potency of seized marijuana 
 Definition: Measures the THC concentration of marijuana seized by law enforcement.  
 Source: Unpublished data extract provided by the Office of National Drug Control Policy 
from the Marijuana Potency Monitoring Program, University of Mississippi/National Institute on 
Drug Abuse.  
 Notes: State-year values represent three-year moving averages of the indicated year and 
the two previous years. Thus, year 2000 values are moving averages of 1998-2000 data. The 
estimates were weighted by seizure quantity to reflect a market share interpretation of THC 
potency. 
 
[m4] Prevalence (%) of marijuana abuse and pregnancy among females entering drug treatment 
 Definition: Measures the percentage of women who were both primary marijuana abusers 
and pregnant upon admission to publicly funded treatment programs. 
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: Data were excluded for state-years in which there was more than 20% missing 
data on either primary substance of abuse or pregnancy status.  
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[m5] Prevalence (%) of marijuana abuse and unemployment among people entering treatment 
 Definition: Measures the percentage of people admitted to publicly funded substance 
abuse treatment programs who were both primary marijuana abusers and unemployed.  
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: Data were excluded for state-years in which there was more than 20% missing 
data on either primary substance of abuse or employment status.  
 
[m6] Marijuana positivity rate among the general U.S. workforce 
 Definition: Measures the proportion of positive marijuana test results relative to all such 
tests performed among the combined U.S. workforce, which includes the general workforce and 
federally mandated, safety-sensitive workers. 
 Source: Unpublished data extract provided by the Office of National Drug Control Policy 
from the Quest Diagnostics Drug Testing Index. 
 
[m7] Prevalence (%) of marijuana use before age 13 among high school students 
 Definition: Measures the percentage of high school students who reported first using 
marijuana before the age of 13. 
 Source: 2001-2009 High School Youth Risk Behavior Survey Data, Centers for Disease 
Control and Prevention. Online: http://apps.nccd.cdc.gov/youthonline. Unweighted estimated for 
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certain states in 2001 and 2003 were obtained from the Morbidity and Mortality Weekly Report 
(June 28, 2002, Vol. 51, No. SS-4; May 21, 2004, Vol. 53, No. SS-2).  
Notes: Data are collected biennially in odd numbered years. State participation increased 
from 37 (22 weighted) in 2001 to 47 (42 weighted) in 2009. Weighted results mean that the 
overall response rate was at least 60%. 
 
[m8] Prevalence (%) of recent marijuana use on school property among high school students
 Definition: Measures the percentage of high school students who reported first using 
marijuana on school property within the past 30 days. 
 Source: 2001-2009 High School Youth Risk Behavior Survey Data, Centers for Disease 
Control and Prevention. Online: http://apps.nccd.cdc.gov/youthonline. Unweighted estimated for 
certain states in 2001 and 2003 were obtained from the Morbidity and Mortality Weekly Report 
(June 28, 2002, Vol. 51, No. SS-4; May 21, 2004, Vol. 53, No. SS-2).  
Notes: Data are collected biennially in odd numbered years. State participation increased 
from 37 (22 weighted) in 2001 to 47 (42 weighted) in 2009. Weighted results mean that the 
overall response rate was at least 60%. 
 
[m9] Average annual marijuana initiation rate among 12-17 year olds 
 Definition: Measures the percentage of 12-17 year olds in the household population who 
first used marijuana in the past 12 months.  
 Source: State Estimates of Substance Use and Mental Disorders from the 2002-2009 
National Survey on Drug Use and Health (Annual 2004-2011). Rockville, MD: Center for 
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Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services 
Administration. 
 Notes: Data coverage includes 2002-2009, as methodological changes in the NSDUH 
design affect comparability with earlier years. Except for 2002, the estimates for a given year 
represent the combined estimates for the indicated and prior year.  
 
[m10] Prevalence (%) of marijuana abuse and homelessness among people entering treatment 
 Definition: Measures the percentage of people admitted to publicly funded substance 
abuse treatment programs who were both primary marijuana abusers and homeless.  
 Source: Treatment Episode Data Set—Admissions (TEDS-A), 2000-2009 [computer 
files]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. Ann Arbor, MI: Interuniversity Consortium for Political and Social 
Research [distributor].  
 Notes: Data were excluded for state-years in which there was more than 20% missing 
data on either primary substance of abuse or living arrangements.  
 
[m11] Marijuana positivity rate among drivers involved in fatal accidents 
Definition: Measures the estimated number of drivers involved in fatal vehicle crashes 
who tested positive for marijuana.  
Source: 2000-2009 Analytic Files, Fatality Analysis Reporting System, National Center 
for Statistics and Analysis, National Highway Traffic Safety Administration.  
Notes: Because of high rates of missing data on drug-related variables, multiple 
imputation was used to estimate missing driver-level crash data. See [d25] for further details.  
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[m12] Percentage of police agencies reporting marijuana contributes most to violent crime 
 Definition: Measures the percentage of police agencies in a state reporting that marijuana 
is the drug that most contributes to violent crime in the area.  
 Source: Unpublished data tables from the National Drug Threat Survey (2003-2009) 
provided by the National Drug Intelligence Center. 
 Notes: Surveys administered prior to 2003 were not representative at the state level. 
 
[m13] Percentage of police agencies reporting marijuana contributes most to property crime 
 Definition: Measures the percentage of police agencies in a state reporting that marijuana 
is the drug that most contributes to property crime in the area.  
 Source: Unpublished data tables from the National Drug Threat Survey (2003-2009) 
provided by the National Drug Intelligence Center. 
 Notes: Surveys administered prior to 2003 were not representative at the state level. 
 
[m14] Percentage of police agencies reporting local marijuana production  
 Definition: Measures the percentage of police agencies in a state reporting any level of 
illicit marijuana production in the area, including indoor and outdoor grows. 
 Source: Unpublished data tables from the National Drug Threat Survey (2003-2009) 
provided by the National Drug Intelligence Center. 
 Notes: Surveys administered prior to 2003 were not representative at the state level. 
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[m15] Outdoor marijuana plots eradicated per 100,000 
Definition: Measures the number of outdoor marijuana plots eradicated by law 
enforcement.  
Source: Sourcebook of Criminal Justice Statistics [Online], Table 4.39 for year 2000, 
Table 4.38 for years 2001-2009, Bureau of Justice Statistics, based on data collected from the 
Domestic Cannabis Eradication/Suppression Program, Drug Enforcement Administration.  
Notes: In 2007, the DEA began including outdoor marijuana seizures made on public 
lands, which may affect comparability with earlier years. 
 
[m16] Indoor marijuana grows seized per 100,000 
Definition: Measures the number of indoor marijuana grows seized by law enforcement.  
Source: Sourcebook of Criminal Justice Statistics [Online], Table 4.39 for year 2000, 
Table 4.38 for years 2001-2009, Bureau of Justice Statistics, based on data collected from the 
Domestic Cannabis Eradication/Suppression Program, Drug Enforcement Administration.  
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APPENDIX D: DETAILED METHODOLOGY AND ROBUSTNESS 
ANALYSES 
 
 This technical appendix provides detailed documentation of the statistical methods used 
in the construction of the core U.S. Drug Consequences Indices (DCIs), including statistical 
treatment of the indicators, internal consistency analysis, weighting and aggregation methods, 
and robustness analyses. The National DCI is discussed first followed by the drug-specific State 
DCIs. 
 
A. NATIONAL DCI 
1. Missing Data 
All of the 30 indicators that inform the National DCI had data availability of at least five 
years over the ten-year period 2000 to 2009. Overall, 22 indicators had complete records, with 
missing data representing just 7.7% of the matrix of 300 observations (30 indicators × 10 years). 
As indicated in Table D-1, missing data for the remaining 8 indicators were imputed using either 
linear interpolation or linear trend analysis. Linear interpolation was used for indicators collected 
biennially (i.e., YRBS indicators collected in odd-numbered years), whereas trend analysis was 
employed for indicators with other missing data patterns. For the interpolation procedure, values 
for 1999 were used to interpolate year 2000 values. For the linear trend analysis, bivariate 
regression was employed to predict missing values with time (i.e., year) as the independent 
variable.   
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Table D-1. National DCI Imputation Methods 
Indicator Missing Years Method 
[d4] Drug-related emergency department visits per 
100,000 (DAWN) 
2000-2004 Linear trend 
analysis 
[d8] Prevalence (%) of drug dependence or abuse among 
persons aged 12+ (NSDUH) 
2000-2001 Linear trend 
analysis 
[d12] Prevalence (%) of illicit drug use among pregnant 
women aged 15-44 (NSDUH) 
2000-2001 Linear trend 
analysis 
[d21] On-campus drug violations per 1,000 enrolled college 
students (CSSS) 
2000 Linear trend 
analysis 
[d22] Percentage of high school students offered drugs on 
school grounds (YRBS) 
2000, 2002, 2004, 
2006, 2008 
Linear 
interpolation 
[d24] Lifetime prevalence (%) of drug injection among 
high school students (YRBS) 
2000, 2002, 2004, 
2006, 2008 
Linear 
interpolation 
[d27] Prevalence (%) of drugged driving among persons 
aged 16+ (NSDUH) 
2000-2001 Linear trend 
analysis 
[d28] Drug-related violent victimizations per 100,000 
(NCVS) 
2006, 2009 Linear trend 
analysis 
 
 
2. Normalization 
To render the indicator values comparable, we normalized by a distance-to-reference 
value, where year 2000 was used as the base year (set to value 100) using equation (1) whereby 
low values are undesirable. It is important to note that this direction was kept only during the 
calculations (for reasons that are explained next in the section on Weighting and Aggregation). 
All final results are presented with high values being undesirable.    
 
(1) 𝑥𝑛𝑒𝑤,𝑡 = 200 −  𝑥𝑟𝑎𝑤,𝑡𝑥𝑟𝑎𝑤,𝑡 0=2000 × 100 
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3. Weighting and Aggregation 
 In order to derive a plausible set of weights for use in constructing the DCIs, we 
consulted with 19 experts in the drug policy and addictions fields. 21 The consultation was 
constructed around an Analytic Hierarchy Process (AHP), a widely used technique for multi-
criteria decision-making (Saaty, 1987; Saaty, 1980, 2005). AHP employs ordinal pairwise 
comparisons of indicators, in which the strength of preference is expressed on a semantic scale  
typically ranging from ‘1’ (equally important) to ‘9’ (extremely more important). The relative 
weights of the indicators are then calculated using an eigenvector technique that serves to resolve 
inconsistencies (e.g., loops such as A better than B better than C better than A; see discussion 
below). For this project, the panel of experts independently assessed the relative importance of 
the nine subdomains for each drug type separately (i.e., heroin, methamphetamine, cocaine, and 
marijuana) and then again for ‘all illicit drugs.’ 22 The latter set of responses was used for the 
National DCI.  
An intrinsic feature of AHP is that it exploits the level of inconsistency in a respondent’s 
assessment of the relative importance of drug consequence subdomains. For example, if one 
expert claims that A is much more important than B, B slightly more important than C, and C 
slightly more important than A, his/her judgment is inconsistent and the results are less 
trustworthy. Inconsistency, however, is part of human nature. For the DCI framework with nine 
                                                 
21 We contacted 36 individuals representing a cross-section of academic backgrounds and expertise for this 
consultation. Of these 36 individuals, 19 agreed to participate, 11 could not be reached or did not respond to the 
invitation, 3 agreed to participate but were not able to fulfill their commitment, and 3 declined to participate.  
22 It was not feasible to require indicator-level comparisons due to the different indicators used across the DCIs and 
the burden that would have been placed upon the AHP participants. Ratings were based on the following scale: (1) 
Equally important—Evidence and judgment suggest the subdomains contribute equally to total harm, (3) Somewhat 
more important—Evidence and judgment slightly favors the influence of one domain over another, (5) Much more 
important—Evidence and judgment strongly favors the influence of one domain over another, (7) Very much more 
important—Evidence and judgment very strongly favors the influence of one domain over another, (9) Extremely 
more important—Evidence and judgment favors the influence of one domain over another to the highest possible 
degree.  
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subdomains, only eight comparisons are actually required to establish weights. 23 However, the 
number of comparisons performed in the AHP exercise was 362/)89( =⋅ . The greater number 
of comparisons results in a set of weights that is less sensitive to errors of judgment. In addition, 
this redundancy allows for an estimation of judgment error, the so called inconsistency ratio. It 
might therefore be adequate to measure the degree of inconsistency in order to make judgments 
about whether to include a particular respondent’s assessment in the final weighting. Small 
inconsistency ratios—the suggested rule-of-thumb is less than 0.1, although 0.2 is often cited—
do not drastically affect the weights (Saaty, 1980). Higher inconsistency ratios are an indication 
that the experts have probably responded to the AHP exercise in a nonsystematic fashion. Of the 
19 expert responses, 13 were considered to meet minimum reliability requirements (i.e., 
inconsistency ratios 0.2 or less). These 13 responses were used to calculate the average weights 
for the National DCI.  
Figure D-1 presents information on the expert-based weights for the subdomains and 
domains of the National DCI; mean, minimum, and maximum weights are shown by the bars and 
error bars. There are considerable differences in the weights proposed by the experts for the same 
subdomain. Interestingly, unanimity is achieved in judging that the ‘drugged driving’ subdomain 
should receive the lowest weight (4%) across the nine areas. On the other hand, experts on 
average agree that the highest weights should be assigned to three of the nine subdomains, 
namely ‘family disruption & child maltreatment,’ ‘crime & nuisance,’ and ‘reduced attainment & 
productivity’ (between 16-20%). 
                                                 
23 The ninth equation is that of the unity sum of weights. 
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 We derived weights for the three domains, 24 showing that the Social & Economic 
domain was given relatively more weight (43%), followed by Crime & Disorder (33%), and 
Health (24%). Furthermore, although equal weights (0.11) fall within the upper and lower 
bounds over the sample of experts, no panel member proposed to weigh all consequences 
equally. For these reasons, we opted not to assume equal weights for the consequences during 
the development of the National DCI. If a single set of weights was to be used to represent the 
expert panel in its entirety, then the mean (or median) weight value would be a proper choice. 
We used the mean weight value across the experts. Below, in the section on robustness analysis, 
we assess the impact that variations in weighting have on the National DCI results. 
                                                 
24 Experts were requested via AHP to assess the relative importance of the nine subdomains only. Conclusions on 
the domains can be derived indirectly, but note that experts were not explicitly asked to do so. 
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Figure D-1. Expert-based Weights for the Subdomains and 
Domains of the National DCI 
Horizontal dotted lines represent equal weights 
for subdomains (0.11) and domains (0.33). 
 125 
 The calculation of the National DCI followed three aggregation steps. First, the scores for 
the subdomains were calculated as simple geometric averages of the normalized indicators using 
equation (2), exemplified for Mortality. 
 
(2) Mortality𝑡 = �(drug‐related deaths𝑡) × (IDU‐related AIDS deaths𝑡)�1/2 
 
Next, scores for the three domains were calculated as expert-weighted geometric averages of the 
three subdomains underlying each domain using equation (3), exemplified for Health 
consequences. 
 
(3) Health𝑡 = (Mortality)𝑡𝑤1 × (Morbidity)𝑡𝑤2 × (Drug‐Exposed Infants)𝑡𝑤3 
 
Finally, the expert-weighted geometric mean of the three domains was calculated as follows: 
 
(4) 𝑌𝑡 = (Health)𝑡𝑤10 × (Social & Economic)𝑡𝑤11 × (Crime & Disorder)𝑡𝑤12  
 
 Note that equation (4) is equivalent to the expert-weighted geometric average of the nine 
subdomains. The final results for the DCI and the three domains on Health, Social & Economic, 
and Crime & Disorder were then scaled using equation (5), whereby high values are undesirable. 
This is done for communication purposes with a view to have the results in the same direction as 
that of the raw indicators. 
 
(5) DCI𝑡 = 200 − 𝑌𝑡 
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 The use of the geometric mean, as opposed to the classical arithmetic mean, to aggregate 
the components of the DCI is guided by both a conceptual and a methodological need. 
Conceptually, in the present context, perfect substitutability among the index components (as is 
the case with an arithmetic mean) is not desirable. Substitutability (or compensability) is 
understood here as the undesirable offsetting of poor performance in some area with good 
performance in others. Methodologically, the use of the arithmetic average would be problematic 
because it would imply that the level of priority to be given to a drug consequences subdomain is 
invariant to the level of attainments. Instead, the geometric mean gives more incentives for 
improvement to low values. Furthermore, the geometric mean is only partially compensatory and 
the rankings produced by the geometric mean are not affected by choice of the reference year at 
the normalization stage. In the case of the arithmetic mean or functions with a constant 
nonunitary elasticity of substitution, multiplying any of the DCI components by a scalar factor 
would lead to a change in the relative weight of that variable. The only functional form that 
allows us to avoid this undesirable result is the geometric mean. In fact, Fleming and Wallace 
(1986) demonstrate that the geometric mean is the only correct mean when averaging normalized 
results that are presented as ratios to reference values.   
 
4. Robustness Analysis 
 Various methodological choices were made when constructing the National DCI: 
structure of the framework, indicator selection, imputation, weighting scheme, aggregation 
formula. The aim of the robustness analysis is to assess the extent to which these choices have 
affected the final results. Hence, robustness analysis is an essential ingredient for validating an 
index by anticipating criticism (Saisana, Saltelli, and Tarantola, 2005; OECD, 2008; Saltelli et 
 127 
al., 2008). The robustness assessment carried out here aimed to estimate the impact of a 
particularly consequential issue: the weights assigned to the nine subdomains.  
 In the field of composite indicators, the issue of weighting is a particularly sensitive and 
subjective. There is no clear consensus among the expert community on composite indicator  
construction as to how to best determine a set of weights for combining diverse issues, such as 
those related to drug consequences. Cox et al. (1992) summarize these difficulties and conclude 
that many published weighting schemes are either based upon too complex multivariate methods 
or have little meaning to society. Cherchye et al. (2007) observe that the “lack of consensus” on 
the relative weights is a defining property of composite indicators, and that while one may 
hypothesize consensus on the indicators to be included in an index, the weights to be assigned to 
them will most likely remain controversial. The point of these considerations is that subjectivity 
and fitness need not be antithetical. They are in fact both at play when constructing a composite 
indicator (OECD, 2008). These, only apparently conflicting, properties underpin composite 
indicators’ suitability for advocacy (Saltelli, 2007). 
 As explained above, we assigned equal weights to the indicators and expert-based 
weights derived from the AHP exercise to the subdomains and domains in order to create the 
National DCI. In order to better understand the impact on the DCI scores of different sets of 
weights, we performed two robustness analyses. First, we used the range of information supplied 
by the experts in the AHP exercise, not just the average weight across the experts. Second, we 
compared the National DCI results to those obtained had an equal weighting scheme been used 
throughout all aggregation steps. These two procedures are described in turn. 
 The impact on the National DCI scores of the thirteen sets of AHP-derived weights (those 
corresponding to inconsistency 0.2 or below) is shown in Figure D-2. The horizontal lines are the 
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National DCI scores (i.e., the reference scores obtained using the average AHP weights), the 
bullets show the scores had equal weights been used, and the vertical lines depict the minimum 
and maximum scores calculated on the basis of the range in thirteen experts’ sets of weights. The 
equal weight scores follow the general trend of the reference DCI scores, and in most years are 
comparable to the AHP-derived weights. The largest differences are found for 2002-2004, when 
an equal weights assumption would have underestimated index scores relative to the reference 
situation by 7-8%. The highest uncertainties in the DCI scores, as reflected by the vertical error 
bars, occur in these same years. Nevertheless, the general conclusion still holds under these 
varying assumptions that drug-related consequences increased during the early 2000s before 
declining and stabilizing in the latter part of the decade.  
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B. STATE INDICES 
1. Missing Data 
 For each state-year matrix of indicators, missing data characterized 26.0% (1,693 / 6,500) 
of the Heroin Index, 22.0% (1,652 / 7,500) of the Methamphetamine Index, 24.6% (1,719 / 
7,000) of the Cocaine Index, and 21.3% (1,702 / 8,000) of the Marijuana Index. These missing 
data were imputed independently for each index using the time-series cross-sectional bootstrap 
expectation-maximization algorithm implemented in the software package Amelia II (Honaker 
and King, 2010; Honaker, King, and Blackwell, 2012; King et al., 2001). This approach has 
comparative advantages over other imputation methods (Blankers, Koeter, and Schippers, 2010), 
and has proven to work efficiently with various datasets and with different degrees of 
missingness.  
 Imputation of missing state-year cells in each DCI matrix proceeded as follows. First, the 
nature and distribution of each indicator was assessed, and transformations were applied as 
appropriate in order to improve imputation estimates. These transformations were executed 
within Amelia II, which has the advantage that the imputation results are reported back in the 
original metric. A ladder of powers framework including tests for normality and visual 
inspection of histograms supported selection of appropriate transformations. The ultimate 
transformations that were used in the imputation models are reported in Table D-2. “Identity” 
refers to untransformed indicators. For indicators transformed logarithmically, a small constant 
value (e.g., 0.01, 0.1) was added prior to imputation if zeros were present. Similarly, for 
indicators transformed logistically, percentages were first expressed as proportions and then 
values of 0 and 1 were replaced with 0.01 and .99 respectively since the logit of 0 or 1 is 
undefined. The transformed indicator values were then passed to Amelia II for imputation. Ten 
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complete datasets were created where missing values were “filled in with a distribution of 
imputations that reflect the uncertainty about the missing data” (Honaker, King, and Blackwell, 
2012:3). For each missing data point in the state-year matrices, the average of the ten imputed 
values was taken as the best estimate. Finally, any previous manual transformations (e.g., adding 
a constant, changing from percentage to proportion) were reversed to return the indicators to 
their original format.  
 
 
Table D-2. State DCI Indicator Transformations Used for Imputation Models 
Heroin Index Methamphetamine 
Index 
Cocaine Index Marijuana Index 
[h1] Square root [a1] Square root [c1] Logarithm [m1] Square root 
[h2] Logarithm [a2] Logarithm [c2] Square root [m2] Logarithm 
[h3] Square root [a3] Square root [c3] Logarithm [m3] Square root 
[h4] Logarithm [a4] Square root [c4] Logarithm [m4] Square root 
[h5] Logistic [a5] Logistic [c5] Logistic [m5] Square root 
[h6] Logarithm [a6] Square root [c6] Square root [m6] Square root 
[h7] Logistic [a7] Logistic [c7] Logistic [m7] Identity 
[h8] Logarithm [a8] Square root [c8] Square root [m8] Identity 
[h9] Identity [a9] Identity [c9] Identity [m9] Identity 
[h10] Logistic [a10] Logistic [c10] Logarithm [m10] Square root 
[h11] Square root [a11] Logarithm [c11] Square root [m11] Identity 
[h12] Logistic [a12] Logistic [c12] Square root [m12] Logistic 
[h13] Logistic [a13] Logistic [c13] Logistic [m13] Logistic 
 [a14] Logistic [c14] Logistic [m14] Logistic 
 [a15] Logarithm  [m15] Logarithm 
   [m16] Logarithm 
 
 
 
 
Several diagnostics were performed to assess and improve the quality of the imputation 
results (Honaker, King, and Blackwell, 2012). First, we compared the densities of the imputed 
and observed values to assess whether the imputed values were plausibly distributed, that is, that 
they did not fall radically outside the range of the observed data. Figure D-3 shows the graph for 
[h4] Inpatient hospital diagnoses for heroin/opiate use disorders per 100,000, indicating that 
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imputations for cases with missing data (43%) were reasonably distributed relative to the 
indicator’s observed values. Second, we examined time series graphs by indicator and state to 
check whether the mean imputed values and imputation distributions (95% CIs) were consistent 
with the state-specific trends. Figure D-4 shows the graph for indicator [h4] for Arkansas, 
confirming the plausibility of the mean imputations for missing years 2000 to 2003. Third, we 
performed the “overimputation” technique developed by Honaker and colleagues (2012) to 
compare observed values to imputations of these values as if they had been missing. Figure D-5 
presents these results for indicator [h4], revealing that for the majority of the observations the 
90% confidence intervals contain the y = x line of perfect agreement. The color coding indicates 
the overall amount of missing information when imputing the observation. These checks were 
performed iteratively for all indicators to arrive at a final imputation model.  
 
Figure D-3. Observed and Imputed Values of [h4] 
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Figure D-4. Time Series of [h4] for Arkansas 
Figure D-5. Observed versus Imputed Values of [h4] 
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2. Data Treatment 
 For each indicator in the final imputed datasets, values falling outside twice the 
interquartile range were checked for reporting errors. 25 As shown in Table D-3, potentially 
problematic indicators (n = 21) that could bias the overall results were identified as having a 
skewness (absolute) greater than 2.0 and kurtosis greater than 3.5, 26 and were treated by 
logarithmic transformation (corrected for zero values by adding a constant of 1). After 
transformation, indicator distributions were checked again to verify that the skewness and 
kurtosis entered within the specified ranges. This was confirmed for all indicators but three ([h8], 
[h11], and [m10]). We treated indicator [h11] with Winsorization since there was only one 
offending value (Alaska 2002 = 9.7), which we recoded to the next highest value + 1 SD (new 
value = 4.4 + 0.8 = 5.2). Alternatively, indicators [h8] and [m10] were truncated to the 95th 
percentile. 
 
Table D-3. State DCI Normality Statistics for Potentially Problematic Indicators Before and 
After Logarithmic Transformation 
Indicator 
Before Transformation After Transformation 
Skewness Kurtosis Skewness Kurtosis 
[h2] Primary heroin treatment admissions per 100,000 TEDS) 2.3 4.6 0.2 -0.8 
[h4] Inpatient hospital diagnoses for heroin/opiate use 
disorders per 100,000 (SID) 
2.3 6.1 -0.2 1.4 
[h5] Prevalence (%) of heroin abuse and pregnancy among 
females entering treatment (TEDS) 
3.6 18.1 1.8 3.9 
[h7] Prevalence (%) of heroin abuse and unemployment 
among people entering treatment (TEDS) 
2.2 5.2 0.7 -0.4 
[h8] Opiate positivity rate among the general U.S. workforce 
(DTI) 
3.5 15.8 2.4 8.1 
[h10] Prevalence (%) of heroin abuse and homelessness 
among people entering treatment (TEDS) 
2.7 8.0 1.2 0.7 
                                                 
25The interquartile range (IQR) is the difference between the upper (75% of values) and the lower (25% of values) 
quartiles, denoted Q3 and Q1 respectively. Thus, values greater than Q3+2(IQR) or values lower than Q1-2(IQR) 
were checked for reporting errors. 
26Groeneveld and Meeden (1984) set the criteria for absolute skewness above 1 and kurtosis above 3.5. The 
skewness criterion was relaxed here to the value 2. 
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Indicator 
Before Transformation After Transformation 
Skewness Kurtosis Skewness Kurtosis 
[h11] Heroin/opiate positivity rate among drivers involved in 
fatal accidents (FARS) 
3.5 29.0 1.7 4.9 
[h12] Percentage of police agencies reporting heroin 
contributes most to violent crime (NDTS) 
2.2 4.3 0.9 -0.6 
[a1] Stimulant-related deaths per 100,000 (MCD) 2.5 7.7 1.3 1.2 
[a5] Prevalence (%) of amphetamine abuse and pregnancy 
among females entering drug treatment (TEDS) 
2.2 5.7 1.1 0.3 
[a6] Children affected by methamphetamine labs per 100,000 
(NSS) 
2.7 8.7 1.2 0.7 
[a7] Prevalence (%) of amphetamine abuse and 
unemployment among people entering treatment (TEDS) 
2.0 4.4 0.6 -0.7 
[a8] Methamphetamine positivity rate among the general 
U.S. workforce (DTI) 
2.2 7.2 1.5 2.6 
[a10] Prevalence (%) of amphetamine abuse and 
homelessness among people entering treatment (TEDS) 
3.8 18.1 1.8 3.1 
[a15] Methamphetamine laboratory seizure incidents per 
100,000 (NSS) 
2.7 8.3 0.6 -0.8 
[c3] Inpatient hospital diagnoses for cocaine poisoning per 
100,000 (SID) 
2.9 11.2 0.1 0.9 
[c4] Inpatient hospital diagnoses for cocaine use disorders 
per 100,000 (SID) 
2.2 6.3 -0.5 1.2 
[m10] Prevalence (%) of marijuana abuse and homelessness 
among people entering treatment (TEDS) 
4.9 32.2 2.2 9.0 
[m12] Percentage of police agencies reporting marijuana 
contributes most to violent crime (NDTS) 
2.2 6.5 0.2 -1.1 
[m15] Outdoor marijuana plots eradicated per 100,000 
(DCE/SP) 
8.7 84.9 1.5 2.6 
[m16] Indoor marijuana grows seized per 100,000 (DCE/SP) 5.2 32.1 1.6 3.6 
 
 
3. Normalization 
To correct for different ranges and measurement units across the indicators, the (imputed 
and transformed) indicator scores were normalized by a min-max scaling using equation (6). In 
all cases the minimum threshold was set to 0, while the maximum threshold was set at 10% 
above the maximum reported (or estimated) value over 2000-2009 for the 50 U.S. states. This 
was done in order to be able to calculate index scores in cases where future values are greater 
than those reported for 2000-2009, without having to recalculate index scores for the previous 
years. Normalization by formula (6) is a linear transformation that converts indicators to a 
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common scale in the range 1 to 100. This scaling allows indicators to be next summarized by a 
geometric average, where zero values would have been problematic since they would have 
produced a zero average.  
 
(6) 𝑥𝑛𝑒𝑤,𝑡 =  max − 𝑥𝑟𝑎𝑤,𝑡max × 99 + 1 
 
 
4. Internal Consistency 
Internal data consistency within each subdomain was verified by principal component 
analysis (PCA), a multivariate exploratory technique that is particularly suitable for statistically 
summarizing data in a parsimonious manner. In other words, PCA is a dimensionality reduction 
technique that is designed to reduce relevant information into a smaller number of transformed 
dimensions. The usefulness of PCA in DCI development is easy to understand: each subdomain 
in the DCI is designed to describe a particular aspect of the latent phenomenon to be measured 
(i.e., drug consequences). Since these aspects are not directly observable, they are measured by a 
set of observable indicators which, by definition, are related to the aspect they are supposed to 
describe and, consequently, to each other. In an ideal situation, each subdomain would show a 
unique, most relevant PCA component accounting for a large degree of the variability associated 
with the full set of indicators underlying the subdomain. Moreover, all indicators within a 
subdomain should contribute roughly to the same extent and point in the same direction as the 
most relevant principal component. 
PCA was helpful in refining the DCI framework. It allowed us to detect noninfluential 
indicators, or indicators describing something else than they were supposed to. We analyzed 
subdomains with three or more indicators, so as to allow for the use of PCA, across all states and 
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years. As shown in Table D-4, the results in the final framework suggest that there is a clear and 
unique “statistical” dimension with a well-balanced contribution of indicators within each 
subdomain. For example, the morbidity subdomain for heroin can be summarized by a single 
principal component that captures 75.8% of the variance in the three underlying indicators, 
which have the same degree of correlation to the first principal component (roughly 0.85-0.88). 
The only exception is the ‘reduced attainment and productivity’ subdomain for cocaine, where 
two principal components were needed to capture most of the variance in the four underlying 
indicators. 
 
Table D-4. Principal Component Analysis Results within DCI Subdomains 
# Eigen-
value 
Total Variance 
Explained (%) 
Indicators Loadings 
1st Latent 
Dimension 
Loadings 
2nd Latent 
Dimension 
Heroin—Morbidity 
1 2.27 75.80 [h2] Primary heroin treatment admissions per 100,000 
(TEDS) 
0.85  
2 0.41 89.49 [h3] Inpatient hospital diagnoses for heroin poisoning 
per 100,000 (SID) 
0.88  
3 0.32 100.0 [h4] Inpatient hospital diagnoses for heroin/opiate use 
disorders per 100,000 (SID) 
0.88  
Heroin—Reduced Attainment & Productivity 
1 1.22 40.79 [h7] Prevalence (%) of heroin abuse and 
unemployment among people entering treatment 
(TEDS) 
0.59  
2 0.95 72.50 [h8] Opiate positivity rate among the general U.S. 
workforce (DTI) 
0.58  
3 0.83 100.0 [h9] Prevalence (%) of lifetime heroin use among high 
school students (YRBS) 
0.73  
Methamphetamine—Morbidity 
1 2.37 79.08 [a2] Primary amphetamine treatment admissions per 
100,000 (TEDS) 
0.89  
2 0.43 93.30 [a3] Inpatient hospital diagnoses for stimulant 
poisoning per 100,000 (SID) 
0.84  
3 0.20 100.0 [a4] Inpatient hospital diagnoses for stimulant use 
disorders per 100,000 (SID) 
0.93  
Methamphetamine—Reduced Attainment & Productivity 
1 1.91 63.71 [a7] Prevalence (%) of amphetamine abuse and 
unemployment among people entering treatment 
(TEDS) 
0.88  
2 0.89 93.47 [a8] Methamphetamine positivity rate among the 0.94  
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# Eigen-
value 
Total Variance 
Explained (%) 
Indicators Loadings 
1st Latent 
Dimension 
Loadings 
2nd Latent 
Dimension 
general U.S. workforce (DTI) 
3 0.20 100.0 [a9] Prevalence (%) of lifetime methamphetamine use 
among high school students (YRBS) 
0.50  
Cocaine—Morbidity 
1 2.29 76.45 [c2] Primary cocaine treatment admissions per 
100,000 (TEDS) 
0.75  
2 0.57 95.55 [c3] Inpatient hospital diagnoses for cocaine poisoning 
per 100,000 (SID) 
0.92  
3 0.13 100.0 [c4] Inpatient hospital diagnoses for cocaine use 
disorders per 100,000 (SID) 
0.93  
Cocaine—Reduced Attainment & Productivity 
1 1.59 39.81 [c7] Prevalence (%) of cocaine abuse and 
unemployment among people entering treatment 
(TEDS) 
0.11 0.88 
2 1.47 76.45 [c8] Cocaine positivity rate among the general U.S. 
workforce (DTI) 
0.49 0.72 
3 0.54 89.94 [c9] Prevalence (%) of lifetime cocaine use among high 
school students (YRBS) 
0.83 -0.20 
4 0.40 100.0 [c10] Prevalence (%) of past-year cocaine use among 
12-17 year olds (NSDUH) 
0.81 -0.35 
Marijuana—Morbidity 
1 1.38 45.87 [m1] Primary marijuana treatment admissions per 
100,000 (TEDS) 
0.68  
2 0.85 74.06 [m2] Inpatient hospital diagnoses for marijuana use 
disorders per 100,000 (SID) 
0.71  
3 0.78 100.0 [m3] Potency of seized marijuana  (PMP) 0.64  
Marijuana—Reduced Attainment & Productivity 
1 2.72 54.47 [m5] Prevalence (%) of marijuana abuse and 
unemployment among people entering treatment 
(TEDS) 
-0.46  
2 0.87 71.92 [m6] Marijuana positivity rate among the general U.S. 
workforce (DTI) 
0.59  
3 0.77 87.25 [m7] Prevalence (%) of marijuana use before age 13 
among high school students (YRBS) 
0.82  
4 0.44 95.99 [m8] Prevalence (%) of recent marijuana use on school 
property among high school students (YRBS) 
0.88  
5 0.20 100.0 [m9] Average annual marijuana initiation rate among 
12-17 year olds (NSDUH) 
0.85  
Marijuana—Community & Environmental Harms 
1 1.52 50.68 [m14] Percentage of police agencies reporting local 
marijuana production (NDTS) 
0.77  
2 0.82 77.92 [m15] Outdoor marijuana plots eradicated per 
100,000 (DCE/SP) 
0.71  
3 0.66 100.0 [m16] Indoor marijuana grows seized per 100,000 
(DCE/SP) 
0.65  
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5. Weighting and Aggregation 
The panel of experts that were consulted via AHP also provided assessments of the 
relative importance of drug-related consequences by drug type. Figure D-6 summarizes the mean 
expert-derived weights used for the development of the drug-specific State DCIs. Weights for the 
consequence subdomains clearly differ across the drugs. For example, the weight for ‘mortality’ 
varies between 3% for marijuana to 14% for heroin. However, the expert weighting, on average, 
suggests that the most important drug consequences are ‘family disruption & child maltreatment’ 
(14-20%) and ‘crime & nuisance’ (15-23%) in almost all cases. On the opposite side, the expert 
weighting, on average, suggests that the least important drug consequences in terms of overall 
harm are ‘drugged driving,’ and ‘drug-exposed infants’ (4-10%).  
Figures D-7 to D-10 summarize the expert-based weights for the subdomains and 
domains of each drug-specific State DCI, showing mean, minimum, and maximum weights. 
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Figure D-6. AHP Weights for DCI Subdomains
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There are considerable differences in the weights proposed by the experts both within and across 
drug types—although there is also a general degree of consistency in their relative rankings of 
consequence areas, especially for the harder drugs (heroin, methamphetamine, cocaine). As 
demonstrated in the following discussion, we did not assume equal weights in development of 
the State DCIs due to the variability in expert-based weights at the domain and subdomain levels. 
Instead, the mean weight value across the experts was used. As for the National DCI, only 
experts with inconsistency ratios 0.2 or below were taken into account in the calculation of the 
mean expert-weights. Thus, we used 12 questionnaires for the Heroin and Methamphetamine 
Indices, 13 questionnaires for the Cocaine Index, and 16 questionnaires for the Marijuana Index.  
For the Heroin Index (Figure D-7), experts suggested that ‘drugged driving,’ ‘stigmatization & 
marginalization,’ and ‘drug-exposed infants’ should, on average, receive the lowest weights (4-
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Figure D-7. Expert-based Weights for the Subdomains and 
Domains of the Heroin Index 
Horizontal dotted lines represent equal weights 
for subdomains (0.11) and domains (0.33). 
 140 
6%) across the nine subdomains. On the other hand, experts on average agreed that the highest 
weight should be assigned to ‘crime & nuisance’ (23%). Despite variability at the subdomain 
level, weights at the domain level are relatively similar: Crime & Disorder (36%), Health (33%), 
Social & Economic (31%).  
 For the Methamphetamine Index (Figure D-8), the experts suggested that ‘drugged 
driving’ and ‘stigmatization & marginalization’ should, on average, receive the lowest weights 
(4% and 6%, respectively). On the other hand, experts on average agreed that the highest weight 
should be assigned to ‘crime & nuisance’ (20%), followed by ‘family disruption & child 
maltreatment’ (18%). Once again, despite weight differences at the subdomain level, weights for 
the three domains are roughly equal: Crime & Disorder (36%), Health, Social & Economic (32% 
each). 
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Figure D-8. Expert-based Weights for the Subdomains and 
Domains of the Methamphetamine Index 
Horizontal dotted lines represent equal weights 
for subdomains (0.11) and domains (0.33). 
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 For the Cocaine Index (Figure D-9), experts suggested that ‘drugged driving’ and 
‘stigmatization & marginalization’ should, on average, receive the lowest weights (4% and 5%, 
respectively). Conversely, experts on average agreed that the highest weight should be assigned 
to ‘crime & nuisance’ (23%). Overall, Health (30%) and Social & Economic (31%) domains 
received almost equal weights, whereas Crime & Disorder was weighted higher (39%).  
Finally, for the Marijuana Index (Figure D-10), experts offered a very different picture 
than for the other three drugs. Intuitively, experts unanimously suggested that ‘mortality’ should 
receive the lowest weight (3%). On the other hand, experts on average agreed that the highest 
weight should be assigned to ‘reduced attainment & productivity’ (18%), followed by ‘family 
disruption & child maltreatment,’ ‘stigmatization & marginalization,’ and ‘crime & nuisance’ 
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Figure D-9. Expert-based Weights for the Subdomains and 
Domains of the Cocaine Index 
Horizontal dotted lines represent equal weights 
for subdomains (0.11) and domains (0.33). 
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(15% each). Overall, it can be derived that the three domains should not receive equal weights: 
Social & Economic consequences outweigh Crime & Disorder and in turn Health (weights 47%, 
35%, and 18%, respectively).  
 Next, the calculation of each drug-specific DCI followed three aggregation steps. First, 
the scores for the subdomains were calculated as simple geometric averages of the normalized 
indicators. Scores for the three domains were then calculated as expert-weighted geometric 
averages of the three subdomains underlying each domain. Finally, each State DCI is the expert-
weighted geometric average of the three domains. Note that this is equivalent to calculating a 
drug-specific DCI as the expert-weighted geometric average of the nine subdomains. The use of 
the geometric average, as opposed to the classical arithmetic average, in order to aggregate the 
components of the State DCIs is underlined by a conceptual need to avoid the perfect 
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Figure D-10. Expert-based Weights for the Subdomains and 
Domains of the Marijuana Index 
Horizontal dotted lines represent equal weights 
for subdomains (0.11) and domains (0.33). 
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substitutability among the index components in an arithmetic average. This was explained in 
detail in the National DCI section above.   
 Currently, due to data limitations, some subdomains do not have underlying indicators. In 
these cases, the expert-driven weights for the other subdomains within a given domain were 
rescaled to the sum of the three subdomains. For example, marijuana has no indicators for 
‘family disruption and child maltreatment.’ Essentially during the calculations, that subdomain 
becomes zero-weighted despite receiving an average 15% weight from the experts. The average 
weights for the other two subdomains—‘reduced attainment and productivity’ and 
‘stigmatization and marginalization’— which were 18% and 15% respectively, were rescaled by 
dividing them by the sum of all three weights (15%+18%+15%). Hence, the adjusted weights for 
‘reduced attainment and productivity’ and ‘stigmatization and marginalization’ are 26% and 
21%, respectively. This re-scaling was done in order for the Social and Economic domain to 
have the same weight despite one subdomain having no measurable indicators and, at the same 
time, to not change the ratio of the weights assigned to the two remaining subdomains.  
 The calculation of the drug-specific State DCIs followed three aggregation steps. First, 
the scores for the subdomains were calculated as simple geometric averages of the normalized 
indicators using equation (7), exemplified for Morbidity for heroin. 
 
(7) 
Morbidity𝑡 = �(treatment admissions𝑡) × (poisoning diagnoses𝑡)  ×  (drug use disorder diagnoses𝑡)�1/3 
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Next, scores for the three domains were calculated as expert-weighted geometric averages of the 
three subdomains underlying each domain using equation (8), exemplified for Health 
consequences. 
 
(8) Health𝑡 = (Mortality)𝑡𝑤1 × (Morbidity)𝑡𝑤2 × (Drug‐Exposed Infants)𝑡𝑤3 
 
Finally, the expert-weighted geometric mean of the three domains was calculated as follows: 
 
(9) 𝑌𝑡 = (Health)𝑡𝑤10 × (Social & Economic)𝑡𝑤11 × (Crime & Disorder)𝑡𝑤12  
 
 Note that equation (9) is equivalent to the expert-weighted geometric average of the nine 
subdomains. The final results for the DCI and the three domains on Health, Social & Economic, 
and Crime & Disorder were then scaled using equation (10), whereby high values are 
undesirable. This is done for communication purposes with a view to have the results in the same 
direction as that of the raw indicators. 27 
 
(10) DCI𝑡 = 100 − 𝑌𝑡 
 
  
                                                 
27 Note that during calculations, high values are preferred over low values. This is necessitated by the use of the 
geometric average, which actually “incentives” a state to make an improvement in those indicators where it 
performs worse (i.e., low values), so as to improve its overall score. However, for communication purposes, scores 
for the subdomains, domains, and overall indices are reported as 100-value, where high values correspond to higher 
drug consequences.    
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6. Post-Aggregation Analysis 
 The DCIs aggregate three domains using weights derived from AHP which are 
understood to reflect an indicator’s importance in the index. We have measured the importance 
of a domain within a DCI via Pearson’s ‘correlation ratio’ (briefly denoted as main effect) with a 
view toward assessing whether the declared importance of the three domains and their main 
effect are similar. The main effect (henceforth Si) describes the expected reduction in the 
variance of DCI scores that would be obtained if a given DCI domain could be fixed. As 
discussed in Paruolo, Saisana and Saltelli (2012), we can take this as a measure of importance. 
Thus, if all three DCI domains are expected to contribute significantly to determining the DCI 
classification of the states in a given year, their Si values should not differ too much. On the 
contrary, if some domains are expected to have a higher weight, then their Si values should be 
greater.  
 
Table D-5. Measures of Importance (Si) of the Domains in the Overall DCI 
 Heroin Meth-
amphetamine 
Cocaine Marijuana 
Health 0.79 0.75 0.67 0.22 
Social & Economic 0.78 0.70 0.59 0.75 
Crime & Disorder 0.84 0.97 0.87 0.40 
Average of the AHP-Derived Expert Weights 
Health 0.33 0.32 0.31 0.18 
Social & Economic 0.31 0.32 0.30 0.47 
Crime & Disorder 0.36 0.36 0.39 0.35 
 
  
 Table D-5 presents the Si values together with the average AHP-derived weights. Results 
are reassuring as the declared importance of the three domains and their main effect are similar. 
For example, for marijuana, the Social and Economic consequences are assessed (based on 
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average AHP weights) to be more important than Crime and Disorder and in turn more 
important than Health consequences. This order of importance is confirmed by the values for the 
main effects of these domains. Note, however, that assigning a higher weight to some domains 
does not necessarily guarantee a higher impact of those domains on the variance of the DCI 
scores. An example where this occurs is for cocaine, where despite the roughly equal AHP 
weights assigned to Health and Social and Economic consequences, their contribution to the 
variance of the Cocaine Index scores is not the same (Health consequences are more influential 
than Social and Economic consequences). This type of analysis is included here in order to 
provide a better understanding of the “importance” of the domains, which cannot be assessed by 
looking at the weights alone. 
 
7. Robustness Analysis 
Various choices must be made when setting up a composite indicator: structure of the 
framework, indicator selection, weighting scheme, aggregation, and many others. The aim of the 
robustness analysis is to assess to what extent these choices might affect the scores or rankings of 
composite indicators (Saisana et al., 2005). The robustness analysis of an index is therefore an 
essential ingredient for validating its message by anticipating criticism (Saisana et al., 2005, 
OECD, 2008; Saltelli et al., 2008). The robustness assessment of the DCI aimed to assess the 
impact of the uncertainty in the weights assigned to the DCI subdomains to the overall index 
scores and ranks. 
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Uncertainty Analysis 
For the main results, we assigned equal weights to the indicators and expert-based 
weights to the subdomains and domains to derive the drug-specific State DCIs. In order to better 
understand the impact on the DCI scores of different sets of weights, we performed three 
robustness analyses. First, we compared the DCI results to those obtained had equal weighting 
been used. Second, we used all the information from the AHP assessment, not just the average 
weight across the experts. Third, we performed data envelopment analysis. These three 
procedures are described in turn. 
Equal weights. The impact of using equal weights for the nine subdomains, as opposed to 
the average expert-derived weights, on the drug-specific DCI scores is shown in Figure D-11. 
The simulated results assuming equal weights are plotted on the horizontal axes. Overall, the 
impact of assuming equal weights for the nine subdomains on the DCI scores is minimal. The 
Pearson product correlation coefficients between the reference and the simulated scores are .982 
for Heroin, .997 for Methamphetamine, .972 for Cocaine, and .969 for Marijuana. It is 
interesting to note that for all drugs, but for Methamphetamine especially, the equal weight 
scores are in general lower (most points lay above the diagonal) compared to the reference 
scores, which suggests that drug consequences are higher under the AHP assumption for 
weights.   
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Figure D-11. Impact of Weights on the DCI Scores: Equal Weights vs. AHP Weights
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 AHP exercise. Next, to exploit all the information on the weights from the AHP exercise, 
we incorporate the “disagreement” in the weights among the experts in the calculation of the 
DCIs, and assess the impact on the results. Figure D-12 summarizes the difference between the 
reference DCI score (based on the average AHP weight) and a simulated score using any of the 
AHP-derived set of weights. 28 The horizontal black line is the median across all cases (50 States 
× 10 years × 12 to 16 sets of weights) and the boxes include 75 percent of the cases. The whole 
distribution of the score differences is displayed by the vertical thin black lines. A median close 
to zero with a small box and a short vertical line indicates that the average expert weight in the 
calculation of the DCIs is suitable in summarizing the panel members opinion, as the use of the 
                                                 
28 Each set of weights derived from a single expert. We remind the reader that only those experts with AHP 
inconsistency ratios 0.2 or below were considered.  
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AHP weights does not affect the final scores in a significant manner. For all four drugs, the 
median is close to zero, and the difference is less than 2 points for 75 percent of the cases.  
Data envelopment analysis. If one opts to compare the multidimensional performance of 
different states by subjecting them to a fixed set of weights, this may prevent acceptance of the 
index on grounds that a given weighting scheme might not be fair to a particular state. This issue 
is addressed here using data envelopment analysis. 
In the absence of reliable information about the true weights to be attached to the nine 
subdomains underlying the DCI conceptual framework, we endogenously selected those state-
specific weights that maximize a state’s score with respect to all states using data envelopment 
analysis (Cherchye, Moesen, and Van Puyenbroeck, 2004; Melyn and Moesen, 1991). This gives 
the following linear programming problem for each state i: 
 
{ }∑
∑
=
∈
== 9
1
9
1
max
max
j
ijcjdatasety
j
ijij
wiji
wy
wy
Y
c
 (bounding constraint) 
Subject to  
 
0≥ijw , where 9,...,1=j , 8,...,1=i  (non-negativity constraint) 
 
In this basic programming problem, the weights are non-negative and a state’s score is between 0 
(worst) and 1 (best). 29 
 However, in the traditional data envelopment analysis approach a state could achieve a 
perfect index score simply by assigning zero weight to those subdomains for which its 
performance is very low. To deal with this limitation, Cherchye et al. (2008) propose an 
                                                 
29 In this calculation, the scores for the nine subdomains are expressed as the higher the better. 
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application of the approach, which imposes restrictions on the pie shares. In our case, the pie 
shares are expressed as the ratio of the weighted subdomain values over the overall DCI score. 
This application of data envelopment analysis is particularly interesting as it directly reveals how 
the respective pie shares contribute to a DCI score as the pie shares have a unity sum. The pie 
shares were elicited from the results of the AHP above, given the minimum and maximum values 
suggested by the experts, and are shown in Table D-6.  
 
Table D-6. Ranges for the Weights’ Bounds in the Data Envelopment Analysis 
 Heroin Meth-
amphetamine 
Cocaine Marijuana 
Mortality [0.025,0.332] [0.018,0.266] [0.015,0.329] [0.012,0.055] 
Morbidity [0.060,0.299] [0.054,0.301] [0.033,0.174] [0.029,0.218] 
Drug-Exposed Infants [0.013,0.220] [0.014,0.275] [0.020,0.220] [0.022,0.175] 
Family Disruption & Child 
Maltreatment 
[0.051,0.230] [0.082,0.336] [0.050,0.335] [0.051,0.266] 
Reduced Attainment & Productivity [0.025,0.345] [0.020,0.220] [0.027,0.205] [0.093,0.377] 
Stigmatization & Marginalization [0.020,0.147] [0.019,0.099] [0.021,0.096] [0.032,0.361] 
Drugged Driving [0.015,0.109] [0.015,0.071] [0.013,0.108] [0.026,0.184] 
Crime & Nuisance [0.102,0.337] [0.017,0.412] [0.083,0.422] [0.048,0.371] 
Community & Environmental Harms [0.021,0.213] [0.030,0.213] [0.027,0.213] [0.022,0.301] 
 
 
 As the data show, ‘mortality’ can account for 2.5% to 33.2% of the DCI score for Heroin, 
or merely 1.2% to 5.5% of the DCI score for Marijuana. Each state is therefore free to decide—
statistically speaking—on the relative contribution of the subdomains to the overall drug-specific 
DCI score, so as to place the state in the best possible position. In other words, the method 
assigns a higher contribution to those subdomains for which a state is strong and a lower weight 
to those subdomains for which the state is comparatively weak. However, by assigning these 
bounds for the shares of the subdomains, we ensure that each state includes all the subdomains 
and no single subdomain dominates the DCI score. In practical terms, given that some 
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subdomains are not currently populated with indicators, the bounds for the data envelopment 
analysis were adjusted as described previously.  
 Though suitable for classifying states into efficient and inefficient ones, the traditional 
data envelopment analysis approach is not very appropriate for ranking states, since the weights 
are state-specific. The cross-efficiency evaluation method, proposed by Sexton et al. (1986), is 
an extension tool that could be utilized to identify good overall performers and to rank states. 
The main idea is to use data envelopment analysis in a peer evaluation instead of a self-
evaluation. There are at least three advantages for the cross-efficiency evaluation method. First, 
it provides a unique ordering of the states. Second, it eliminates unrealistic weight schemes 
without necessarily requiring the elicitation of weight restrictions from subject area experts 
(Anderson, Hollingsworth, and Inman, 2002). However, given that an AHP exercise was 
conducted for the purposes of the DCI, such restrictions on the weights (more accurately on the 
pie shares) were introduced in the analysis below. Finally, the cross-efficiency evaluation 
method can effectively differentiate between good and poor performers (Boussofiane, Dyson, 
and Thanassoulis, 1991). Therefore, this method is widely used for ranking the performance of 
decision-making units (Sexton et al., 1986). 
 In the cross-efficiency data envelopment analysis, the linear programming problem is 
solved for each state and the fifty sets of weights are used to calculate fifty scores for each state. 
The average of these fifty scores for each state is used for the overall assessment of states’ 
relative performance. Figure D-13 presents the comparison between the drug-specific DCI scores 
for the 50 states obtained using the average AHP-derived expert weights versus the simulated 
scores obtained using the cross-efficiency data envelopment analysis. Overall, the impact on the 
results is moderate as suggested by the high values for the Pearson product correlation 
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coefficients between the reference and the data envelopment analysis scores (.981 for 
heroin, .978 for methamphetamine, .981 for cocaine, and .900 for marijuana). 
 An important final remark is that the uncertainty results presented herein do not inform 
on the quality of the framework of the drug-specific DCIs; this was already done in the previous 
sections. Instead, the results here can only provide information on the validity of inferences 
associated with the state scores for the four drug-specific DCIs over 2000-2009. In fact, the four 
drug-specific DCIs proved to be very robust to changes in the weights for the majority of the 
states. 
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Figure D-13. Impact of Weights on the DCI Scores: DEA Weights vs. AHP Weights
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ACRONYM GLOSSARY 
 
AAPCC American Association of Poison Control Centers 
ACF  Administration for Children and Families 
ACHA  American College Health Association 
ADAM Arrestee Drug Abuse Monitoring 
AERS  Adverse Event Reporting System 
AFCARS Adoption and Foster Care Analysis and Reporting System 
AHP  Analytic Hierarchy Process 
AHRQ  Agency for Healthcare Research and Quality 
ARCOS Automation of Reports and Consolidated Orders System 
ATF  Bureau of Alcohol, Tobacco, Firearms and Explosives 
ATDSR Agency for Toxic Substances and Disease Registry 
BJS  Bureau of Justice Statistics 
BLS  Bureau of Labor Statistics 
CASA  Center on Addiction and Substance Abuse 
CDC  Centers for Disease Control and Prevention 
CI  Composite Index 
CSAT  Center for Substance Abuse Treatment 
CSSS  Campus Safety and Security Survey 
DAWN  Drug Abuse Warning Network 
DCE/SP Domestic Cannabis Eradication/Suppression Program 
DCI  Drug Consequences Index 
DEA  Drug Enforcement Administration 
DOD  Department of Defense 
DTI  Drug Testing Index 
EPIC  El Paso Intelligence Center 
FARS  Fatality Analysis Reporting System 
FBI  Federal Bureau of Investigation 
FDA  Food and Drug Administration 
GES  General Estimates System 
HCUP  Healthcare Cost and Utilization Project 
HCUP-NIS Healthcare Cost and Utilization Project-National Inpatient Sample 
HCUP-SID Healthcare Cost and Utilization Project-State Inpatient Databases 
HHS  Department of Health and Human Services 
HIDTA High Intensity Drug Trafficking Areas 
HUD  Department of Housing and Urban Development 
IDU  Injection Drug Use 
ISA  International Survey Associates 
IRS  Internal Revenue Service 
LEMAS Law Enforcement Management and Administrative Statistics 
MAPS  Multidisciplinary Association for Psychedelic Studies 
MCD  Multiple Cause of Death 
MTF  Monitoring the Future 
NCANDS National Child Abuse and Neglect Data System 
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NCHS  National Center for Health Statistics 
NCJTPS National Criminal Justice Treatment Practices Survey 
NCRP  National Corrections Reporting Program 
NCVS  National Crime Victimization Survey 
NDACAN National Data Archive on Child Abuse and Neglect 
NDIC  National Drug Intelligence Center 
NDTS  National Drug Threat Survey 
NHTSA National Highway Traffic Safety Administration 
NIAAA National Institute on Alcohol Abuse and Alcoholism 
NIBRS National Incident Based Reporting System 
NICHD National Institute of Child Health and Human Development 
NIDA  National Institute on Drug Abuse  
NIJ  National Institute of Justice 
NIS  National Inpatient Sample 
NJRP  National Judicial Reporting Program 
NLSY97 National Longitudinal Survey of Youth 1997 
NLSY79 National Longitudinal Survey of Youth 1979 
NMVCCS National Motor Vehicle Crash Causation Survey 
NPDS  National Poison Data System 
NPHS  National Pregnancy and Health Survey 
NRS  National Roadside Survey 
NSDUH National Survey on Drug Use and Health 
NSS  National Seizure System 
N-SSATS National Survey of Substance Abuse. Treatment Services 
NSYC  National Survey of Youth in Custody 
NTSIP  National Toxic Substance Incidents Program 
NVSS  National Vital Statistics System 
OECD  Organisation for Economic Co-operation and Development 
OJJDP  Office of Juvenile Justice and Delinquency Prevention 
ONDCP Office of National Drug Control Policy 
OPE  Office of Postsecondary Education 
OSDFS Office of Safe and Drug-Free Schools 
OTIS  Online Tuberculosis Information System 
PDFA  Partnership for a Drug Free America 
PMP  Potency Monitoring Program 
PRAMS Pregnancy Risk Assessment Monitoring System 
SAMHSA Substance Abuse and Mental Health Services Administration 
SBIRT  Screening, Brief Intervention, and Referral to Treatment 
SIFSCF Survey of Inmates in Federal and State Correctional Facilities 
SILJ  Survey of Inmates in Local Jails 
TEDS  Treatment Episodes Data Sets 
TLCS  Theft or Loss of Controlled Substances 
UCR  Uniform Crime Reports 
USSC  United States Sentencing Commission 
YRBS  Youth Risk Behavior Survey   
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